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Summary
Cancer cells frequently exhibit defects in apoptosis, contributing to increased survival and 
resistance to chemotherapy. This can result from decreased expression of pro-apoptotic 
proteins such as Bax, through abnormal proteasomal degradation. The central hypothesis of 
this project is that this abnormal proteasomal degradation in cancer cells will result in the 
generation of peptides that bind to MHC class I molecules, and displayed at the cell surface 
for CD8+ T cell recognition. If this is correct, then T cells directed against Bax peptides 
should be able to recognize and kill human cancer cells.
To test this hypothesis, candidate HLA-A2 binding peptide epitopes were identified from 
Bax and T cell immunogenicity tested using IFNy ELISpot assays. Positive T cell responses 
were detected against Bax peptides in 10/16 healthy donors. The specificity of a CD8+ T 
cell clone (KSIVB17) derived from one donor, was mapped to two similar peptide epitopes, 
B ax,36-144 (IMGWTLDFL) and Baxi3 5 .i4 4  (TIMGWTLDFL). In addition to recognition of 
peptide pulsed target cells, this clone was also able to recognise primary tumour cells from 
CLL (chronic lymphocytic leukaemia) patients, and kill cervical carcinoma and 
osteosarcoma cell lines. T cell reactivity correlated with abnormal proteasomal degradation 
of Bax in cancer cells.
Attempts to generate Bax-specific T cells in CLL patients demonstrated that naive and 
memory T cell responses were compromised compared to healthy donors. This 
compromised T cell immunity appeared to result from increased expression of 
immunosuppressive molecules, increased frequency of Treg cells and a skewed memory T 
cell phenotype in CLL patients.
Overall, this research supports the novel concept that proteins such as Bax, which are 
abnormally degraded in cancer cells, can be targets for CD8+ T cells. However use of Bax 
in immunotherapy will require strategies to overcome suppression of T cell responses in 
CLL and other cancers.
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Chapter 1: Introduction
Chapter 1 
Introduction
1.1 Cancer
Cancer is a group of more than 200 diseases characterized by the uncontrolled growth 
of abnormal cells that have the ability to spread locally by invasion and systematically to 
other organs by metastasis. Most cancers acquire crucial capabilities during their 
development. These physiologic changes include insensitivity to growth-inhibitory signals, 
self-sufficiency in growth signals, limitless replicative potential, sustained angiogenesis, 
evasion of programmed cell death (apoptosis), and tissue invasion and metastasis. Each of 
these alterations in cell physiology helps to breach the anticancer defence mechanism present 
in normal cells and tissues (Hanahan & Weinberg, 2000).
It is imperative to understand and control cancer, because to date cancer is one of the 
leading causes of death worldwide. More than a quarter of a million new cases of cancer are 
diagnosed each year in the UK (Cancer Research UK). There is great interest in developing 
new and effective strategies to complement conventional methods of cancer treatment, such 
as surgery, radiation, and chemotherapy. One such area is the use of the immune system to 
mediate tumour protection and regression.
1.2 The immune system
The immune system provides protection against infectious pathogens. Host defence is 
composed by the early responses of innate immunity and the later responses of adaptive 
immunity. Innate immunity mediates a rapid induced, non-specific response against 
infections, which does not result in immune memory. Adaptive immunity arises from a breach 
in the innate immune response resulting in the generation of antigen specific effector cells,
1
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and memory cells that will limit or prevent subsequent infection with the same organism 
(Abbas et al. , 2007).
1.2.1 Innate immunity
The innate immune system detects a pathogen and acts as the front line of defence. 
This system is made up of several distinct components, including epithelia, cells present in the 
circulation and tissues, cytokines and plasma proteins, which includes proteins of the 
complement system. A major component of the innate system is the physical barrier provided 
by epithelia (skin, gastrointestinal tract, and respiratory tract), which can prevent the entrance 
of pathogens and therefore an infection from becoming established. Where epithelial defences 
have been breached, a number of other innate system components come into play to control or 
destroy pathogen (Janeway et al., 2008).
The components of innate system recognise structures called pathogen-associated 
molecular patterns (PAMPs) that are characteristic of microbes. The receptors that bind to 
these conserved structures are called pattern recognition receptors (PRRs) and are expressed 
on the cell surface or secreted. PRRs can recognise various bacterial components, which 
include receptors for lipids (Toll-like receptor 4 (TLR4)), bacterial carbohydrates (mannose 
and glucan receptors), and other pathogen-derived components (scavenger receptor, and 
TLRs) The main functions of these molecules are activation of pro-inflammatory signalling 
pathways, opsonisation of the microorganism, activation of the lectin pathway of the 
complement, phagocytosis, and induction of apoptosis (Janeway & Medzhitov, 2002).
The principal effector cells of the innate immune responses are phagocytes 
(neutrophils, monocytes/macrophages), natural killer (NK) cells, and dendritic cells (DCs). 
Phagocytes, including neutrophils and macrophages, are recruited to sites of infection, where 
they identify, ingest (phagocytose) and destroy microbes. Monocytes ingest microbes in the 
circulation and in tissues, where these cells mature and become macrophages. Neutrophils
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ingest microbes in the blood, and can also migrate and enter tissues at sites of infections. 
Once at the site of infection, neutrophils and macrophages ingest the microbes by 
phagocytosis for intracellular destruction, secrete cytokines that contribute to an inflammatory 
response, and promote tissue remodeling at the sites of infection (Janeway et al., 2008).
NK cells are lymphocytes that are mainly important in the clearance of virally infected 
and malignantly transformed cells. The activation of these cells depends on the balance 
between activating and inhibitory signal provided by cell surface receptors. NK cells 
preferentially kill target cells that express few or no major histocompatibility complex (MHC) 
class 1 molecules. NK cell lytic activity can be induced by the down regulation of MHC class 
I expression by virally infected cells and cancer cells (Karre, 2002). This down regulation is 
an immune evasion strategy acquired by a number of viruses and cancer cells in order to 
avoid recognition by cytotoxic T lymphocytes (CTLs).
NK cells kill by either engaging Fas or releasing perforin and granzyme, which are 
associated with cytotoxicity. The activated NK cells will mediate their activities through the 
release of cytokines, such as interferon-y (IFNy), which is involved in activating macrophages 
and neutrophils, and upregulation of HLA class I and class II expression on antigen 
presenting cells (APCs) (Boehm et al., 1997). NKT cells are innate-like lymphocytes that are 
characterised by the co-expression of semi-variant a p  T cell receptor (TCR) together with NK 
cell associated receptors. The TCRs of NKT cells recognise CD Id  molecules displaying 
glycolipid or non-peptidic ligands (Janeway et al., 2008).
Another type of innate-like lymphocytes are the y5 T cells. In humans, y5 T cells make 
up 50% of intraepithelial lymphocytes and represent 1-5 % of lymphocytes that circulate in 
the blood. These lymphocyte express both the TCRy5, that recognises non-peptidic ligands, 
and the NK associated NKG2D (natural-killer group 2, member D) receptor (Carding & Egan, 
2002).
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Dendritic cells have phagocytic capabilities and respond to microbes by secreting 
cytokines. They have an important role in adaptive immune responses by capturing, 
processing and presenting microbial antigens to T lymphocytes (Banchereau & Steinman, 
1998) (later discussed in section 1.2.2). Therefore, DCs have a critical function in linking 
innate and adaptive immune responses. This is particularly important when pathogenic 
microbes successfully invade and replicate in the cells and tissues, and protection against 
these pathogens requires the more specialized mechanisms of the adaptive immunity.
1.2.2 Adaptive immunity
Adaptive immunity develops more slowly, but is a more highly evolved system than 
the innate system, mediating a more efficient defense against infections. In this context, it 
provides responses to specific regions (epitopes) of a foreign molecule (antigen). These 
responses are accompanied by the generation of immunological memory allowing a more 
rapid and effective response upon subsequent exposure to the pathogen. The adaptive immune 
system is mediated by lymphocytes and their products, such as antibodies. There are two 
types of adaptive immunity, humoral immunity and cell-mediated immunity, which provide 
defense against extracellular microbes and intracellular microbes, respectively.
1.2.2.1 Humoral immunity
The humoral immunity is mediated by antibodies produced by B lymphocytes. This 
type of immune responses neutralizes and eliminates extracellular microbes and microbial 
toxins. B lymphocytes are activated through their B cell receptor to produce antibodies that 
bind to foreign antigens, which results in neutralization of viruses or bacteria or in tagging of 
pathogens to be destroyed by innate immune system.
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1.2.2.2 Cell-mediated immunity
The cell-mediated immunity is governed by T lymphocytes. These cells express TCRs 
on their cell surface that recognise foreign antigens in the form of short peptides presented by 
MHC molecules (human leukocytes antigens (HLA) in humans, H-2 molecules in mice) 
expressed on the surface of APCs (Engelhard, 1994; Rudensky et al., 1991). T cells can be 
categorised into two types based upon the cell surface expression of either CD4 or CD8. As a 
general principle, MHC class I molecules present antigenic peptides derived from intracellular 
proteins for CD8+ T cell recognition and MHC class II molecules present peptide epitopes 
derived from extracellular antigens for CD4+ T helper (Th) cell recognition. MHC class I is 
expressed in all nucleated cells, whilst MHC class II molecules are mainly found on cells of 
the immune system with a specialized antigen presenting function (Engelhard, 1994).
APCs in priming T cell responses
The principal APCs include DCs, macrophages and B cells (professional APCs). 
APCs have an important task in the generation of epitope specific T cell responses. DCs are 
the most effective APCs and are especially fundamental in the activation of naive CD4+ and 
CD8+ T cells during a primary immune response (Guery & Adorini, 1995; Hart, 1997). B 
cells ingest protein antigens and display them to CD4+ Th cells during humoral immune 
responses. Macrophages phagocytose microbes and present antigens of these microbes to 
effector CD4+ T cells. All these APCs are able to activate CD4+ T cells as they express MHC 
class II molecules and costimulatory molecules. But, DCs are the only APCs with a unique 
capacity to stimulate naive CD4+ and CD8+ T cells and initiate (prime) T cell responses 
(Celia e ta l., 1997).
During an immune response, DCs must accomplish two main functions, namely 
antigen processing and antigen presentation to T cells. Immature DCs enter the peripheral 
blood system and the circulating DCs are then deposited in peripheral tissues where they are
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able to constantly monitor the local environment for the presence of antigenic material 
through macropinocytosis of soluble proteins (Sallusto et al., 1995). These DCs capture 
microbial protein antigens and transport the antigens to lymph nodes. After encountering 
microbial components, the DCs mature during migration to lymph nodes and become 
competent at presenting antigens and stimulating naive T cells.
The immature DCs can phagocytose microbes and apoptotic or necrotic bodies. The 
internalised material is processed within a phagolysosome, producing peptide fragments 
which bind to either HLA class I (through cross-priming) (Albert et a l ,  2001) or HLA class II 
molecules which are then displayed on the surface of the DC (Banchereau & Steinman, 1998). 
DCs can be activated by microbes and also by CD40 ligation (Celia et al., 1996) and presence 
of pro-inflammatory cytokines such as tumour necrosis factor a  (TNFa) and interleukin-lp 
(IL -lp) secreted by infected tissue. These DCs lose their adhesion for epithelial and start to 
express CCR7, a chemokine receptor that is specific for chemokines produced in the T cell 
zones of lymph nodes.
Once activated, DCs secrete a number of cytokines such as M IP -la , IL-8 and 
RANTES that are involved in the recruitment of T cells, NK cells, phagocytes and further 
DCs (O'Neill et al., 2004; Sallusto et al., 1999b). Maturation is characterised by the up- 
regulation of a number of adhesion molecules (ICAM-1, ICAM-3 and LFA-3) and co­
stimulatory molecules (CD80, CD86) that are respectively required for the migration of the 
DC and the priming of T cells (Timmerman & Levy, 1999). The maturation of the DCs is 
specifically directed towards efficient antigen presentation rather than phagocytosis and 
antigen processing.
In the lymph nodes, mature DCs present the antigen (complexed with a HLA 
molecule) to naive T cells. A T cell recognises a peptide through its expression of a unique 
TCR. The recognition of an epitope by the TCR is not sufficient by itself to completely 
activate a naive T cell. Secondary signals provided by the ligation of co-stimulatory
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molecules on the DC (CD80 and CD86) with their cognate molecule (CD28) on the T cell, are 
required for full activation and clonal expansion of T cells (Linsley et al., 1991; Sansom et 
al., 2003).
CD4+ T cells and their effector subsets
Naive CD4+ T cells become primed and activated through the recognition of their 
cognate epitope presented by MHC class II molecules expressed on mature DC. Once 
activated, CD4+ Th cells proliferate and differentiate into subsets of effector cells that 
perform different functions. The main subsets of CD4 effector T cells are T h l, Th2, and 
T hl7 . (CD4+ T cells can also be differentiated into regulatory T cells, which will be 
discussed separately in this section.) The first subsets to be defined were T hl and Th2 
(Mosmann & Coffman, 1989), and more recently T h l7 (Harrington et al., 2005). The 
development of these Th subsets is regulated by the stimuli that naive CD4+ T cells receive 
when they encounter antigens. These three subsets produce distinct sets of cytokines and 
perform different functions (Zhu & Paul, 2008) (F igurel.l). Upon triggering, CD4+ T cells 
can orchestrate the activation of B cells, macrophages, and CD8+ T cells, and also the 
activation and recruitment of neutrophils.
It has been shown that during their interaction with mature DCs, CD4+ Th cells can 
provide some form of stimulatory signal, enhancing the DCs capacity to effectively activate 
naive CD8+ T cells via a cross-priming mechanism of antigen processing (Bennett et al., 
1997). This stimulation by the CD4+ Th cell is believed to be dependent on the ligation of 
CD40L on the activated Th cell with CD40 on the DC. This ligation has been shown to result 
in enhanced surface expression of co-stimulatory molecules such as CD80 and CD86, cell 
adhesion molecules such as 1CAM-1 and also high levels of IL-12 production (Caux et al., 
1994; Celia et al., 1996; Shinde et al., 1996). In the absence of CD4+ T cell help, the 
interaction between mature DCs and naive CD8+ T cells can result in T cell tolerisation.
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Figure 1.1 Differentiation of T helper cells (adapted from  Zhu & Paul, 2008). The development of 
the CD4+ T cell subsets Thl, Th2, Thl7 (and Tregs) is dependent on the stimuli that naive T cells 
receive when they ncounter antigens. These subsets produce distinct sets of cytokines and perform 
different functions (indicated on the diagram).
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In vitro studies have revealed that this need for CD4 help can be bypassed through the 
addition of CD40L (Albert et al., 2001). CD40/CD40L ligation is clearly an essential pathway 
through which CD4+ T cells provide cognate help. Murine studies have revealed that 
although CD4+ T cell help is not always required for a primary CD8+ T cell response, it is 
important for the generation of a robust CD8+ T cell memory population (Janssen et al., 
2003: Shedlock et al., 2003)
CD8+ T cells and their cytotoxicity
Naive CD8+ T cells recognise MHC class I-associated peptide antigens and 
differentiate into effector CTLs. As all nucleated cells express MHC class I molecules, this 
allows CTLs to eradicate infected or transformed cells in all types of tissues. CTLs play a 
crucial role in immune responses against many viruses, tumors cells and other intracellular 
pathogens, such as bacteria and parasites. CD8+ T cell responses are directed against peptides 
generated in the cytosol of virus-infected or transformed cells. However, these virus-infected 
or transformed cells are not professional APCs and are not be capable of activating naive T 
cells. For that reason, DCs have an important role in priming naive CD8+ T cells (Basta & 
Alatery, 2007: Heath & Carbone, 2001). DCs are able to acquire antigen from virus-infected 
or tumour cells, and then present peptides on their MHC class I to naive CD8+ T cells. This is 
defined as cross-presentation and termed cross-priming when it leads to the activation of 
CD8+ T cells (Chen e ta l., 2004: Huang e ta l., 1994: Sigal e ta l., 1999).
The activation of naive CD8+ T cells and their differentiation may require 
involvement of CD4+ Th cells. As previously described, Th cells may contribute by secreting 
IL-2, which promotes CD8+ T cell differentiation, and/or by enhancing DC ability through 
CD40-CD40L interaction (Janeway et al., 2008). The requirement for CD4+ T cell help in the 
generation of a primary CD8+ T cell response can differ depending on the infecting virus. The 
clearance of non-cytopathic or poorly immunogenic viruses such as hepatitis C virus (HCV)
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appears to need CD4+ T cell help (Godkin et al., 2002), whereas it is not necessary for 
viruses such as Influenza A (Albert et al., 2001).
Subsequent to activation, CD8+ T cells proliferate and differentiate into effector 
CTLs. The activated CTLs migrate into inflamed tissue in search of virally infected or 
transformed cells, which are detected by the presentation of virus or tumour-derived epitopes 
complexed with MHC class I molecules on the cell surface. The CTLs have 3 effector 
functions -  secretion of cytokines, induction of apoptosis via release of cytolytic granules and 
induction of apoptosis via engagement of the death receptors such as Fas and tumour necrosis 
factor receptor (TNFR) on the surface of targets (Figure 1.2). Once a target cell has been 
eliminated, the CTL disengages and can then continue to kill other target cells.
The principal mechanism through which a CTL kills is the release of pre-formed 
cytotoxic granules (Figure 1.2A). CTLs (and NK cells) have granules that contain several 
cytotoxic mediators, including perforin and granzyme, which contribute to target cell 
apoptosis. The granule membrane expresses lysosomal associated membrane glycoproteins 
(LAMPs), including CD107a (LAMP-1), CD107b (LAMP-2) and CD63 (LAMP-3), which 
become transiently exposed on the cell surface during degranulation (Betts et al., 2003; Peters 
et al., 1991). During T cell killing, cytotoxic granules are transported to the cell membrane, 
releasing the cytotoxic mediators into the immune synapse between the effector T cell and the 
target (Betts et al., 2003). Both perforin and granzymes are required for efficient CTL killing 
of the target cells. Perforin helps by delivering the contents of the granules into the cytoplasm 
of target cells. Once in the cytoplasm of the target cell, granzymes trigger apoptosis by 
targeting the pro-apoptotic protein Bid and also caspases. It was originally thought that 
perforin created pores in the plasma membrane to permit the entrance of the proteolytically 
active granzymes (Heusel et al., 1994). However, it has been shown that perforin and 
granzymes form multimeric complexes with the proteoglycan serglycin which acts as a 
scaffold (Metkar et al., 2002). Although, how this is accomplished is still not well understood.
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Figure 1.2 Effector functions of CTLs (adapted from Andersen et al., 2006). (A) Induction of 
apoptosis in target cells via the release of cytotoxic granules. (B) Induction of apoptosis via death 
receptors triggering. (C) Indirect killing by release of cytokines (TNFa and IFNy).
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Perforin appears to perform as a translocator of these complexes and direct the release of the 
bound granzymes into the cytosol thereby triggering apoptosis of the target cell (Metkar et al. , 
2002 ).
CTL can also induce apoptosis via the interaction of Fas ligand (FasL) with Fas 
(CD95) expressed on the target cell (Figure 1.2B). This activates a signaling pathway 
downstream of Fas which culminates in the activation of caspases resulting in apoptosis of the 
target cell (Nagata, 1996). A further effector function of CTL when they recognise specific 
target cells is the production of cytokines such as IFNy and TN Fa (Jassoy et al., 1993) 
(Figure 1.2C). These cytokines can indirectly assist in apoptosis by up-regulating 
intermediates involved in apoptosis (Barber, 2000; Mitsiades et al., 2003), and in CTL 
mediated apoptosis by upregulating expression of molecules involved in antigen processing 
and presentation, such as MHC class I, transporter associated with antigen processing (TAP) 
and ICAM-1 (Epperson et al., 1992). IFNy can activate macrophages, leading to their 
recruitment to sites of infection. In addition, it has also been reported that TN Fa and IFNy can 
synergistically induce apoptosis, where apoptosis is not induced by one or the other 
(Sasagawa et al.. 2000) and to restore Fas mediated apoptosis in previously Fas apoptosis 
resistant cells (Spanaus et al., 1998).
T  regulatory cells
In addition to the CD4+ T cells subsets described earlier, there is another CD4+ T cell
population to which a regulatory or suppressive function has been attributed, known as T
regulatory cells (Tregs). These cells are considered to play a central role in self-tolerance
(Sakaguchi, 2000). They have been categorized into two subgroups, the natural Tregs and the
adaptive (induced) Tregs (Bluestone & Abbas, 2003). Natural Tregs develop in the thymus
and recognise self antigen via their TCRs. These cells are characterised by the expression of
CD4 and CD25 and the transcription factor Foxp3. Although all activated T cells express
CD25, Tregs express the highest levels of CD25. Their principal function is to suppress the
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activity (activation, proliferation and IL-2 production) of CD4+ and CD8+ T cells by cell to 
cell contact, and play a role in controlling autoreactive T cells (Piccirillo & Shevach, 2001; 
Woo et al., 2002). It has also been suggested that they may also function by producing IL-10 
and TGF-P cytokines that can inhibit T cell proliferation (Roncarolo et al., 2006).
The adaptive Tregs are generated in the periphery under diverse tolerogenic 
circumstances. They are induced from naive T cells by specific antigen mode stimulation. The 
adaptive Tregs include the T rl subset, which secrete high levels of IL-10 and the Th3 subset, 
which produce TGF-P (Carrier et al., 2007; Roncarolo et al., 2006). These cytokines suppress 
both naive and memory T cell responses and down-regulate the expression of co-stimulatory 
molecules and inflammatory cytokines by APCs (Roncarolo et al., 2006).
An increase of Tregs in the peripheral blood and the presence of Tregs at the tumour 
site have been reported for several types of human cancer, indicating that these cells may 
suppress T cell-mediated antitumour immunity (Liyanage et al., 2002: Ormandy et al., 2005; 
Piccirillo & Shevach, 2001: Wolf et al., 2003; Woo et al., 2002). Several groups have utilised 
murine models to investigate the effect of removing CD4+ CD25+ Treg cells on breaking 
immunotolerance to tumours (Jones et al., 2002; Shimizu et al., 1999). Interestingly, in the 
absence of these Treg cells, tumour-specific CD4+ CD25- and CD8+ T cell responses 
develop, resulting in protection against transplanted tumours (Casares et al., 2003).
M em ory T  cells
Following resolution of an infection the effector T cell population contracts, leaving 
behind some of the T cells as antigen-specific memory T cells that persist at much higher 
levels than the initial naive T cell frequency. Memory T cells are maintained over long 
periods of time and function to permit an increasingly rapid and potent immune response with 
each subsequent exposure to a specific pathogen (Murali-Krishna et al., 1998). The memory T 
cell pool consists of two predominant heterogeneous populations. Although not totally 
distinct, these can differ in their expression of cell surface markers such as adhesion
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molecules, in the tissues in which they reside and also in their ability at exerting effector 
function. The two main populations are central memory T cells ( T Cm ) and effector memory T 
cells ( T e m ) (Sallusto et al., 1999a).
Both T cell memory subsets can be found in the blood and spleen. T Cm  constitutively 
express lymphoid homing molecules CD62L and CCR7, high levels of IL7R and reside 
primarily in secondary lymphoid organs, thereby patrolling against systemic antigenic 
challenge. Furthermore, when compared to Tem cells, Tcm are more sensitive to antigen, 
exhibit an enhanced ability to proliferate and secrete IL-2 that leads to a rapid recall response 
(Masopust et al., 2001; Sallusto et al., 1999a; Wherry et al., 2003). Whereas, Tem do not 
express these lymphoid homing molecules and are located in non-lymphoid tissues, such as 
the gut, liver, and lungs. These cells are rapidly recruited to sites of inflammation and 
infection, where upon antigenic re-stimulation they exhibit immediate effector functions 
including the production of IFNy and cytoxicity, thus operating as sentinels for immediate 
protection against pathogen (Masopust et al., 2001; Sallusto et al., 1999a; Weninger et al., 
2001; Wherry et al., 2003).
The issue of how memory T cells develop from the initial pool of activated T cells is 
not completely understood. It remains controversial whether the transition of activated T cells 
to Tem cells and Tcm cells is linear (linear differentiation models) or they develop as separate 
lineages (branched differentiation model) (Baron et al., 2003; Bouneaud et al., 2005). Several 
studies support the linear differentiation pathway, in which naive cells upon encounter with an 
antigen mature into Tcm. which differentiate to Tem and finally to (terminally) highly 
differentiated effector cells, known as T e m r a  (Naive-* T c m ~ >  T e m - *  T e m r a )  (Figure 1.3). Data 
on telomere length supports a linear pathway of differentiation. T e m  and T e m r a  exhibit a 
shortened telomere length in comparison to naive and Tcm cells, suggesting they have 
undergone multiple rounds of division, and are thus further along in the linear
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Figure 1.3 Differentiation from naive to memory T cells. T cells can be distinguished by the 
expression o f  CD45RA, CD45RO, CCR7, CD28 and CD27. Additional heterogeneity occurs among 
T em  (subsets T e m i, Tem2» T Em3 and T Em 4) and T Em ra  (subsets T Em r a i, T Em ra2, and T Em ra 4)  by the 
particular expression patterns o f costimulatory receptors CD28 and CD27. (based on Appay et al., 
2002; Okada et al., 2008; Romero et al., 2007; Takada & Takiguchi, 2006; and Tomiyama et al., 
2002)
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differentiation pathway (Champagne et al., 2001; Sallusto et al., 2004; Sallusto et al., 1999a; 
Tomiyama et al., 2002).
Surface expression of isoforms of tyrosine phosphatase CD45 (CD45RA and 
CD45RO) and CCR7 have been widely used to delineate four major subsets of T cells. 
(Champagne et al., 2001; Sallusto et al., 2004; Sallusto et al., 1999a; Tomiyama et al., 2002). 
The particular expression patterns of costimulatory receptors CD28 and CD27, in conjunction 
with the expression of CD45RA/CD45RO and CCR7, uncovered additional heterogeneity 
among the TEM. T cells sequentially downregulate CCR7, CD28, and CD27 surface 
expression that corresponds to an increase in cytokine production and cytotoxic potential and 
reduced ability to proliferate (Appay et al., 2002; Okada et al., 2008; Romero et al., 2007; 
Takata & Takiguchi, 2006; Tomiyama et al., 2002). However, recent experiments in mice 
have also shown that CD8+ and CD4+ memory T cells can rise from effector cells that have 
not irreversibly lost replicative ability (Bannard et al., 2009; Harrington et a l., 2008).
The factors that establish T cell differentiation and generation of memory T cells are 
not fully understood. Memory T cells persist in an antigen-independent manner under the 
influence of homeostatic cytokines, particularly IL-7 and IL-15, with IL-7 enhancing survival 
and IL-15 inducing proliferation (Lanzavecchia & Sallusto, 2005). Signals provided from 
cytokine receptors can influence T cell differentiation. The presence of either IL-2 or IL-15 
during activation has been shown in in vitro studies to influence the migratory properties of 
the memory T cells that are generated. IL-15 preferentially generates Tcm cells, whereas IL-2 
promotes the formation of TEm cells (Weninger et al., 2001).
CD4+ Th cells contribute to CD8+ T cell function, persistence and capacity to control 
a secondary challenge by a pathogen (Janssen et al., 2003; Sun et al., 2004). The precise 
mechanism of CD4+ help remains controversial. It may take place during CD8+ T cell 
priming (Janssen et al., 2003) and seems to be required for the maintenance of memory CD8+ 
T cells (Sun et al., 2004). Absence of CD4+ T cell help during priming results in CD8+ T
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cells that can mediate effector functions upon restimulation, but are unable to mount recall 
responses and undergo TRAIL (TNF related apoptosis inducing ligand)-mediated activation- 
induced cell death upon re-challenge. However, CTL responses against certain viruses can be 
primed without CD4+ T cell help, either to direct infection of APC or inducing inflammatory 
host responses (Janssen et al., 2005). Furthermore, Tregs have been shown to negatively 
influence memory CD8+ T cell proliferation and responsiveness (Murakami et al., 2002; 
Suvas et al., 2003).
1.3. MHC and antigen presentation
The ability of a T cell to specifically recognise foreign antigen on the surface of either 
APCs or infected cell is mediated by the interaction of the TCR with MHC-peptide 
complexes. This refined system permits the immune system to screen both the intracellular 
and extracellular environment of a host for pathogens. The task of displaying cell-associated 
antigens for recognition of T cells is performed by MHC molecules (HLA in humans, H-2 
molecules in mice). There are two main types of MHC molecules, called MHC class I 
molecules and MHC class II molecules.
1.3.1 MHC class I structure and function
1.3.1.1 Structure
MHC class I molecules are able to present endogenous peptides derived from an 
intracellular pathogen to CD8+ T cells. The MHC I molecule is a membrane-bound 
heterodimer consisting of an a  chain associated non-covalently with p2-microglobulin (P2m). 
The a  chain contains 3 extracellular globular domains. The polymorphic a l  and a 2  regions 
form the walls of a cleft on the surface of the molecule, called the peptide binding groove 
(Bjorkman et al., 1987). The a3-dom ain is linked to the cell surface via a transmembrane- 
domain. The a 3  domain interacts with the T cell accessory molecule CD8, whilst the peptide
binding groove is contacted by the antigen-specific TCR (Engelhard, 1994). The ends of the
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peptide binding groove are closed, thereby restricting the length of peptide that can be 
accommodated. MHC class I restricted peptides tend to be between 8 and 11 amino acids in 
length (Rammensee, 1995) (Figure 1.4).
1.3.1.2 Antigen processing and presentation 
Degradation o f cytosolic proteins
MHC class I molecules present peptides that are derived from cytosolic proteins, most 
of which are synthesized in nucleated cells. Antigens in the cytosol may be products of 
viruses or other intracellular microbes. Alternatively, protein antigens that may also be 
produced by mutated or overexpressed genes in tumour cells. The breakdown of intracellular 
proteins that may take place during a viral or bacterial infection or with cancer allows the 
immune system to screen for infected or transformed cells.
In order to produce short peptides that will bind to MHC class I molecules the proteins 
are degraded in the cytoplasm by the ubiquitin-proteasome pathway. Many intracellular 
proteins to be degraded in the cytoplasm are first modified by ubiquitin (Michalek et al.,
1993). Ubiquitination may unfold the target proteins and act as recognition components for 
cytosolic proteasome complexes. Once a protein has been ubiquitinated, it is rapidly degraded 
by the proteasome (Ciechanover, 1994; Pamer & Cresswell, 1998).
Proteasomes are multicatalytic proteases that mediate the majority of cytoplasmic 
protein degradation and have an important role in the generation of MHC class I-associated 
peptides. Ubiquitinated proteins are rapidly degraded by the 26S proteasome complex, which 
is found in the cytoplasm of most cells (Goldberg et al., 2002; Rock & Goldberg, 1999). The 
26S proteasomes contain a barrel-shaped 20S catalytic core particle, which is arranged in four 
stacked rings. The outer two rings consist of seven homologous a-subunits which provide the 
proteasome structure, surrounding a central opening through which the substrates appear to 
enter. The two inner rings are each composed of seven homologous p-subunits which
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surround a central chamber where proteolysis occurs. Three of the p-subunits display 
proteolytic activity (Pamer & Cresswell, 1998).
Exposure of cells to IFNy induces the expression of three additional p-subunits, 
namely LMP2, LMP7 and MECL1 that are preferentially incorporated into newly assembling 
proteasomes in place of their homologous constitutive counterparts. This results in a change 
in the susbstrate specificity of the proteasome, so that peptides produced contain carboxy- 
terminal basic and hydrophobic amino acids, and this presumably enhances the production of 
peptides capable of associating with MHC class I molecules or changes the repertoire of 
peptides presented (Eleuteri et al. , 1997; Fruh et al., 1994). Along with increase of MHC- 
class I expression, this is one mechanism by which IFNy modulates antigen presentation. 
Proteasomes containing the IFN-induced subunits are termed immunoproteasomes, indicating 
their special role in antigen presentation. Immunoproteasomes are constitutively expressed by 
APCs (Eleuteri et al., 1997; Kloetzel, 2004; Macagno et al. , 1999).
It is now evident that degradation of proteins by the proteasome is the key step in the 
generation of most antigenic peptides. Several studies have shown that proteasome inhibitors 
were able to not only block the degradation of most cellular proteins but also block most 
MHC class I antigen presentation of peptides derived from cytosolic proteins (Rock et al.,
1994). Initial studies used peptide aldehydes, for example, to demonstrate inhibition of 
antigen presentation (Harding et al., 1995; Rock et al., 1994). Several other structurally 
unrelated extremely specific proteasome inhibitors, such as lactacystin, also showed a 
reduction of class I antigen presentation (Cerundolo et al., 1997; Craiu et al., 1997).
The inhibitors appear to block the assembly of stable MHC class I molecules, resulting 
in an accumulation of MHC class I continuously bound with TAP in the endoplasmic 
reticulum (ER) due to the lack of proper antigenic peptides. Moreover, this loss of stable 
MHC class I complexes in proteasome-inhibitor cells can be reversed by the addition of 
antigenic peptides (Rock et al., 1994). However, in some reports treatment with proteasome
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inhibitors only partially prevented or even enabled presentation of particular epitopes 
(Morishima et al., 2007; Schwarz et al., 2000; Valmori et al., 1999; Vinitsky et al., 1997). 
One of the explanations could be that in these cases the generation of antigenic peptides or 
their precursors involved proteases other than proteasome (Vinitsky et al., 1997). It could also 
be that proteasomal inhibition may be only partial and the remaining proteasomal activities 
created different peptides that might be better suited for MHC class I binding or that 
proteasomes were destroying epitopes (Schwarz e ta l., 2000).
Proteasomes generate the correct C-terminus of antigenic peptides but it appears that 
some of the resultant peptides are further trimmed in the cytosol, or in the ER by 
aminopeptidases that generate the correct N-terminal sequences of presented epitope. 
Peptidases can also destroy epitopes by trimming peptides and making them too short to bind 
to MHC class I molecules. Some of the peptides escape destruction in the cytosol and bind to 
MHC class I in the ER (Rock et al., 2004).
Peptide translocation into the ER
Peptides generated in the cytosol are transported into the lumen of the ER via TAP. 
TAP is a heterodimer that contains TAP-1 and TAP-2, encoded by genes in the MHC closely 
linked to the LMP2 and LMP7 genes. The TAP protein is located in the ER membrane, where 
it mediates the active, ATP-dependent translocation of peptides with 9-13 residues in length 
from the cytosol into the ER lumen (Pamer & Cresswell, 1998). On the luminal side of the ER 
membrane, the TAP protein acts as scaffold for the final stage of MHC class I assembly, as it 
is noncovalently attached to newly synthesized MHC class I molecules by a linker protein 
called tapasin.
Assembly of MHC class I complexes
Translocated peptides bind to newly assembled MHC class 1 molecules in the ER.
Assembly of MHC class I molecules involves a multistep process in which binding of a
peptide plays an important role. Class I a  chains and P2 m are assembled in the ER, which is
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mediated by the sequential interaction of class I a  chains and p 2 m with a set of ER-resident 
chaperones, namely calnexin, calreticulin and Erp57. These chaperones have a quality control 
function and ensure that misfolded proteins and incomplete MHC complexes do not leave the 
ER (Pamer & Cresswell, 1998). The MHC class I/p 2 m complex, associates with TAP along 
with tapasin, Erp57 and calreticulin to form a peptide loading complex (Farmery et al., 2000). 
Tapasin forms a bridge between MHC class I molecule and TAP, and has been proposed to 
aid an efficient loading of the peptide into the MHC class I binding groove, so that peptides 
are bound with optimum affinity (Williams et al., 2002). Peptide translocation by TAP 
eventually results in the formation of a stable MHC class I-peptide complex, which 
dissociates from the chaperone proteins, and is transported from the ER through the Golgi 
apparatus to the cell surface. MHC class I molecules with bound peptides are structurally 
stable and expressed on the cell surface for recognition by peptide-specific CD8+ T cells 
(Figure 1.5A).
Cross-priming
The cross-priming is a process by which APC such as DCs, can process exogenously 
derived antigen, and present the resulting peptides complexed with HLA class I molecules to 
CD8+ T cells. APC acquire antigen via endocytosis and phagocytosis. There are several 
proposed mechanisms as to how the antigen gains access to the HLA class I pathway. One of 
the major pathways is thought to involve the release of antigen from the phagosomes into the 
cytosol. The antigen is then degraded by the proteasome, and the resulting peptides are 
transported via the TAP complex into the ER where they bind to newly synthesised HLA 
class I molecules (Kovacsovics-Bankowski & Rock, 1995). The second main pathway is 
independent of TAP and proteasome activity. Instead the antigen is processed in the 
phagosome by the cysteine protease cathepsin S (Shen et al., 2004). The resulting peptides 
bind to HLA class I molecules within the endocytic compartment, however the precise 
mechanism through which this occurs is not clear.
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MHC class I 
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MHC class II 
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Figure 1.4 Structure of MHC class I and MHC class II molecules (adaptedfront DeFranco et al.y 
2007). The MHC class I heterodimer consists of an a  chain, non-covalently associated with (32- 
microglobulin (left). The a  chain contains 3 extracellular globular domains ( a l ,  a2  and a3), with the 
polymorphic a l  and a2  regions forming the peptide binding groove. The a  chain also contains a 
transmembrane domain and a cytoplasmic tail. The MHC class II heterodimer consists o f an a  and a (3 
chain (right). These chains both contain two domains ( a l /a 2  and (31/p2), a transmembrane domain 
and a cytoplasmic tail. The a l  and p i domains o f the chains come together to form a polymorphic 
peptide binding groove.
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Figure 1.5 MHC class I and II pathways (adaptedfrom DeFranco et al., 2007). (A) The MHC class I 
pathway presents peptides derived from endogenously generated proteins. The proteins are degraded by 
the proteasome (and in some cases, are further cleaved by aminopeptidases), generating short peptide 
fragments, which can then be transported via the TAP complex into the ER. In the ER, peptide 
fragments associate with the HLA class 1 heterodimer, assisted by several chaperone molecules. The 
MHC class I- peptide complex is then transported to the cell surface, where it is presented to CD8+ T 
cells. (B) The MHC class II pathway predominantly presents peptides derived from an exogenous 
source o f protein. Protein is endocytosed by APC and enters the endocytic pathway, where it progresses 
through increasingly acidic endosomes, finally fusing with a lysosome. The resulting peptide fragments 
are introduced to the HLA class II molecules in the MHC class II compartment (MIIC). Peptide loading 
requires the release o f the CLIP fragment from the MHC class II binding groove, which is facilitated by 
the HLA-DM heterodimer. The MHC class Il-peptide complex is then transported to the cell surface 
where it is presented to CD4+ T cells.
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1.3.2 MHC class II structure and function
1.3.2.1 Structure
MHC class II molecules are able to present exogenous peptides derived from 
extracellular pathogens to CD4+ T cells. The HLA class II molecule consists of an a  and p 
chain. These chains are integral membrane glycoproteins, each consisting of two domains, 
a l / a 2  and p l/p 2 . The a l  and p i domains of the chains come together to form a polymorphic 
peptide binding groove. The a2  and P2 domains link the molecule to cell surface, via a 
transmembrane domain, and add to its overall stability. The p2 segment contains the binding 
sites for CD4 (Engelhard, 1994). The extremities of the binding groove are open, allowing the 
bound peptide to protrude from each end. Therefore, the length of peptide capable of binding 
is far less restricted than for HLA class I, ranging in lengths of 12-25 amino acids 
(Rammensee, 1995), although most commonly identified peptides are 13-17 amino acids in 
length (Rudensky et al. , 1991) (Figure 1.4).
1.3.2.2 Antigen processing and presentation
Uptake o f  extracellular proteins and  processing
MHC class II expression, in contrast with MHC class I molecules, which are
expressed on all nucleated cells, is limited to specific antigen presenting immune cells,
including macrophages, B cells and DCs. Extracellular proteins that are internalised by
specialised APCs are processed in vesicles and displayed by MHC class II molecules. A
protein antigen enters the APC by endocytosis, which includes specific receptor-mediated
endocytosis and non-specific adsorptive endocytosis or phagocytosis. Endocytosed protein is
then delivered into the endocytic pathway, where it progresses through
endosomes/phagosomes (which become increasingly acidic), finally fusing with lysosomes.
The acidic endosome environment activates a number of acid proteases, in particular
cathepsins (Watts, 2001). For efficient proteolysis the antigen must be unfolded. This requires
the breaking of intramolecular disulphide bonds which is catalysed by GILT (IFNy-inducible
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lysosomal thiol reductase) (Phan et al., 2000). This proteolytic pathway produces peptide 
fragments, some of which are capable of binding to the MHC class II molecules.
Synthesis and  trafficking o f  the M H C  class I I  molecule
Newly synthesised MHC class II a  and p chains enter the ER where they form a p  
heterodimers. The newly formed MHC class II heterodimer then interacts with a non- 
polymorphic protein called the invariant chain (Ii). Occupation of the MHC class II peptide 
binding groove with a region of the Ii protein known as the CLIP domain prevents binding of 
ER resident peptides (Romagnoli et al., 1993). The ap -Ii complex are then exported to 
specialised endosomal compartments via the Golgi apparatus.
Within the endocytic vesicle, acid proteases, such as cathepsin S, proteolytically 
cleave the Ii chain, leaving the CLIP domain bound to the MHC class II heterodimer 
(Villadangos et al., 1999). The precise vesicular compartment where peptide loading of the 
MHC class II molecule occurs has not been clearly defined, but is believed to be late in the 
endosomal pathway. It is referred to as the MIIC (MHC class II compartment) (Hiltbold & 
Roche, 2002). The CLIP domain is removed by the action of a molecule called HLA-DM, 
which is also found in the MIIC compartment (Busch et al., 2005). Peptides generated by 
proteolysis of internalized protein antigens are then able to bind to MHC class II molecules. 
MHC class II molecules are stabilised by the bound peptides and these complexes are 
delivered to the surface of the APC for CD4+ T cell recognition (Figure 1.5B).
1.3.3 The HLA genes
The human HLA region is located on the chromosome 6 and extends over 4 x l0 6 base 
pairs of DNA. It can be divided into three major regions. The first contains the HLA class I - 
A, -B,-C,-E, -F and -G genes. The second region contains the HLA class II -DR, -DP and -DQ 
genes, as well as HLA-DM and the genes encoding TAP and low molecular weight proteins 
(immunoproteasome subunits LMP). The class III region is situated between the class I and II
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regions and contains over 75 genes including those encoding several complement proteins. 
HLA genes can be highly polymorphic allowing the presentation of a huge range of potential 
peptide epitopes. There are multiple alleles for each gene, for example, HLA class I have 
2678 known alleles (IMGT/HLA database, 2009). The HLA-A2 is the largest allele family at 
the HLA-A locus. The HLA-A*0201 is frequent in all ethnic groups and in the study 
population carried out by Ellis et al. (2000) showed that it was found in 35% of African- 
Americans and 50% of Caucasians. Because HLA-A2 is so widely present in the human 
population, peptides that bind HLA-A2 are frequently considered for peptide-based vaccines 
(Ellis et al., 2000). In fact, several in vitro studies and clinical trials have used HLA-A2 to 
present melanoma-derived epitopes to CTLs (Clay et al., 1999; Rosenberg & Dudley, 2004; 
Wolfel e t a l ,  1989).
1.4 The T cell receptor (TCR)
1.4.1 TCR structure
The TCR is an antigen-specific membrane-bound molecule present on the surface of 
T cells (Figure 1.6). Between 90 and 99% of peripheral T cells express TCR a p  chains, whilst 
the remaining population expresses TCR y8 chains. The TCR of MHC-restricted CD4+ and 
CD8+ T cells consists of a a  chain and p chain, covalently linked by disulphide bonds. Both 
a  chain and p chain consists of a N-terminal region (which contains a variable (V) and 
constant (C) domain), a transmembrane region and a cytoplasmic tail (Bentley & Mariuzza, 
1996). Each TCR chain is encoded by multiple gene segments that undergo somatic 
rearrangements during early stages of lymphocyte maturation. The constant region is encoded 
by a constant gene (C), whilst the variable domain is encoded by a variable gene (V), a 
joining gene (J), and in the case of p chains, a diversity gene (D). The somatic rearrangement 
of the V-J (a) or V-D-J (p) genes occurs in the thymus. This results in the generation of large 
numbers of T cells expressing diverse TCRs and is referred to as combinatorial diversity.
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Thymic selection narrows the peripheral TCR repertoire, eliminating cells with inept or auto­
reactive receptors (Goldrath & Bevan, 1999).
The constant domain of the TCR chains continues into short hinge regions in which 
cysteine residues form disulfide bonds, which contributes to a link between the two chains. 
The variable domain of both TCR chains contain three hypervariable or complementarity- 
determining regions (CDR1-3) which are involved in the recognition and binding of the 
MHC-peptide complex. The CDR1 and CDR2 regions are responsible for contacting mostly 
with the MHC surface, whilst CDR3 binds mostly to the exposed peptide residues. The CDR3 
regions are the most variable section of the TCR chain, and are the principal determinants of 
specificity (Goldrath & Bevan, 1999). The TCR has an extremely diverse variable region to 
allow it to specifically recognise the vast diversity of antigenic peptides. TCR diversity of an 
individual is estimated to be approximately 106 unique TCRP chain CDR3 sequences (Arstila 
e ta l., 1999).
1.4.2 T  cell activation
Efficient T cell signalling is a necessary event in the activation of T cells and their 
subsequent proliferation. T cells express the CD8 or CD4 coreceptors that bind to non- 
polymorphic regions of MHC class I and II molecules, respectively. These coreceptors act 
synergistically with TCR during antigen recognition to strengthen the adhesion between the T 
cells and the target and to increase the sensitivity of TCR responsiveness (Zamoyska, 1998). 
Upon initial T cell stimulus, a structure is formed around the region of contact between the 
APC and T cell, called the immunological synapse, as a consequence of a reorganisation of T 
cell membrane proteins, which it is thought to further facilitate TCR signalling (Grakoui et 
al., 1999). Components required for TCR signalling congregate at the immunological synapse 
and form supramolecular activation clusters (SMACs). Adhesion molecules such as leukocyte 
function-associated antigen-1 (LFA-1) and CD2 segregate to the peripheral SMAC (p- 
SMAC), surrounding a central cluster (c-SMAC) (Monks et al., 1998).
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Figure 1.6 Structure of the TCR (adapted from Cooper, 2000). The schematic diagram o f the a p  
TCR shows the domains o f a typical TCR specific for a peptide-MHC complex. The TCR is a 
heterodimeric membrane bound molecule consisting o f an a  and p chain which are covalently linked by 
disulphide bonds. The chains consist o f an N-terminal region containing a variable and constant 
domain, a transmembrane region and a cytoplasmic tail. The variable domains are encoded by the 
variable gene (V), the joining gene (J), and in the case o f the P chain the diversity gene (D) (not 
shown). The antigen-recognition site o f the TCR consists o f a flattened region formed by the a  and p 
chain.
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The central SMAC (c-SMAC) includes engaged TCRs, the CD3 complex, CD28 and 
intracellularly the protein tyrosine kinases Lck and Fyn. The p-SMAC ensures that the APC 
and T cell remain together for a sufficient duration to allow signal transduction, providing an 
adhesive anchoring of the T cell to the APC, whereas the c-SMAC contains the necessary 
proteins for TCR signal transduction, forming a protected zone for TCR signalling (Monks et 
al. , 1998).
The TCR recognises antigens, but it is not able to transmit biochemical signals to the 
interior of the cell. The TCR is therefore non-covalently associated with a complex of 
polypeptide chains that make up the CD3 complex (ey and e5 heterodimers), and a 
homodimer called £ chain (Call et al., 2002). These form the TCR complex that transduce 
intracellular signals required to initiate effector functions when the T cell is activated.
In conjunction with signaling through the TCR, signals from accessory molecules 
(costimulatory receptors) are required for full activation of T cells and clonal expansion. The 
costimulatory molecule, CD28, is constitutively expressed by T cells and binds to the 
costimulatory ligands CD80 (B7.1) and CD86 (B7.2), which are expressed by activated 
APCs. CD28-mediated signaling is fundamental for initiating the response of naive T cells. In 
the absence of CD28-B7 interactions, engagement of the TCR alone is not capable of 
activating T cells, and may induce a state of T cell unresponsiveness (Acuto & Michel, 2003; 
Lucas et al., 1995). The necessity for costimulation ensures that naive T cells are activated 
fully by APCs that carry harmful antigens, and not by other bystander cells that express 
harmless foreign substances.
In addition to CD28, other costimulatory molecules, which are expressed by T cells 
once activated, help to sustain or increase costimulatory signals for T cell responses. These 
include CD40L, CD27, ICOS (inducible costimulator) and 4-1BB (CD137) that are expressed 
by activated T cells and bind to counter-molecules expressed on activated APCs. These
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costimulatory molecules provide additional signals that favour T cell activation and 
proliferation (Croft, 2003).
T cells also express inhibitory receptors that are important in regulating the immune 
response. Proteins homologous to CD28 are essential for limiting or terminating T cell 
responses. CTLA-4 is an additional receptor for B7 molecules but delivers an inhibitory 
signal to the activated T cells. CTLA-4 limits production of IL-2 and thereby the proliferative 
response of the T cell (Chen, 2004). Another member of CD28 family is the programmed 
death-1 (PD-1), which is express transiently by activated T cells and can bind to two ligands, 
PD-L1 (constitutively expressed by a range of cells) and PD-L2 (expressed by APCs during 
an inflammatory response). The binding of PD-1 on T cells to its ligands inhibits T cell 
activation and plays a role in maintaining peripheral tolerance (Keir et al., 2008; Okazaki & 
Honjo, 2006).
Peripheral tolerance is induced when mature T cells recognise self-antigens or without 
adequate levels of costimulation that are required for T cell activation in the peripheral tissue. 
This leads to anergy, deletion by apoptosis (activation-induced cell death) or suppression by 
Tregs (see section 1.2.2.2). Anergy is the functional inactivation of T cells. T cells may 
engage inhibitory receptors such as CTLA-4 and PD-1 that block activation and consequently 
induce functional unresponsiveness. Self-antigen recognition by T cells without costimulation 
may also lead to an excess of intracellular proapoptotic proteins or expression of death 
receptors and their ligands, resulting in the apoptotic death of the cells (see section 1.9 
Apoptosis) (Srinivasan & Frauwirth, 2009).
1.5 Tumour Immunity
The immune system plays an essential role in tumourigenesis, which can be associated 
with either the success or failure to protect against tumour development. It is involved in: 
early tumourigenesis, where the immune system can provide surveillance against cancer, thus 
preventing tumour development (e.g. NK and T cells); and also in established tumours, in part
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through tolerance (e.g Tregs). In fact, one of the features that allow malignant tumours to 
grow is the ability of tumour cells to evade or overcome the immune system mechanisms.
Understanding the complex involvement of the immune system in tumourigenesis is 
crucial for the development of cancer immunotherapeutic approaches.
1.5.1 Tumour antigens
The expression of a molecule that is abnormal in appearance, concentration, or 
location, or is expressed at an unusual time during development in a tumour cell, may be 
recognised as a foreign antigen by the immune system. A wide variety of tumour antigens 
have been identified in humans and animal cancers. Two different approaches have been used 
in an attempt to identify T cell epitopes from tumour antigens. The first approach is direct and 
often called genetic immunology, and allowed the identification of the first tumour antigen, 
melanoma antigen genes-1 (MAGE-1) (van der Bruggen et al., 1991). This approach typically 
involves tumour-reactive T cells derived from mixed lymphocyte-tumour cultures, in which T 
cells from a cancer patient are stimulated in vitro with autologous tumour cells. The tumour- 
reactive T cells are used to screen cDNA libraries prepared from autologous tumour cells for 
expression of a potential antigen. Such approach has been most successful in identifying 
melanoma-associated antigens. However, it has been difficult to employ this method for the 
identification of other cancer antigens because it is difficult to isolate and grow tumour cell 
lines from the majority of cancers. Another limitation is the requirement of large numbers of 
long-term stable T cell clones or lines for screening, which frequently cannot be achieved.
An alternative approach has been widely used to overcome these limitations, known as 
a reverse immunology approach. Firstly, a candidate tumour antigen is proposed based on its 
differential expression pattern in cancer. Potential peptide epitopes are predicted from the 
protein sequence using computer-based prediction of peptide:MHC binding. Several 
algorithms have been developed to identify candidate peptides based on their predicted 
binding affinities to MHC, such as BIMAS and SYFPEITHI. Synthetic peptides are then used
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to prime or restimulate T cells in vitro, which allows for the identification of peptides that are 
immunogenic. This is followed by the generation of a T cell line or clone that specifically 
recognises the peptide, then testing of the T cells against tumour cells that naturally express 
the antigen of interest, in effect providing validation of the protein as a tumour antigen. This 
approach is not dependent on the availability of autologous tumour cells, requires isolation of 
fewer lymphocytes from patients when compared to the direct approach, and allows for rapid 
screen of a large number of candidate antigens (Viatte et a l.y 2006). However, the algorithms 
are not completely accurate in predicting peptides, thus there is a risk that the predicted 
peptides are not actually epitopes and T cells generated against those peptides may not kill 
tumour cells.
Tumour antigens can be classified by various specifications. The earliest classification 
consists of two groups based on their patterns of expression: tumour-specific antigens (TSA), 
which are unique to tumour cells but not found in normal cells, and tumour-associated 
antigens (TAA), which can be found in normal cells but their expression in tumour cells is 
aberrant or dysregulated. However, a more comprehensive division of tumour antigens is 
based on their molecular structure and source, which includes products of mutated genes, 
overexpressed or abnormally expressed normal proteins, altered glycolipid and glycoprotein 
antigens, oncofetal antigens, tissue-specific differentiation antigens, and antigens of 
oncogenic viruses (Abbas e ta l . , 2007).
In many tumours, cellular oncogenes or tumour suppressor genes are frequently 
affected by mutations, deletion, chromosomal translocations or viral gene insertion. The 
products of these cellular oncogenes or tumour suppressor genes are required for malignant 
transformation and are synthesized in the cytoplasm of tumour cells. Therefore, this may lead 
to the production of altered peptides from these products by the MHC class 1 processing 
pathway. These altered genes and their peptides are not present in normal cells, thereby 
potential epitopes could be created for T cell recognition. Examples of oncogenes known to
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be prone to having transforming mutations and used to generate potential epitopes are Ras 
(Linard et al., 2002), p53 (Ciemik et al., 1996) and Bcr-Abl (Yotnda et al., 1998). Randomly 
mutated genes whose products are not associated in tumourigenesis may also produce tumour 
antigens.
In several human tumours, the antigens that elicit immune responses appear to be 
normal proteins that are overexpressed, or whose expression is normally limited to a 
particular tissue or stage of development, but is dysregulated in the tumours. Normal cellular 
genes can undergo amplification during malignancy, resulting in a higher level of expression 
by tumour cells when compared to normal cells, for example Her-2, which is normally 
expressed by cardiac tissue but is overexpressed in breast cancer cells (Peoples et al., 1995). 
Overexpression of Her-2 has also been reported in melanoma, ovary, lung, pancreas and 
prostate cancers. Human telomerase reverse transcriptase (hTERT) (Minev et al. , 2000) and 
W ilm ’s Tumour 1 (WT1) (Oka et al., 2004) proteins are also overexpressed proteins and are 
examples of targets for immunotherapy.
Tumour antigens can also be proteins that are overexpressed in cancer cells and 
normally found in a developing fetus, but not in adult tissue. Carcino-embryonic antigen 
(CEA) is an example of an oncofetal antigen. CEA is normally expressed in the liver, 
pancreas and intestines of a human foetus but has been shown to be increased in cancer cells 
found in the colon, pancreas, lung, and breast (Kawashima et al., 1999). Tumour specificity 
can also be conferred by tumour antigens derived from altered glycolipids and glycoproteins. 
Alterations in protein glycosylation are frequent in cancers and are often related with 
progression. Elevated expression of glycolipid and some glycoprotein antigens are 
characteristics of many tumours, and these molecules are often structurally different from 
those expressed in normal cells. These tumour antigens include a variety of gangliosides, 
blood group antigens and mucins. For example, the glycoprotein MUC-1 has been shown to
33
Chapter 1: Introduction
be overexpressed and contain aberrant carbohydrate modifications in breast cancer and 
several other cancers (Brossart et a l., 1999).
Differentiation antigens are molecules present on tumour cells and their normal cell 
counterparts. The best studied differentiation antigens are from melanoma, for example, 
Melan-A/MART-1 (Coulie et al., 1994), gplOO (Kawakami et al., 1995) and tyrosinase 
(Wolfel et al., 1994), which are expressed by melanoma cells as well as normal melanocytes. 
Other solid tumours, such as prostate cancer, also contain proteins that have been described as 
tissue specific differentiation antigens, which include prostate specific membrane antigen 
(PSMA) (Horiguchi et al., 2002). Cancer/testis antigens are a type of antigens that are 
expressed on male germ cells and on a variety of tumours, but not in normal somatic cells. An 
example of which are MAGE (Chaux e ta l., 1999) and NY-ESO-1 (Jager e ta l., 1998).
In malignancies associated with viral infection, virally expressed proteins may also act 
as tumour antigens. Various human cancers have viral associations and are characterized by 
expression of viral gene products, for example, the Epstein-Barr virus (EBV) and human 
papillomavirus (HPV), which are associated with B cell lymphomas and cervical carcinoma, 
respectively (Khanna et al., 1998; Ressing et al., 1995). Because viral peptides are considered 
foreign and exist only in infected cells, it makes viral antigens attractive tumour antigens.
Table 1.1 Types of tumour antigens
Type of Antigen Examples of human tumour antigens
Products of mutated genes Ras (Linard et al., 2002), p53 (Ciemik et al., 1996), Bcr-Abl (Yotndaetal . ,  1998)
Overexpressed normal proteins Her-2 (Peoples et al., 1995), hTERT (Minev etal., 2000), WT1 (Oka et al., 2004)
Differentiation antigens 
(Tissue-specific)
Oncofetal antigens
Melan-A (Coulie et al., 1994), gplOO (Kawakami et al.,
1995), PSMA (Horiguchi etal . ,  2002)
CEA (Kawashimaetal., 1999)
Cancer/Testis antigens MAGE (Chaux etal .,  1999), NY-ESO-1 (Jager et al., 1998)
Altered glycolipid & glycoprotein antigens MUC-1 (Brossart et al., 1999)
Antigens of oncogenic viruses EBV (Khanna et al. , 1998), HPV (Ressing et al. , 1995)
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1.5.2 Immunity to tumours
Both innate and adaptive components play an important role in tumour 
immunosurveillance, which involves the detection and eradication of tumour cells (Dunn et 
al., 2004). Mice lacking expression of the recombinase activating genes (RAG) 1 and 2 have 
provided evidence for the role of lymphocytes in the prevention of tumour development, as 
they are unable to somatically re-arrange their antigen receptors and therefore cannot produce 
a p  T cells, B cells, NKT cells or y6 T cells (Shinkai et al., 1992). These mice have been 
shown in several studies to have a higher incidence of carcinogen induced tumour formation 
and also spontaneous tumour development as they age (model for immunosurveillance) 
(Shankaran et al. , 2001; Smyth et al. , 2001).
These studies collectively suggest several mechanisms for tumour 
immunosurveillance that may be operating simultaneously:
1) Expression of tumour specific markers and pro-inflammatory danger signals: promote the 
immune system to act. Cells of the innate system (NK cells, NKT cells, y5 T cells, 
macrophages and DCs) are recruited to the tumour site. The infiltrating lymphocytes such 
as the NK, NKT or y§ T cells are stimulated to produce IFNy (Dunn et al., 2002).
2) Production of IFNy: In both humans and mice with malignancies, the lack of IFNy 
production leaves the host susceptible to tumour progression. Mice lacking either IFNy, 
STAT-1 (which is a component of the IFNy signalling pathway) or the IFNy receptor have 
a significantly greater incidence of carcinogen induced, spontaneous and genetically 
driven tumour progression (Shankaran et a l., 2001; Street et a l., 2001; Street et a l., 2002).
3) Chemokines and angiogenesis: IFNy also promotes the production of chemokines 
(CXCL10, CXCL9) that can inhibit angiogenesis by blocking the formation of new blood 
vessels within the tumour. The lack of blood supply and the effect of IFNy accelerate 
tumour cell death. Tumor cell debris produced as a result of tumor death is then ingested
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by DCs, followed by the migration of DCs to the draining lymph nodes (Dunn et al., 
2002).
4) Cytotoxicity induced by innate immune cells: The chemokines produced during the 
inflammatory responses recruit more immune cells to the site. The recruited tumour- 
infiltrating NK and macrophages produce IL-12 and IFNy, which kill more cells by 
TRAIL, perforin and reactive oxygen and nitrogen intermediates (Dunn e ta l., 2002).
5) NK cell mediated cytotoxicity: NK cells are capable of killing various types of tumour 
cells, particularly cells that have reduced MHC class I expression. NKG2D is a lectin-type 
activating receptor expressed at the surface of NK cell as well as on y5 T cells. Its ligands 
are MICA/B (MHC-class I polypeptide related sequence A/B), and ULBPs (UL16 binding 
proteins) in humans, and RAE1 (retinoic acid early transcript 1) and H60 in mices. Such 
ligands can be expressed at the surface of infected, stressed or tumour cells (Diefenbach & 
Raulet, 2002). Mice depleted of both NK and NKT cells by using the an ti-N K l.l 
monoclonal antibody or with anti-asialo-GM l, which depletes NK but not NKT cells, 
were more susceptible to MCA-induced tumourigenesis than the wild-type (Smyth et a l., 
2001) .
6) NKT cells: Mice that are injected with NKT cell-activating ligand (a-galactosylceramide) 
can block tumour metatasis, which is mediated by the production of IFNy by NKT cells 
(Hayakawa et al., 2003).
7) v5 T cells: In vivo studies have shown that mice deficient for y5 T cells (TCR y5'/ ) have a 
higher incidence of carcinogen induced tumour formation (Girardi et al., 2003; Girardi et 
al., 2001). It has also been suggested that y8 T cells may also be an important source of 
IFNy during the initial stages of tumour surveillance (Gao et al., 2003).
8) Induction of adaptive immunity: DCs trigger the differentiation of CD4+ T hl cells in 
draining lymph nodes, which in turn helps the development of CD8+T cells. Tumour- 
specific CD4+ and CD8+ T cells then migrate to the tumour site, where CTLs carry out
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the perforin/granzyme-mediated cytolysis of the antigen-bearing tumour cells that remain 
at the site (Dunn et a l ,  2002). In further support of the role of a p  T cells in tumour 
surveillance, mice lacking a p  T cells (TCRp-/-) are more susceptible to carcinogen 
induced tumour formation (Girardi e t a l ,  2003).
9) Induction of cytotoxic effector cells: The ability of the immune system to kill tumour cells 
is a crucial effector function of tumour immunosurveillance, particularly the release of 
perforin which is present in the cytotoxic granules from CD8+ T cells, NKT, NK and y8 T 
cells. In vivo studies showed that mice that are deficient for perforin have an increased 
incidence of carcinogen induced and spontaneous tumour formation (Street et a l ,  2001; 
van den Broek et a l ,  1996).
There are several lines of evidence showing that tumour immunosurveillance exists in 
humans. Individuals with immunodeficiencies have a higher incidence of tumour 
development when compared with immunocompetent individuals. Moreover, transplant 
patients on immunosuppressive therapy are predisposed to developing tumours, especially 
virally induced malignancies, but other tumours with no known viral association can also 
occur, such as melanoma (Buell et a l ,  2005; Swann & Smyth, 2007). More direct evidence 
for tumour surveillance in humans comes from the positive association between the presence 
of infiltrating lymphocytes in a tumour and increased patient survival. A correlation between 
positive prognosis and tumour infiltrating lymphocytes was first observed in patients with 
melanoma, showing that patients with high levels of CD8+ T cell infiltration survive longer 
(Clark et a l ,  1989; Clemente et a l ,  1996). In concurrence with this observation, correlations 
have also been found in patients with other cancers, such as breast, bladder, colorectal, 
prostate and ovarian cancers (Mercader et a l ,  2001; Ropponen et a l ,  1997; Tomsova et a l ,  
2008).
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1.5.3 Tumour escape
It has now become apparent that interaction between the immune system and 
tumourigenesis is dynamic and complex, with the immune system playing a fundamental role 
in shaping tumour development. The tumour may escape elimination and exist in a state of 
equilibrium, where it is chronically maintained by the immune system in a sub-clinically 
observed state (Dunn et al., 2002). One example of tumour equilibrium has been 
demonstrated in transmission of cancer from organ transplant donor to recipients. Two organ 
transplant recipients developed mestastic melanoma, post kidney transplant from the same 
donor. It was found that the kidney donor had been treated for primary melanoma sixteen 
years prior to donation indicating that the tumour had been maintained in a state of 
equilibrium by the immune system of the donor (MacKie et al. , 2003).
However, the genetic instability of a tumour allows it to evolve and consequently 
escape the attention of the immune system. The surviving variant tumour cells acquire 
insensitivity to immunological detection and/or elimination and begin to expand in an 
uncontrolled way. Many malignant tumours have mechanisms that enable them to evade or 
resist host immune responses:
1) Antigen loss: Tumour immunogenicity decreases under selective pressure of a fully 
functional immune system, which could allow selective growth of antigen-loss mutants. 
Tumour cells can lose their antigens by mutation, which could be a loss of the whole 
protein or changes in immunodominant T cell epitopes, and therefore affect their 
recognition by T cells, antigen processing or binding to the MHC (Campoli e ta l., 2002).
2) Alteration of antigen processing and presentation: A mechanism by which tumour cells 
avoid immune detection is by altering or losing molecules involved in the antigen 
processing and presentation pathways, such as TAP and the immunoproteasome subunits 
LMP2 and LMP7 (Seliger et al., 2000). Tumours are able to evade CTL mediated immune 
rejection by downregulation or loss of MHC class I molecules (Campoli et al., 2002).
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3) Tumour unresponsiveness to IFNy: indirectly leads to antigen processing or presentation 
defects due to the lack or abnormal function of the IFNy receptor signalling pathway, and 
consequently failure to upregulate their existing low levels of MHC class 1 (Kaplan et al., 
1998).
4) Immunosuppressive cytokines & Trees: IL-10 and TGF-p can act in an autocrine fashion 
to directly facilitate tumour growth and also alter or inhibit an immune response, directly 
or indirectly by activating Treg cells (Chen et a l ,  2005; Kawamura et al., 2002). Tregs 
can suppress anti-tumour CTL responses and their presence at the site of tumour 
development is associated with poor survival of cancer patients (see section 1.2.2.2).
5) Escape apoptosis: tumour cells express molecules that are able to prevent cell death, e.g. 
anti-apoptotic proteins survivin and BCL-Xl (Dohi et al., 2004; Hinz et al., 2000).
6) Resistance to cytotoxic pathways: by mutations in the gene encoding Fas, or mutations in 
the gene encoding TRAIL (Shin et al., 2001; Wohlfart et al., 2004). Upregulation of FasL 
by the tumour cells can directly affect T cell responses, as FasL engagement of Fas on T 
cell can induce T cell death.
7) Tolerogenic environment: Tumour cells may suppress the induction of proinflammatory 
danger signals, which lead to impaired DC differentiation, maturation and function. This 
in turn renders the T cells that engage these DCs to be anergized rather than activated. The 
tumour environment may promote the development and recruitment of suppressive 
immune cells, e.g. IL-13-producing NKT cells, and Tregs (Terabe & Berzofsky, 2004). 
Tumour instructed immature myeloid cells can overproduce nitric oxide or arginase-1, 
which can inhibit T cell function. Some tumours can also overproduce inhibitors of T cells 
function such as IDO (indoleamine 2,3-dioxygenase and galectin-1) (Serafini et al., 2006).
Taking these observations together, it is evident that both innate and adaptive
immunity participate not only in the protection the host from tumour development but also in
shaping or editing the immunogenicity of tumours that may ultimately appear. A term known
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as cancer immunoediting has been proposed to encompass tumour surveillance (elimination), 
tumour equilibrium and escape (Dunn et al., 2002)
1.6 Tumour immunotherapy
There are currently several conventional treatment strategies to tackle a developing
tumour, including surgery, radiotherapy and chemotherapy. These treatments have increased
the overall survival rate of cancer patients. For example, the use of chemotherapy following
surgery reduces the risk of death from operable pancreatic cancer by around 30% (Cancer
Research UK). The first step in cancer treatment is often surgery, which involves removing
the primary tumour and often the surrounding tissue. Surgery is obviously not an option when
the malignancy is diffuse, such as leukaemias, nor when the tumour has metastasised to
multiple sites throughout the body.
Conventional radiotherapy and/or chemotherapy are normally implemented after
surgery was performed or ruled out. Both therapies exploit the continuous proliferative
capacity of tumour cells by targeting rapidly dividing cells, and therefore this enables the
tumour cells to be targeted over resting cells that undergo normal rounds of proliferation.
However, these therapies may also have harmful short and long term side effects that often
affect the quality of life of the cancer patient. The side effects, such as nausea, vomiting and
loss of ability to fight infection, arise because radiation and many chemotherapeutic drugs can
also harm normal, rapidly dividing cells. The effectiveness of chemotherapy is often limited
by toxicity to other tissues in the body. Accumulation of the chemotherapeutic drugs and their
metabolites can occur in the liver and kidney, leading to hepatic and nephritic toxicity.
Unfortunately, the high doses of radiation and chemotherapeutic drugs that are applied may
encourage tumour cells to become resistant to these treatments (Mak & Saunders, 2006).
Because of the inefficiencies, tumour resistance, and side effects associated with
conventional therapies, the treatment of cancer still remains challenging. For these reasons,
novel treatments used as an alternative, or in combination with conventional therapies are
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required. There is a great interest in developing approaches that harness the immune system 
or its components to arbitrate tumour protection and regression. The major strategies for 
cancer immunotherapy strive to provide anti-tumour effectors to patients, actively immunize 
patients against their tumours, and stimulate the patients’ own anti-tumour immune responses. 
There are two broad classes of immunotherapies: active and passive immunotherapy. Passive 
immunotherapy involves adoptive transfer of ex vivo activated immune cells, tumour-specific 
antibodies or immunomodulators (cytokines), thus conferring anti-tumour immunity to a 
tumour-bearing host. Conversely, active immunotherapy is designed to elicit or augment an 
anti-tumour response within a tumour-bearing host in order to mediate tumour regression 
(Rescigno et al. , 2007).
1.6.1 Monoclonal antibodies
Monoclonal antibody therapy has proven to be one of the most successful forms of 
immunotherapy for a variety of haematologic malignancies and solid tumours. Several 
monoclonal antibodies that target tumour antigens, such as tumour growth factors, are 
clinically approved for tumour treatment, with less toxicity than conventional therapy. Their 
effects are exerted by mechanisms which include antibody dependent cellular cytotoxicity 
(ADCC), activation of complement, functional interference of pathways essential for tumour 
growth, and recruitment of other immune effector cells to mediate lysis (King et a l , 2008).
Successful therapy has been seen with monoclonal antibodies that bind to surface
proteins that are highly expressed on hematologic malignancies, which include, for example,
CD20 in non-Hodgkin’s lymphoma (rituximab) (Maloney, 2005), CD52 in chronic
lymphocytic leukaemia (CLL) (alemtuzumab) (Keating et al. , 2002), and CD33 in acute
myelogenous leukaemia (AML) (gemtuzumab) (Bross et al., 2001). Other monoclonal
antibodies have been approved for the treatment of solid tumours, which include monoclonal
antibodies directed against Her-2 (trastuzumab) for breast cancer (Hudis, 2007), vascular
endothelial growth factor (VEGF) (bevacizumab) for colorectal and lung cancer (Ferrara et
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al., 2004), and epidermal growth factor receptors (EGFR) (cetuximab) for colorectal cancer 
(Galizia et al., 2007). Some monoclonal antibodies may also be conjugated with toxins or 
with radioisotypes so that the antibodies deliver these toxic agents specifically to the tumour 
cells. The immunoconjugate kills the tumour cells because the toxin or radioisotype is 
internalised following antibody binding to the tumour cell (Dougan & Dranoff, 2009).
The potential of use monoclonal antibodies with immune-modulating activity in 
humans is being evaluated for cancer treatment. These include antibodies that block CTLA-4, 
which plays an important role in regulating immune responses by reducing the proliferation of 
activated T cells. However, a common complication of the treatment using anti-CTLA-4 
antibodies in clinical trials has been the development of autoimmune reactions (O'Day et al.,
2007). Another example is the negative immunoregulatory receptor PD-1, which is currently 
been evaluated in clinical trials as an antibody target for immunotherapy (Hirano et al., 2005).
Antibodies against CD28 are also known to potentiate anti-tumour immunity. Some 
anti-CD28 antibodies, known as superagonists, bind to a particular epitope in CD28 and can 
induce T cell proliferation in absence of antigen recognition. These superagonist anti-CD28 
antibodies were evaluated in clinical trials (Suntharalingam et al., 2006). However, a phase I 
clinical trial with agonist antibodies against CD28 (TGN1412) resulted in a dramatic clinical 
toxicity in a cohort of normal volunteers. This led to over activation of T cells and a violent 
cytokine storm (substantial increases in the concentration of several inflammatory cytokines), 
precipitating the release of endogenous molecules affecting other cells. Each of the volunteers 
receiving the first dose required hospitalization for cytokine-release syndrome, including 
severe cases of multiorgan failure (Suntharalingam et al., 2006). The outcome of this trial 
clearly indicates that caution must be taken with the clinical development of other 
immunostimulatory antibodies and very careful preclinical and clinical testing in humans is 
required to minimise toxicity risks.
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An alternative approach to direct the cytotoxic potential of effector cells has been the 
use of bispecific T cell engagers (BiTE) antibodies. BiTEs are based on single-chain 
antibodies, recognising with one arm a cell surface protein on tumour cells (like a 
conventional monoclonal antibody) and with the other arm, recognising the CD3 complex 
associated with TCR, leading to the formation of synapse and consequently lysis of tumour 
cell without requirement of TCR or peptide:MHC complex. Clinical activity of a BiTE 
antibody known as blinatumomab, with dual specificity for CD19 and CD3 has been 
evaluated in non-Hodgkin’s lymphoma patients. All seven patients treated with low doses of 
blinatumomab experienced tumour regression. A phase II trial is currently investigating the 
activity of this BiTE antibody in acute lymphoblastic leukaemia (Bargou et al., 2008). The 
activity has a passive effect and will be ceased once the reagent is removed from the body and 
involves effector cells that have no specificity for the target.
The efficiency of monoclonal antibody application is dependent on the presence of a 
tumour antigen on the cell surface that can be bound successful by an antibody, the extent to 
which antibodies distribute once administered, and the expression profile of the target antigen. 
It has a number of limitations, which include requirement of repeated antibody infusions 
because of their half-life and clearance from circulation; a memory response is not generated 
with this type of therapy; also antibodies can only recognise specific proteins presented on the 
surface. As intracellular proteins are processed into large numbers of peptides and expressed 
on the cell surface in association with MHC (see section 1.3), these peptides-MHC complexes 
can then be recognised by T cells, and therefore T cell based immunotherapy may target a 
wider range of intracellular tumour antigens (King et al., 2008).
1.6.2 Cytokines
Many cytokines have the potential to induce nonspecific inflammatory responses,
which by themselves may have anti-tumour reactivity (see section 1.5.2). Cytokine based
tumour therapies involve the systemic transfer of purified cytokines to tumour-bearing
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patients, in order to promote an anti-tumour response. IL-2 promotes the expansion of 
tumour-specific T ceils and counteracts the effects of immunosuppressive cytokines. 
However, IL-2 has only been effective in approximately 10-20% of patients with melanoma 
and renal cell carcinoma (Atkins et al., 1999; Rosenberg et al., 1994). A limitation of 
cytokine based therapies is the toxic side effects of administering high systemic 
concentrations of cytokine that are necessary to induce an anti-tumour response. In order to 
overcome this problem, approaches have been generated to deliver cytokines to the site of 
tumour development in a sustained manner, instead of systemic administration (Veelken et 
al., 1997). However, the generation of cytokine-expressing cells can be time-consuming and 
often delays treatment, allowing the tumour to advance.
1.6.3 Prophylactic and Therapeutic Vaccines
Vaccine administration to combat tumourigenesis presents an attractive aim of tumour 
immunotherapy. With respect to cancer prevention, the only prophylactic vaccines currently 
available are those that prevent infections by pathogens that have the potential to induce 
cancer development. The most common pathogen cancer vaccines are those directed against 
the oncogenic viruses. The ongoing vaccination program against hepatitis B virus has resulted 
in a reduction of hepatocellular carcinoma (Chang et al., 2000). More recently, newly 
developed HPV vaccines promise to reduce the incidence of cancers associated with HPV 
infections. Indeed, these vaccines have been shown to be clinically successful for protection 
from infection and cervical diseases associated with HPV16 and/or HPV18 types (Garland et 
al., 2007; Kahn & Burk, 2007). In addition, a vaccine against Helicobacter pylori is under 
development, with the purpose of reducing the incidence of gastric lymphomas and 
carcinomas (W onge ta l., 2004).
Development of prophylactic vaccines for tumour with non-pathogen aetiology would
be ideal but has yet to be accomplished. Therapeutic vaccines are aimed to activate the
patient’s own immune system to combat already established cancer. They provide an
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advantage over antibody therapy that, if successful, can induce long-lasting immunological 
memory that can protect against tumour recurrence. Although various attempts are being 
made to generate therapeutic vaccines against various cancers, encouraging results have only 
been seen in a small number of clinical trials, and there is currently no FDA (Food and Drug 
Admnistration) approved therapeutic vaccine. Various approaches for generating therapeutic 
immune responses to tumours have been endeavoured, including antigen-specific vaccines 
(peptide, protein, DNA), whole tumour cell vaccines, heat shock protein (HSP) vaccines, and 
DC vaccines (Dougan & Dranoff, 2009; Itoh et al., 2009).
Peptide based vaccines involves the transfer of either peptide or the protein from 
which the antigenic peptides are derived. A concern when using a whole protein is the 
competition between the desired and already existing peptides for MHC binding. Another 
concern is the condition of in vivo processing by either the standard proteasome or 
immunoproteasome, which if absent may prevent the generation of the desired peptides. 
Vaccination using peptide or recombinant protein along with adjuvants has been conducted in 
several trials involving patients with metastatic melanoma, eosophogeal, colon, breast and 
prostate cancer (Dougan & Dranoff, 2009; Itoh e ta l., 2009).
Most clinical research to date on humans using tumour antigens has been done with 
melanoma and cancer-testis antigens, as these are usually highly immunogenic and therefore 
easier to mount an antigen-specific response. For example, vaccination of melanoma patients 
with peptides derived from tyrosinase, gplOO or MelanA/MART-1 antigens have induced 
immune responses against these peptides, with tumour regression occurring in all three cases 
(Jager et al., 1996). NY-ESO-1-based vaccines have also been examined in multiple trials for 
a variety of cancers, including melanoma, ovarian carcinoma and non-small cell lung cancer 
(Gnjatic et al., 2006). Peptide-specific immune responses have also been observed in 92% 
patients with breast cancer received Her-2 vaccine plus GM-CSF (Disis et al., 2002), and in
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55% of prostate cancer patients vaccinated with prostate-specific antigen (PSA) (Perambakam 
et al., 2006).
The results from clinical trials of peptide vaccines suggest that few cancer patients 
show improved clinical benefits that correlate with peptide-specific immune responses. 
Alternatives to transferring the tumour antigen alone have been considered to increase the 
likelihood of generating an anti-tumour response, such as the use of whole tumours, HSPs, 
DCs, or cytokines as adjuvants (Dougan & Dranoff, 2009; Itoh et al., 2009) .
An approach to stimulate immune responses against tumours is to vaccinate patients 
with autologous or allogeneic tumour cells, which can be genetically modified and/or 
administered in the presence of adjuvant. Clinical responses have been shown in several 
initial clinical studies but these studies failed to show significant efficacy in the randomized 
phase III trials (Itoh et al., 2009). For example, treatment with a combination of allogeneic 
melanoma cells with BCG (Canvaxin trial) showed efficacy in the early stages of clinical 
development (5 years overall survival: 49% treated patients vs 37% controls), but further 
evaluation of this approach in phase III trials showed no significant difference between 
patients receiving this treatment compared with the controls (Faries & Morton, 2005). Other 
treatments involving the immunisation of prostate cancer patients with a vaccine that consists 
of two prostate cancer lines genetically modified to secrete GM-CSF (GVAX) did not 
succeed in showing clinical benefits in the phase III and the trials were discontinued (Itoh et 
al., 2009; Small e ta l., 2007).
A major drawback to whole tumour cell vaccines is the weak antigen presentation and 
therefore poor ability to stimulate a potent immune response. Tumour cells, such as allogeneic 
cells, might not be an appropriate source of a therapeutic vaccine for all cancer patients. 
These cells may induce immune response to irrelevant antigens that can competitively 
suppress anti-tumour responses. Other disadvantages of this approach are the cost and time to
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grow autologous tumour cells from a patient, which sometimes are impossible to isolate in 
sufficient quantity to provide adequate source material (Itoh e ta l ,  2009).
Tumour-derived HSPs have been evaluated as cancer vaccine adjuvants for various 
types of cancer. HSPs are not antigen themselves but can promote immune responses. They 
can act as chaperones for peptides between necrotic cells and APCs, therefore contributing to 
the process of T cell cross-priming. HSPs are not particularly specific for peptides and 
proteins they chaperone, allowing both known purified peptides or a mixture of peptides from 
tumour cell lysates to be combined with HSPs prior to transfer. A major disadvantage of this 
approach is the requirement of personalized vaccine preparation for each patient. Although 
there are contradictory views about the efficacy of HSP-based vaccines, a vaccine using HSP 
as adjuvant was recently approved in Russia for the treatment of patients with kidney cancer 
at intermediate risk for disease recurrence (Itoh e ta l., 2009; Wood e ta l., 2008).
DCs are potent inducers of adaptive immunity, driving the activation of T cells and 
therefore they are an attractive approach for tumour vaccination. Their ex vivo activation may 
also overcome the lack of in vivo inflammatory signals that can leave DCs in an immature 
state (see section 1.5.4). The delivery of antigen to DCs may be tumour cell lysates, antigenic 
peptides or a mixture of long overlapping peptides, exposure to whole recombinant proteins, 
transfection of antigen-encoding DNA or RNA, and fusion with irradiated tumour cells 
(Dougan & Dranoff, 2009; Itoh et al., 2009). Although a number of DC cancer vaccine trials 
have shown some encouraging preliminary results, only one has thus far succeeded in 
showing clinical benefits in phase III trials. Results from a phase III clinical trial 
demonstrated for the first time that a cancer vaccine known as Sipuleucel-T/Provenge, which 
consisted of autologous DCs loaded ex vivo with PAP/GM-CSF, can significantly prolong 
overall survival by 4.1 months in patients with advanced prostate cancer (Higano eta l., 2009). 
It is expected that Sipuleucel-T will be approved by the FDA by 2010.
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Apart from the success of this trial, DC-based vaccines for other cancers have not 
been successful in showing clinical benefits. This is a personalized treatment, and it is 
difficult and expensive to grow large number of autologous DCs from all the patients. 
Inconsistency in trials results may be associated with a number of variables, such as the type 
and quality of DCs that vary with method of generation and maturation, choice of tumour 
antigen target and the form it takes, choice of adjuvant and frequency of vaccination. 
Collectively, the results from clinical trials suggest that DCs as vehicle for therapeutic cancer 
vaccination could hold the promise to circumvent some of the strategies tumours use to evade 
the immune system, but there are still technical issues to be resolved before the development 
of an effective therapeutic DC-based vaccine.
Despite the encouraging initial results observed in several clinical trials using different 
approaches, unfortunately clinical efficacy of cancer vaccines has so far been disappointing. 
According to response evaluation criteria in solid tumours (RECIST), only less than 5% 
overall objective response rates were observed in patients with metastatic cancer who 
underwent different types of active immunotherapy (Itoh et al., 2009; Rosenberg et al., 2004). 
Overall, there are significant hurdles to be overcome before therapeutic cancer vaccines are to 
be considered effective in mediating cancer regression.
Given that established tumours clearly subvert the immune system, it is possible that 
single components therapies such as vaccine-only strategies are unlikely to ever be effective. 
Inadequate numbers or low avidity of T cells, failure of tumour to activate lymphocytes, 
tolerance, suppressor functions of tumour cells or the immune system itself are among the 
factors that prevent an effective anti-tumour T cell response and clinical responses upon 
active vaccination. Therefore, elimination of both tumour and lymphocyte-mediated 
immunosuppressive mechanisms without affecting anti-tumour effector cells seems to be a 
promising way to improve current therapy. Indeed, approaches that target multiple parts of
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immunity and integrate elements that target tumour escape simultaneously are more likely to 
result in clinical success (Andersen et a l., 2008; Copier e ta l., 2009).
Combination of anti-cancer vaccination with other immunotherapeutic agents, or with 
conventional therapy are been evaluated for treatment of cancer. Various studies are focussed 
on combining vaccines with cytokines such as IL-2 and GM-CSF, with immunomodulatory 
antibodies such as those against CTLA-4, PD-1, or specifically blocking secreted 
immunosuppressive molecules such as TGF-p, IL-10 as well as eliminating Treg cells may 
also be required (Andersen et al., 2008; Copier et al., 2009; Dougan & Dranoff, 2009). 
Further investigation of these manipulations in conjunction with vaccination may lead to a 
greater magnitude of immunological and clinical responses, and ultimately improve the 
efficacy of current immunotherapy.
1.6.4 Adoptive cell transfer
In attempts to overcome the obstacles associated with therapeutic vaccination, 
alternative T cell immunotherapy strategies have been considered. One strategy that carries 
great potential for generation of productive tumour immunity is adoptive cell transfer (ACT). 
ACT therapy relies on the in vitro expansion of T cells with appropriate specificity and 
avidity to mediate tumour regression upon reintroduction to a cancer patient. T cells can be 
obtained from various sites, including the peripheral blood, malignant effusions, lymph nodes 
and tumour biopsies (Rosenberg et a l., 2008).
Multiple clinical trials have been performed to establish the efficacy of using adoptive
T cell therapy. ACT therapy has been particularly successful with EBV associated
malignancies. The transfer of EBV specific allogeneic or autologous PBMC or T cell lines
has shown to be efficient for the prevention and treatment of EBV-related diseases. These
malignancies can develop in patients receiving immunosuppressed drugs after organ or bone
marrow transplantation (Khanna et al., 1999; Rooney et al., 1998). The effectiveness of ACT
directed against EBV has shown the feasibility of developing ACT approaches for solid
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cancers, by demonstrating that administration of an anti-tumour T cell with high avidity and 
targeting a highly expressed antigen can indeed result in cancer regression (June, 2007).
ACT has achieved clinical responses in a small number of patients with metastatic 
melanoma. In one trial, CD8+ T cells specific for MelanA/MART-1 were purified from the 
PBMC of patients with metastatic melanoma, expanded ex vivo in the presence of IL-2 and 
reintroduced to patients. Eight out of twenty patients exhibited minor, mixed or stable anti­
tumour responses (Yee et al., 2002). Encouragingly, this resulted in T cell infiltration into 
both the skin and tumour tissue, but there was a selective outgrowth of tumours lacking 
expression of MART-1 (Yee et al., 2000). Similarly, in another trial using T cells specific for 
MART-1, CTLs engrafted successfully, but disappointingly selected for tumours that did not 
express the antigen (Mackensen et al., 2006). These results highlight the limitation of 
transferring monoclonal tumour specific CD8+ T cells, since tumour cells that either lack 
expression of the antigen or evolve under the selective pressure of the T cells to not express 
the antigen, are not affected and continue to develop. It is possible that the emergence of 
antigen escape variants can be overcome by, for example, infusing CTL clones with multiple 
antigenic specificities (June, 2007).
Another strategy of ACT is the use of CD8+ tumour infiltrating lymphocytes (TILs), 
which are isolated from tumour biopsy specimens. The tumour-specific T cells are selected ex 
vivo using IL-2 and various cell culture methods (June, 2007). TILs might have an advantage 
over CD8+ T cells purified from blood since the T cell population in this context may have 
higher frequency of tumour-reactive cells and is most likely to be polyclonal for the antigens 
expressed by the tumour and have already express homing receptors.
In human clinical trials, the transfer of TILs to patients with metastatic melanoma or 
renal cancer has proven to be unsuccessful in reaching objective clinical responses (Dreno et 
al., 2002; Figlin et al., 1999). However, in effort to improve clinical outcome of ACT therapy 
trials involving TILs, patients with metastatic melanoma were conditioned with chemotherapy
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(cyclophosphamide and fludarabine), which have an immunosuppressive effect but no anti­
melanoma activity, prior to the transfer of the expanded lymphocyte population (Dudley et 
a l ,  2002; Dudley et al., 2005). In a clinical trial of thirteen patients, there was an overall 50% 
objective response rate (Dudley et a l ,  2002). Importantly, prolonged engraftment of TILs was 
observed in patients who were lymphodepleted by nonmyeloablative chemotherapy, and this 
was correlated with the clinical responses (Dudley et al., 2005; Rosenberg & Dudley, 2004).
In two additional sequential trials of ACT with autologous TILs in patients with 
metastatic melanoma, host immunodepletion (consisting of chemotherapy and radiotherapy) 
followed by TILs transfer and IL-2 resulted in an objective response rate of 72% (Dudley et 
a l ,  2008). These findings indicate that combination of chemotherapy and radiotherapy prior 
to cell transfer would help improve the therapeutic results of ACT.
It seems important to lymphodeplete patients, prior to adoptive transfer of cells, in 
order for those cells to persist in vivo. This conditioning regimen may augment the anti­
tumour efficacy of ACT therapy by increasing levels homeostatic cytokines (such as IL-7 and 
IL-15), reducing competition with endogenous T cells, clearing host suppressor cells like 
Tregs, immunosuppressive cytokines required for tumour growth and improving the 
immunogenicity of the tumours, and by these means allow the transferred T cells to function 
in an optimal way and mediate tumour regression (Wrzesinski & Restifo, 2005) .
Current limitations that may preclude the efficacy of using TILs as a model therapy 
include the difficulty of obtaining cells from tumour biopsies of all patients and cancers, and 
also the time it takes to generate sufficient numbers to infuse back to patients and the 
possibility of autoimmunity and infection. Several areas need to be addressed in order to 
accomplish objective clinical responses during ACT therapy using CD8+ T cells. In addition 
to lymphodepletion prior to transfer, the ability to acquire and generate tumour reactive CD8+ 
T cells is crucial. The CD8+ T cells used for ACT therapy are required to be of correct 
specificity and contain sufficiently avid TCRs and be in optimal stage of differentiation.
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Moreover, CD4+ T cell help or associated cytokines, such as IL-2, IL15, and populations of 
CD8+ T cells with multiple specificities may also improve the effectiveness of ACT therapies 
(June, 2007).
The genetic modification of T cells used in ACT approaches may improve the anti­
tumour capabilities of the T cells and most importantly the clinical outcome of such therapies. 
It may circumvent obstacles associated with the absence of CD8+ T cells with the required 
TCR specificity and avidity for antigen clearance, and also the difficulty in obtaining CD8+ T 
cells from certain types of tumours. T cells harvested from patients can be engineered to 
express the a  and p chains of TCRs with known avidity and antigen specificity for tumour 
recognition (Dougan & Dranoff, 2009). A goal of such ACT therapy is to establish a 
persistent memory response to prevent recurrence of tumour.
Clinical trials have been performed using adoptively transferred CD8+ T cells that 
were transduced with genes encoding a TCR with specificity for a MART-1 peptide. Patients 
were also lymphodepleted prior to ACT. The T cells persisted in vivo, trafficked to the site of 
tumour development and mediated tumour regression in 2 out of 15 patients (Morgan et al., 
2006). This study demonstrated that retroviral TCR gene transfer can be used to provide anti­
tumour specificity, and that T cells can engraft in patients and persist at high levels. However, 
TCR gene therapy using retrovirus may carry potential risk of retroviral insertional 
mutagenesis that may lead to malignancies in some circumstances. A further potential risk of 
TCR gene transfer may be autoimmunity. The possibility of novel TCR combinations 
encompassing the introduced and endogenous a  and P chains could generate mixed TCR 
dimers with new specificities, and consequently recognise self antigens with high affinity and 
be autoreactive. The development of strategies that could suppress endogenous TCR 
expression or ensure that the exogenous TCR chains preferentially pair could potentially 
eliminate these concerns. Very few engineered TCRs are available and only single epitopes 
can be used with this strategy, therefore limiting the possibility to recognise tumours, as they
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might not express that epitope. Another limitation of this approach is that TCR recognition of 
an antigen is MHC restricted and thus the engineered T cells can only be used in patients with 
matched MHC alleles (K inge ta l., 2008).
MHC restriction can be bypassed by introducing chimeric antigen receptors, termed T- 
bodies, to CD8+ T cells. T-bodies consist of an external antibody-based domain, that confers 
specificity and the cytosolic domains containing the signal components of the TCR complex. 
These T-bodies can directly bind tumour antigens, leading to T cell activation, and provide a 
T cell with antigen specificity in a non-MHC class I restricted manner. Transfer of T cells 
expressing T bodies has been tested in renal cell carcinoma, neuroblastoma and ovarian 
carcinoma (Dougan & Dranoff, 2009). Although this approach seems safe and T-bodies are 
well tolerated, severe autoimmune hepatitis developed in renal cell carcinoma patients 
(Lamers et al., 2006). This approach requires further optimisation with regards to the 
persistence of the transferred cells, expression of the transgene, the correct avidity of the T- 
bodies and the identification of suitable antigens in order to circumvent some adverse effects 
due to the reactivity of transduced T cells against the target antigen expressed on normal 
tissue (June, 2007) .
On the whole, the results of ACT therapy appear promising by showing potent anti­
tumour T cell activity, particularly in melanoma patients. However, as with other 
immunotherapy strategies, adoptive T cell therapy alone may not be sufficient to confer 
clinically significant responses in most cancer patients. Combination of therapies, such as 
anti-cancer vaccination to increase the frequency of tumour-reactive T cells prior, or 
immediately after, ACT therapy may be another mechanism to boost immune and clinical 
responses, and thus improve overall treatment effectiveness of immunotherapy.
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1.7 Prostate cancer (PCa)
PCa is the most common male cancer in the UK, with almost 35,000 newly diagnosed 
cases and 10000 deaths in 2005 (Cancer Research UK). Although radical prostatectomy or 
radiation therapy is successful for patients diagnosed with localised PCa, tumour clearance is 
not always achieved and 20-40% of the patients develop recurrent disease (Coen et al., 2002; 
Roehl et a l ,  2004).
Hormone therapy can also be used in combination with radiotherapy for localised 
disease, and is widely used for recurrent disease or control of metastatic disease. Hormone 
therapies attempt to suppress the growth of the cancer by reducing androgen levels, which 
result in rapid and massive apoptosis of tumour cells. This androgen deprivation increases the 
overall median survival time of the patients, with almost all patients with advanced PCa 
responding initially to this therapy, but most patients eventually develop androgen- 
independent PCa. Chemotherapy is usually the next treatment option for hormone-refractory 
disease, but it only provides short-term control of the cancer. Therefore, novel treatment 
strategies that prolong the hormone-sensitive stage and that are valuable for hormone- 
refractory disease are required.
The short-term delay in disease development during androgen-dependent state 
provides opportunity in these patients to study additional adjuvant treatments. Significant T 
cell infiltration of prostate tissues can be observed after androgen deprivation treatment 
(Mercader et al., 2001), and reversal of tolerance in prostate specific T cells can also be 
shown with androgen withdrawal in mouse models (Drake et al., 2005). Androgen 
deprivation treatment and its resulting tumour cell apoptosis provide potentially beneficial 
immunological consequences, and thus might have significant implications for the 
development of immunotherapeutic strategies to treat PCa.
Immunotherapeutic strategies involving tumour-specific CTL are an attractive option 
for PCa treatment. Given that the prostate is a non-essential organ, immune destruction of
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normal prostate cells is likely to have fewer side effects than conventional treatments. Several 
candidate antigens that are typically expressed in prostate tissue have been proposed for PCa 
immunotherapy, including PSA (Correale et al., 1997), PSMA (Horiguchi et al., 2002), 
prostatic acid phosphatase (PAP) (Machlenkin et al., 2005), prostate stem cell antigen 
(PSCA) (Kiessling et al., 2002), and prostein (Kiessling et al., 2004). Other potential tumour 
antigens that are overexpressed in various tumours, including PCa, have also been suggested, 
which comprise six-transmembrane epithelial antigen of the prostate (STEAP) (Rodeberg et 
al., 2005), parathyroid hormone-related protein (PTH-rp) (Yao et al., 2004), hTERT 
(Hernandez et al., 2002), survivin (Schmitz et al., 2000), Her-2, and EGFR (Kiessling et al.,
2008).
Subsequent to identification of these potential targets for tumour-reactive T cells, 
several clinical trials have been conducted to determine immunological and clinical responses. 
In clinical studies, vaccination with peptides, proteins, DNA, tumour cells, or tumour antigen- 
pulsed DCs indicate that these treatments were feasible and safe, but only few induced 
immunological and clinical responses in patients with PCa (Kiessling et al., 2008). A 
promising approach in PCa immunotherapy is vaccination of patients with DCs. Results from 
phase III clinical trial, in which metastatic hormone-refractory PCa patients were vaccinated 
with sipuleucel-T (DCs loaded with PAP/GM-CSF) demonstrated an increase in the overall 
survival by 4.1 months (Higano et al., 2009).
Despite the mounting evidence of the impact of immunotherapy on PCa, the clinical 
efficacy for most of patients with mestatatic PCa is still inadequate. It seems unlikely that 
single immunotherapy will produce long-term remissions in most of patients with advanced 
PCa. Thus, further investigation of current treatment modalities, with appropriate design and 
end points, is required to improve the response rates and the duration of response. This may 
be achieved by combining immunotherapy with other standard treatments, including
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radiation, hormone therapy or chemotherapy, or even combining multi immunotherapy agents 
(Drake, 2008).
1.8 B-cell chronic lymphocytic leukaemia (B-CLL/CLL)
CLL is the most common type of leukaemia in the Western world, representing 22-
30% of all leukaemia cases, with a worldwide incidence between 1 and 5.5 / 100,000 people.
The incidence of CLL increases considerably with age and is far more frequent in the elderly
(Redaelli et al., 2004). CLL is a B cell malignancy characterised by an accumulation of
neoplastic B cells in the blood, bone marrow and peripheral lymphoid organs. The excess of
neoplastic B cells is caused mainly by a failure of apoptosis rather than increased cell
proliferation. CLL cells derive from antigen-experienced mature B lymphocytes that have
functional competence and escape death due to interactions with factors produced by other
cells, including T cells. This disease is defined by a unique phenotypic profile, which includes
strong expression of CD 19, CD5 and CD23, and weak expression of CD22 and CD79b
(Keating et al. , 2003).
CLL is a dynamic disease with a heterogeneous clinical course. Patients can be
divided into those with a rapid disease progression and those with a more stable indolent
course of disease that may not require treatment. Several studies have demonstrated these two
subtypes can be defined by somatic mutations present in rearranged Ig variable region genes,
IgVH. Ig variable gene rearrangments occurs during B cell development in bone-marrow.
Somatic hyper-mutations of Ig variable regions occur in the germinal centres of lymphoid
follicles. A worse clinical outcome has been correlated in patients carrying unmutated IgVH
genes as they tend to show evidence of advanced, progressive disease and resistance to
therapy (Damle e ta l .,  1999; Hamblin et al., 1999).
Surface expression of CD38, cytoplasmic expression of (^-associated protein 70 (ZAP-
70) and the presence of chromosomal abnormalities are also associated with a more
progressive clinical course and shorter survival duration, and are frequently correlated with
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other important poor prognosis markers, including unmutated IgVn genes (Damle eta l., 1999; 
Van Bockstaele et al., 2009). The most common chromosomal abnormalities in CLL patients 
are deletions of chromosomes 13q, l lq ,  17pl3 and trisomy 12. Aberrations in 17p and l l q  
occur almost exclusively in the unmutated subset, and have been considered to have the 
strongest adverse prognostic factors (Van Bockstaele e ta l., 2009).
Elevated numbers of circulating T cells with a reduced CD4/CD8 ratio have been 
frequently reported in CLL, particularly in the more advanced stages of the disease (Dianzani 
et al., 1994; Platsoucas et al., 1982; Totterman et al., 1989). Despite the associated expansion 
of both neoplastic B cells and T cells, CLL patients have an abnormal T cell function. T cell 
dysfunction can be explained by several aspects, including poor antigen presenting function 
of CLL cells, increased expression of CTLA-4 on T cells (Rossmann et al., 2003), impaired 
immune synapse formation between CLL cells and T cells (Ramsay et al., 2008), secretion of 
immunosuppressive cytokines, and expression by CLL cells of molecules like CD200 that 
actively suppress cytotoxic T cell responses and promote the induction of Tregs (Kretz- 
Rommel et al., 2007; Pallasch et al., 2009). An abnormal maturation and function of DCs 
resulting in inability to stimulate an effective T cell-mediate immune response has also been 
observed in CLL patients (Ravandi & O'Brien, 2006). All these factors undeniably change the 
ability of T cells to respond to tumour-specific antigens and form a tolerised environment in 
which the tumour is able to grow.
Furthermore, T cells of patients with poor prognosis (CD38+/ZAP-70+) showed 
significantly shorter telomeres than those from patients with good prognosis, implying that T 
cell expansion is occurring in response to malignant cell growth and is probably playing a role 
in the growth and survival of the tumour cells (Roth et al., 2008). T cells, as well as stromal 
cells, appear to have a function in amplifying a microenviroment that favours the extended 
survival and proliferation of malignant B cells. CLL cells from lymph nodes and bone 
marrow are active players in shaping the microenviroment by secreting a chemokine (CCL22)
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that attracts activated T cells expressing its receptor CCR4. T cells with their CD40L bind to 
CD40 on the CLL cells, providing signals that in turn induce proliferation and progressive 
accumulation of neoplastic cells (Ghia eta l., 2002).
There is considerable interest in the identification of tumour antigens in CLL not only 
for their prospective use in immunotherapy, but also as means of monitoring tumour specific 
T cell responses during the course of treatment and disease. In contrast to several solid 
tumours, there are relatively few tumour-associated antigens that have been identified for 
CLL. The mutated Vh genes found in malignant B cells result in surface expression of unique 
clonotypic Ig receptors (idiotype). The Ig idiotype is the best characterised antigen in CLL 
(Trojan et al., 2000; Zirlik et al., 2006), but a problem in using idiotype vaccination strategies 
is that idiotypes are poorly immunogenic. Furthermore, use of idiotypes requires personalised 
tumour vaccines and individualised monitoring of idiotype of immune endpoints (Ramsay & 
Gribben, 2008). Other tumour antigens have also been suggested as tumour antigens based on 
their expression in B-CLL, including CD23 (Bund et al., 2007), CD229 (Bund et al., 2006), 
fibromodulin (Mayr et al., 2005), MDM2 (Mayr et al., 2006), hTERT (Kokhaei et a l., 2007), 
and survivin (Schmidt et al., 2003).
The most common treatment for patients with aggressive disease is chemotherapy, 
such as fludarabine (purine analogue) and chlorambucil (alkylating agent). Results from a 
randomised trial comparing the use of fludarabine and chlorambucil as initial treatment for 
CLL showed that fludarabine has a higher complete remission rate (20%) than chlorambucil 
(4%) (Rai et al., 2000). Monoclonal antibodies are emerging as attractive agents in the 
treatment of CLL. Alemtuzumab, a humanized anti-CD52 antibody, is already approved for 
use in flurarabine-refractory CLL (Keating et al., 2002). In addition, rituximab is a 
monoclonal antibody against CD20 and has been incorporated in combination regimens. 
Regimens combining chemotherapeutics agents with monoclonal antibodies have achieved 
higher complete remission rates. For example, in previously untreated patients, the
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combination of fludarabine, cyclophosphamide and rituximab treatment resulted in a 
complete remission rate of 70% (Keating et al., 2005). However, a main side effect of using 
these therapies is the depletion of normal lymphocytes and thereby contributing to an 
increased risk of infections (Auer eta l., 2007).
Autologous and allogeneic stem cell transplantation (SCT) is considered as another 
treatment options for patients with CLL. Results of autologous SCT in CLL showed that it is 
safe and feasible procedure but there is a high incidence of subsequent relapse. As for 
allogeneic SCT, initial results showed high treatment-related mortality, but did demonstrate 
that cure was possible in some patients. A consensus opinion suggests that allogeneic SCT is 
a procedure with evidence-based efficacy in poor-risk CLL, and a reasonable treatment option 
for younger patients with non-response or early relapse after purine analogues, relapse after 
achieving a response with combination therapy or autologous transplantation, and patients 
with p53 abnormalities requiring treatment (Gribben, 2007). Recently, it was demonstrated 
that an immunomodulatory drug, lenalidomide, with antitumour activity is clinically active in 
CLL. Lenalidomide has a T cell stimulatory effect and has been shown to enhance immune 
synapse formation between T cells and autologous CLL cells (Ramsay et al., 2008).
Although these regimes can control CLL, the disease remains incurable and new 
adjunct treatments are needed. There is strong rationale for the use of T cell based 
immunotherapy as a potential adjunct treatment for leukaemia. A variety of vaccine strategies 
have been studied in CLL patients, including vaccination with DCs, oxidized CLL cells or 
modified autologous leukaemia cells. In addition, attempts to circumvent the T cell defects 
clinically, for example, by modulating CD40:CD40L interactions or vaccination have also 
been studied in CLL. Clinical trials using these vaccine strategies have so far provided very 
encouraging results, demonstrating anti-leukaemia immune responses, but failed to show 
significant clinical benefits to patients (Ramsay & Gribben, 2008). There is limited 
knowledge of tumour antigens expressed by CLL, and further identification and
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characterisation will be of particularly importance for the development of successful 
immunotherapeutic strategies for CLL.
1.9 Apoptosis
Apoptosis, or programmed cell death, is an essential component of the development 
and health of muticellular organisms. It plays an important role in development, 
morphogenesis, proliferation/homeostasis, regulation and function of the immune system and 
in the elimination of damaged, altered or malignant cells. Apoptosis is a form of death in 
which a cell initiates a suicide programme and characteristic morphologic alterations are 
observed in dying and dead cells. These changes include chromatin condensation, nuclear 
disruption, cytoplasmatic contraction, and membrane blebbing, leading to phagocytosis of the 
cell. The decision for apoptosis can come from the cell itself, from the surrounding tissue or 
from a cell that is part of the immune system, and may be initiated in various circumstances, 
such as induction of DNA damage by radiation or toxic chemicals, the activation of a stress 
response, the lack of growth factors, and the triggering of specific signalling responses (Jin & 
El-Deiry, 2005).
1.9.1 Pathways
There are two major pathways that can trigger apoptosis, the extrinsic pathway and the 
intrinsic pathway, both of which culminate in a common death program, the activation of a set 
of proteolytic enzymes, called caspases (Figure 1.7). The extrinsic pathway, also known as 
the death receptor pathway, is initiated through the triggering of cell surface receptors of the 
TNF-receptor family. In contrast, the intrinsic pathway, also called mitochondrial pathway, is 
initiated through specialised proteins that induce mitochondrial leakiness, leading to release of 
death-inducing proteins that are normally sequestered within mitochondria. The induction of 
cell death is generally linked to the activation of caspases. The p53 tumour suppressor protein 
can also promote the expression of various pro-apoptotic gene products that initiate the
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extrinsic and intrinsic pathways. Signals from both pathways activate initiator caspases, 
which cleave and activate effector caspases, which in turn cleave various proteins that are 
crucial for cellular integrity and also induce enzymes that promote the death of the cell. Both 
pathways use caspases 3, 6 and 7 as effector caspases (Jin & El-Deiry, 2005).
1.9.1.1 Extrinsic pathway
In the extrinsic pathway, ligands bind to transmembrane death receptors on the target. 
The death receptors are members of the TNF receptor family, such as Fas, TNF-receptors and 
TRAIL-receptors, and contain a conserved domain known as the death domain (DD) in the 
cytoplasmic side of the receptor. For example, CTL can also induce apoptosis via the 
interaction of FasL with Fas expressed on the target cell. The binding of the death receptor to 
its ligand on the target cell recruits an adaptor protein known as Fas-associated death domain 
protein (FADD), which interacts with the DD of the death receptor. FADD, in turn, recruits 
caspase-8, an initiator protein, to form the death inducing signal complex (DISC). Through 
the recruitment of caspase-8,10 to DISC, caspase-8,10 are activated and able to directly 
activate caspase-3, an effector protein, to initiate degradation of the cell. When TNF-receptors 
are stimulated by their ligands, the adapter protein, TNFR-associated death domain (TRADD) 
is recruited to the receptor. When TRADD binds to FADD, the pathway proceeds to apoptosis 
as described above. In other cells, TNF-receptor signalling promotes the induction of pro- 
inflammatory responses (Jin & El-Deiry, 2005). Although extrinsic pathways can induce 
apoptosis without requiring mitochondrial changes, death receptor signalling is amplified in 
some cell types by positive feedback mechanism involving mitochondria. In these cells, 
caspase-8 can also cleave a pro-apoptotic BH3-only protein (Bid), which acts as a signal to 
the mitochondrial pathway via Bak and Bax (Khosravi-Far & Esposti, 2004).
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Figure 1.7 Extrinsic and Intrinsic apoptotic pathways (adapted front Ashkenazi, 2008). The two 
pathways can initiate apoptosis: extrinsic pathway acts through cel 1-surface death receptors and 
intrinsic pathway acts through intracellular Bcl-2 proteins. Extrinsic pathway: The ligand binding 
induces death receptor clustering and recruitment of the adaptor protein FADD and the initiator 
caspases 8 and 10 as pro-caspases, forming the complex DISC. This triggers activation of the 
caspases, which in turn activate the effector caspases 3, 6 and 7; Intrinsic pathway: cellular stress 
activates the p53 tumour-suppressor protein. p53 initiates the intrinsic pathway by upregulating Puma 
and Noxa, which in turn activate Bax and Bak. Bax and Bak permeabilise the outer mitochondrial 
membrane, resulting in release of cytochrome c, which binds to the adaptor Apaf-1 to recruit the 
initiator procaspase 9 into a signalling complex termed the apoptosome. Activated caspase 9 then 
cleaves and activates the effector caspases 3, 6 and 7 to trigger apoptosis. The mitochondrial protein 
Smac/DIABLO augments apoptosis by binding inhibitor of apoptosis proteins (IAPs) and reversing 
their activity on several caspases. Cross-talk between the pathways: p53 mainly stimulates the intrinsic 
pathway, but it also upregulates some of the pro-apoptotic receptors and augments extrinsic signalling. 
Extrinsic-pathway activation leads to caspase 8-mediated processing of Bid; truncated Bid 
subsequently stimulates Bax and Bak to engage the intrinsic pathway.
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1.9.1.2 Intrinsic pathway
The intrinsic pathway is triggered by cellular stress, specifically mitochondrial stress, 
caused by factors such as DNA damage, or when the cell does not receive extracellular 
signals that are needed for cell survival. This pathway eradicates irreparably damaged cells 
with dangerous mutations, which may arise as a result of cell injury, during cell division or 
recombination events. It typically involves the release of cytochrome c and other proteins 
from mitochondria, which triggers the activation of caspases. Following release, cytochrome c 
binds to a protein called apoptosis-activating factor-1 (Apaf-1). Apaf-1-cytochrome c 
complex, also known as the apoptosome, binds to and activates an initiator caspase, pro­
caspase 9, which in turn stimulate the activation of effector caspases as in the extrinsic 
pathway. Activated caspases in the cytosol associate with and are held in check by a family of 
inhibitors known as inhibitor of apoptosis proteins (IAPs), such as survivin. The other 
released mitochondrial proteins, Smac/Diablo and Omi/HtrA2, bind to and antagonise the 
activity of the IAPs and thus promote caspase activity and the induction of apoptosis (Jin & 
El-Deiry, 2005).
The intrinsic pathway is tightly regulated by interactions between members of the Bcl- 
2 family. The Bcl-2 family of proteins can be divided into two groups, the anti-apoptotic and 
pro-apoptotic proteins. These proteins are characterised by the presence of one or more Bcl-2 
homology (BH) domains. The anti-apoptotic Bcl-2 family members are important regulators 
of apoptosis and promote cell survival. Multidomain anti-apoptotic proteins, including the 
Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfll/A-1, and Bcl-B, typically contain four BH domains. These 
contribute to mitochondrial stability and block the release of cytochrome c. The precise 
mechanism is not completely understood but they may act by directly blocking the effects of 
the pro-apoptotic members (Wong & Puthalakath, 2008) .
Many pro-apoptotic proteins are single domain BH3-only proteins, such as Bid, Bim, 
Puma and Noxa, and are essential initiators of the intrinsic pathway by acting as antagonists
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of anti-apoptotic proteins and/or as agonists of pro-apoptotic multidomain proteins Bax and 
Bak. They may directly interact with pro-apoptotic Bax and Bak proteins in the cytoplasm, 
cause them to change conformation, translocate to the outer mitochondrial membrane and 
oligomerise. Multidomain pro-apoptotic proteins, such as Bax and Bak, contain three BH 
domains and are the executioner proteins, the downstream mediators of the intrinsic pathway. 
When activated, these proteins translocate to the outer mitochondrial membrane, where they 
become anchored, oligomerise and generate an increase in mitochondrial permeability. The 
loss of mitochondrial membrane integrity results in the release of key mitochondrial inducers 
of apoptosis and subsequently activation of caspases that leads to the death of the cell (Wong 
& Puthalakath, 2008).
1.9.2 Pro-apoptotic Bax protein and its dysregulation in cancer
One of the hallmarks of cancer is the evasion of cellular signals to undergo apoptosis 
(Hanahan & Weinberg, 2000). Various human malignancies overexpress anti-apoptotic Bcl-2 
family proteins or have dysregulated or loss of pro-apoptotic proteins (Figure 1.8). The 
expression of Bax or Bak is considered to play a key role in suppressing cancer development, 
and thus loss of Bax or Bak would accelerate tumourigenesis. Indeed, decreased Bax levels in 
malignant cells can lead to resistance to apoptosis, and have been associated with resistance to 
cancer therapy. Instability of Bax has been observed in a number of cancers, such as 
leukaemia, prostate cancer, cervical cancer and primary melanoma (Fecker et a l , 2006; Li & 
Dou, 2000; Magal et al., 2005). Low levels of Bax protein was significant associated with 
poor prognosis in prostate cancer and primary melanoma (Fecker et al., 2006; Li & Dou, 
2000). Decrease of Bax has also been reported as a negative prognostic marker for CLL, 
ovarian, pancreatic and breast cancer (Friess et al., 1998; Krajewski et a l ,  1995; Tai et al., 
1998).
Overexpression of Bcl-2 is one of the main causes of resistance of CLL cells (and
other malignacies) to therapy. However, low levels of Bax have been observed in advanced
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CLL and also play an important role in chemoresistance in CLL (Pepper et al., 1997; Pepper 
et al., 1998; Starczynski et al., 2005). Several studies have revealed that Bax protein has a 
shortened half-life in cancer cells due its abnormally increased degradation by the proteasome 
(Agrawal et al., 2008; Li & Dou, 2000; Liu et al., 2008). Bax protein has been reported as a 
target for the ubiquitin-proteasome pathway of protein degradation in CLL and PCa. 
Enhanced degradation of Bax is particularly observed in advanced stages of disease, which 
correlates with very low levels of Bax protein being detected in patients with highest grade of 
cancer and thus with poor prognosis (Agrawal e ta l., 2008; Li & Dou, 2000).
The proteins or protein patterns that have a crucial role in cancer development or 
suppression may represent model targets for therapeutic purposes. These features are 
important for all cancers, and thus therapies based on targeting these would be broadly 
relevant to most, if not all cancers. In this regard, it has been proposed that proteins that 
regulate apoptosis may be widely applicable targets for immunotherapy. Various regulators of 
apoptosis, such as Bcl-2 and survivin, have been described as tumour antigens in a large 
number of different cancers (Andersen et al., 2005). Strategies designed to target regulators of 
apoptosis have gained considerable interest for the treatment of cancer.
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Figure 1.8 Cancer cells and dysregulation of anti-apoptotic and pro-apoptotic proteins. Cancer 
cells frequently exhibit defects in apoptosis. Impaired apoptosis can result from overexpression of 
anti-apoptotic proteins, such as survivin, Bcl-2, and Mcl-1, and decreased expression of pro-apoptotic 
proteins such as Bax, Bak and Bid. These dysregulations contribute to the survival o f cancer cells and 
prevention of their cell death.
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1.10 Aims of project
The main aim of this project is to investigate the immunotherapeutic potential of the 
pro-apoptotic protein Bax in human cancer. Bax could serve as a novel tumour antigen for 
therapeutic CTL responses because of its unique pattern of expression in cancer. The central 
hypothesis of this project is that the abnormal degradation of Bax in cancer cells will result in 
the generation of peptides that bind to MHC class I molecules and are displayed at the cell 
surface. In cancer cells, we propose that Bax is short-lived and can be targeted for rapid 
degradation by the ubiquitin-proteasome pathway and thus there is a more efficient generation 
of peptides. By contrast, in healthy tissue, Bax has a long half-life, predominantly localised in 
the cytosol or loosely attached to outer mitochondrial membranes in an inactive form and may 
not be efficiently targeted by the proteasome. So, it is expected that there would not be 
substantial quantities of Bax-derived peptides for MHC class I binding. Therefore, it can be 
proposed that the abnormally enhanced degradation of Bax in cancer cells will provide 
tumour specific peptides for CD8+ T cell recognition (Figure 1.9).
This is a novel concept because definition of tumour antigens usually relies on stable 
over-expression of proteins in cancer cells. Here, it is proposed that a protein with low or 
unstable expression can be a candidate tumour antigen. At the onset of this project, T cell 
responses against Bax had not been reported. Therefore, the main objectives of this project 
are:
1. Investigate T cell responses against Bax peptides in cancer patients and healthy donors.
a) Define novel Bax specific T cell epitopes
b) Generate a T cell line/clone which specifically recognises the defined Bax epitopes
c) Test Bax specific T cells against a panel of human cancer cells
2. Analyse whether Bax expression in cancer cells is regulated by proteasomes.
3. Study CLL as a model system for generating human tumour-specific T cell responses.
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Figure 1.9 Schematic overview of the main hypothesis of the project: Degradation of Bax protein 
in healthy & cancer cells.
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Chapter 2 
Materials & Methods
2.1 Tissue culture basics
2.1.1 Tissue culture media and buffers
FCS-RPMI media:
RPMI 1640 (Invitrogen) was supplemented with 2mM L-glutamine (Invitrogen), 100 
units/ml penicillin, lOOpg/ml streptomycin (Invitrogen), 25mM HEPES (Sigma), and 10% 
foetal calf serum (FCS) (Invitrogen).
FCS-DMEM:
Dulbecco’s Modified Eagles Medium (DMEM) (Invitrogen) was supplemented as above. 
FCS-McCOYS media:
McCOYS media (Sigma) was supplemented as above.
Serum free media:
RPMI 1640 was supplemented as above but without FCS.
AB media:
RPMI 1640 (Sigma) was supplemented with 10% human AB serum (Welsh Blood 
Transfusion Service), 2mM L-Glutamine, lOOunits/ml Penicillin, lOOpg/ml streptomycin, 
and 25mM HEPES Buffer.
Freezing Mix
40% RPMI 1640, 10% Dimethyl Sulphoxide (DMSO) (Sigma), and 50% FCS.
Red cell lysis buffer
8.3g ammonium chloride (Sigma), lg  potassium bicarbonate (Sigma), 37mg potassium 
EDTA (Sigma) into 1 litre of distilled H 2 O (pH adjusted to 7.4 on ice).
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MACs buffer
0.5% BSA (Sigma), 2mM EDTA (Sigma), GIBCO PBS (Invitrogen). Sterile filtered using a 
0.2pm bottle top filter.
FACS buffer 
PBS+ 1%FCS
2.1.2 Tissue culture plastics
All tissue culture flasks (T25 and T75) and plates (24, 48 and 96 wells) were obtained from 
Nunc, Greiner, Fisher or Falcon.
2.1.3 Cell viability counting
Cells were examined for viability by mixing 15pl of trypan blue (Sigma) with an equal 
volume of well mixed cell suspension. Cells were counted using a haemocytometer. Non- 
viable cells are shown as distinctive blue colour under microscope. The percentage of total 
cells counted as white represents the viability of the culture.
2.1.4 Routine maintenance of cell lines
Culturing established cell lines
Non-adherent cell lines and adherent cell lines were cultured in 25cm3 (T25) or 75cm3 (T75) 
flasks in FCS-RPMI media or FCS-DMEM. Cells were routinely split 1:3 or 1:5 when 
confluent (every 3-4 days). Adherent cells were washed with sterile GIBCO PBS 
(Invitrogen) and incubated at 37°C with either lm ls in T25 or 5mls in T75 EDTA-trypsin 
(Invitrogen). After cells detached from the flasks, the cells were split between new flasks. 
FCS-RPMI or FCS-DMEM media was added to the cells and flasks were incubated at 37°C. 
Thawing crvopreserved cells:
Cells were thawed using a 37°C water bath and then added to FCS RPMI media. Cells were 
centrifuged at 1500rpm for 5 minutes and resuspended in the appropriate serum containing 
RPMI media (10% FCS or 10% AB serum).
70
Chapter 2: Materials & Methods
Table 2.1 Description of established cell lines used
T2
Human T- and B-lymphoblast hybrid cell line that does 
not express HLA-DR & is MHC class II negative. It 
expresses only the HLA-A*0201 allele and is defective in 
endogenous antigen-processing which enhances the 
effectiveness of exogenous peptide loading. (Salter et al., 
1985)
Cultured in FCS- 
RMPI and split 1:3, 
2-3 times a week
PC3
Human Caucasian prostate carcinoma adherent cell line. It 
was derived from a bone metastasis of grade IV prostatic 
adenocarcinoma and is not hormone sensitive. (Kaighn et 
al,  1979)
Cultured in FCS- 
RPMI and split 1:3, 
1 - 2  times a week
LNCaP
Human Caucasian prostate carcinoma adherent cell line. It 
was derived from a biopsy of the left supraclavicular 
lymph node of a male with metastatic prostate carcinoma. 
(Horoszewicz et a l , 1983)
Cultured in FCS- 
RMPI and split 1:3, 
2-3 times a week
DU145
Human Caucasian prostate carcinoma adherent cell line. It 
was derived from brain and is not detectably hormone 
sensitive. (Stonee ta l,  1978)
Cultured in FCS- 
RMPI and split 1:3, 
2-3 times a week
CA-HPV10
Human Caucasian prostate carcinoma adherent cell line. It 
was derived from a prostatic adenocarcinoma of Gleason 
grade 4/4. It is HPV-18 transfected. (Weijerman et al, 
1994)
Cultured in FCS- 
RMPI and split 1:3, 
2-3 times a week
CaSki
Human cervical carcinoma adherent cell line. It was 
derived from a small bowel metastasis in a 40 year old 
Caucasian female with cervical carcinoma. It contains 
between 60 and 600 copies of HPV16 genome per cell 
integrated at various sites in the Caski cell genome. (Baker 
e ta l,  1987)
Cultured in FCS- 
RMPI and split 1:3, 
2-3 times a week
SiHa
Human cervix squamous carcinoma adherent cell line. It 
contains 1 to 2 copies of HPV16 genome integrated into 
the cell genome. (Baker et a l , 1987; Friedl e ta l ,  1970)
Cultured in FCS- 
DMEM and split 
1:5, 2-3 a week
SiHa-A2
SiHa cells that were stably transfected with a recombinant 
expression vector pcDNA3 conferring neomycin 
resistance (Invitrogen), cloned with HLA-A*0201. 
(generated in the lab (Youde et a l,  2005))
Cultured in FCS- 
DMEM
supplemented with 
400pg/ml G418 
(Sigma) and split 
1:5, 2-3 a week
MS751
Human Caucasian cervical carcinoma adherent cell line. It 
was isolated from established lymph node metastasis in a 
47 year old Caucasian female with cervical carcinoma. It 
contains HPV45 sequences. (Pater & Pater, 1985)
Cultured in FCS- 
DMEM and split 
1:3, 2-3 times a 
week
C33A
Human cervix carcinoma adherent cell line. It was derived 
from a cervical cancer biopsy. These cells are negative for 
human papillomavirus sequences. (ATCC HTB 31)
Cultured in FCS- 
DMEM in split 1:5, 
2-3 times
C33A-HPV16
C33A transfected with a recombinant plasmid containing 
the HPV16 genome, (kindly provided by Prof. J. Dillner, 
Sweden)
Cultured in FCS- 
DMEM
supplemented with 
400pg/ml G418 
and split 1:5, 2-3 a 
week
TK143 (143b) Human bone osteosarcoma adherent cell line derived from 
a 13 year old Caucasian female.
Cultured in FCS- 
DMEM and split 
1:5, 2-3 a week
Saos>2 Human osteosarcoma adherent cell line isolated from the Cultured in FCS-
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primary osteogenic sarcoma of an 11-year-old Caucasian 
female. (ECACC, Catalogue No: 89050205)
McCOYS and split 
1:3, 2-3 times a 
week
U20S
Human osteosarcoma adherent cell line established from a 
moderately differentiated sarcoma of the tibia of a 15 year 
old Caucasian female. (ECACC, Catalogue No: 
92022711)
Cultured in FCS- 
McCOYS and split 
1:3, 2-3 times a 
week
HepG2
Human Caucasian hepatocyte carcinoma adherent cell 
line. It was derived from a liver biopsy of a 15 year old 
male with a well differentiated hepatocellular carcinoma. 
(ECACC, Catalogue No: 85011430 )
Cultured in FCS- 
DMEM and split 
1:3, 1-2 times a 
week
BJAB EBV negative human cell line similar to Burkin’s 
lymphoma, (kindly provided by Prof. Martin Rowe)
Cultured in FCS- 
RMPI and split 1:5, 
2-3 times a week
BV173 Human B cell precursor leukaemia line, (kindly provided 
by Dr. Paul Brennan)
Cultured in FCS- 
RMPI and split 1:5, 
2-3 times a week
Daudi
Human negroid Burkitt’s Lymphoma cell line, EBV 
positive with defects in HLA class I. (kindly provided by 
Prof. Martin Rowe)
Cultured in FCS- 
RMPI and split 1:5, 
2-3 times a week
DG75 Human B cell lymphoma cell line, EBV negative, (kindly 
provided by Prof. Martin Rowe)
Cultured in FCS- 
RMPI and split 1:5, 
2-3 times a week
MDA231
Human breast adenocarcinoma cell line isolated from a 
pleural infusion in a 51-year-old female with breast 
cancer.
Cultured in FCS- 
RMPI and split 1:3, 
2-3 times a week
K562 Human chronic myelogenous cell leukemia cell line. It is 
easily killed by NK cells.
Cultured in FCS- 
DMEM with 
400pg/ml G418 
and split 1:3, 2-3 a 
week
SK29mel Human melanoma adherent cell line that expresses Melan- 
A/MART-1. (kindly provided by Dr.V. Cerundolo)
Cultured in FCS- 
DMEM and split 
1:5, 2-3 a week
2.2 Peptide Antigens
2.2.1 Positive peptide pool (PPP)
PPP contained common recall antigens for both CD 8 + T cells and CD4+ T cells and it was 
used as positive control for T cell responses detected by ELISpot (Table 2.2) (Smith et a l ,  
2005). It was added to cultures at lOpg/ml. Several different antigen sources (Tetanus, 
Influenza, CMV, and EBV) were included. Each peptide synthesized (Severn Biotech) was 
>90% pure. Individual peptide stocks were made by dissolving each peptide in DMSO. The
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PPP mixture was made by combining aliquots taken from each peptide stock, with each 
peptide being present at lOpg/pl. Peptide stocks and PPP aliquots were stored at -20°C.
Table 2.2 Positive Peptide Pool (PPP)
PKYVKQNTLKLAT Influenza A HA 306-324 DR4/DR7/DR11
QYIKANSKFIGITEL Tetanus toxoid 830-844 Multiple DR
FNNFTV SFWLRVPK V S ASHLE Tetanus toxoid 947-967 Multiple DR
TSLYNLRRGTALA EBV EBNA1 515-527 DR1*0701
AGLTLSLLVICSYLFISRG EBV BHRF1 171-181 DR 15 (2)
IVTDFSVIKAIEEE EBV EBNA3c 416-429 A ll
LTKGILGFVFTLTVPSERG Influenza A Ml 55-73 A2
IQNAGLCTLVAMLEE EBV BMLF1 276-290 A2
RPFFHP V GE AD YFE Y EBV EBNA1 403^117 B35
QEFFWDANDIYRIFA CMV pp65 511-525 B44
EENLLDFVRF EBV EBNA3c 281-290 B44
RKTPRVTGGGAMAGA CMV pp65 415-429 B7
RPQKRPSCIGCKGT EBV EBNA1 71-85 B7
RKCRAKFQLLQHYR EBV BZLF1 187-201 B8
CTELKLSDY Influenza A NP 44-52 Al
ILRGSVAHK Influenza A NP 265-273 A3
2.2.2 MART-1/Melan-A peptide
MART-1 (ELAGIGILTV) is a melanoma peptide analogue that is HLA-A*0201 restricted 
and highly immunogenic. It shows better HLA*0201 binding properties and antigenicity than 
the natural MART-1 peptide (27-35) AAGIGILTV (Valmori et a l ,  1998). MART-1 peptide 
was synthesized by Prolmmune with >70% purity. This peptide was dissolved in DMSO to 
give a working stock of lOmg/ml. Peptide stocks were stored at -20SC.
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2.2.3 Bax peptide pools
Bax pool 1-15
Bax pool 1-15 consists of 9-and 10-mer peptides generated from Bax-a protein (192aa). 
Using two predictive computer algorithms (BIMAS and SYFPEITHI) for HLA binding, 
fifteen peptides have been identified for HLA binding. Ten are predicted to bind to HLA- 
A*0201, three to HLA-A3 and two to HLA-B7 (Table 2.3). The peptides were synthesized 
with purity greater than 40% (Mimotopes). Individual peptides were dissolved in DMSO to 
give stock solutions of lOmg/ml and 50mg/ml. Total concentration of this peptide pool is 
lOmg/ml. All individual peptide and Bax pool stocks were stored at -20°C.
Table 2.3 Bax peptide pool 1-15
1 KLSECLKRI 58 A2 344 24
2 ALFYFASKL 1 1 2 A2 300 25
3 IMGWTLDFL 136 A2 163 2 2
4 WIQDQGGWV 151 A2 129 19
5 ALCTKVPEL 124 A2 49 30
6 PVPQDASTK 49 A3 30 30
7 VLKALCTKV 1 2 1 A2 23 23
8 IMKTGALLL 19 A2 2 2 2 2
9 ALFYFASKLV 1 1 2 A2 257 2 1
1 0 VVYNAFSLRV 209 A2 126 17
1 1 KLVLKALCTK 119 A3 135 28
1 2 VVALFYFASK 1 1 0 A3 27 27
13 VPQDASTKKL 50 B7 80 2 1
14 KPPHPHHRAL 163 B7 80 2 2
15 LVLKALCTKV 1 2 0 A2 2 2 2 2
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Bax pool 601-23
Bax pool 601-23 consists of 9-and 10-mer peptides also generated from Bax-a protein 
(192aa) but were identified using five/six predictive computer algorithms (BIMAS, 
SYFPEITHI, SMM, MHCpep, NET MHC, EpiJen) for HLA binding. This pool includes 23 
peptides for HLA binding, fourteen of which are predicted to bind to HLA-A*0201, one to 
HLA-A3, one to HLA-B7, two to HLA-A1, two to HLA-B8  and three to HLA-B44 (Table 
2.4). The peptides were synthesized with purity greater than 40% (Mimotopes). Individual 
peptides were dissolved in DMSO to give stock solutions of lOmg/ml and 50mg/ml. Total 
concentration of this peptide pool is lOmg/ml. All individual peptide and Bax pool stocks 
were stored at -20°C.
Table 2.4 Bax peptide pool 601-23
601 RMGGEAPEL 37 A2 6 / 6 73
602 QIMKTGALL 18 A2 4/6 37
603 LLSYFGTPT 161 A2 4/6 77
604 LLQGFIQDRA 26 A2 3/6 83
605 GLLSYFGTPT 160 A2 3/6 79
606 FVAGVLTASL 176 A2 3/6 67
607 ELQRMIAAV 75 A2 5/6 69
608 ALDPVPQDA 46 A2 4/6 65
609 LLLQFIQDR 25 A2 4/6 83
610 TIMGWTLDFL 135 A2 3/6 51/95.7
611 FLRERLLGWI 143 A2 3/6 76
612 KLSECLKRI 58 A2 6 / 6 36
613 IMGWTLDFL 136 A2 6 / 6 6 8  / 96.4
614 ALCTKVPEL 124 A2 6 / 6 64
615 DELDSNMEL 6 8 B44 3/3 51
616 MELQRMIAA 74 B44 3/3 77
617 SEQIMKTGAL 16 B44 3/3 6 8
618 CLKRIGDEL 62 B8 2/3 49
619 ASKLVLKAL 117 B8 2/3 37
620 GGWDGLLSY 156 Al 2/5 59
621 DTDSPREVF 84 Al 4/5 84
622 VALFYFASK 1 1 1 A3 5/5 78
623 SPREVFFRV 87 B7 3/3 84
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2.3 Peptide binding assay
T2 cell line was used to determine the binding affinity of peptides. This cell line is an antigen 
processing mutant and expresses unstable class I molecules on the surface. Expression can be 
stabilised by the addition of exogenous peptide providing an indication of MHC allele 
specific binding of test peptides (Cerundolo et al., 1990). 1x10s T2 cells were resuspended at 
lx l0 6/ml in serum-free media and lOOpl added/well of a 96-well plate. Peptide was added at 
50pg/ml in DMSO and incubated overnight at 37°C. The appropriate controls were also 
included, a non A2-binding peptide and a known HLA-A2 binding peptide -  the Flu matrix 1 
(Flu M l 58-66) peptide GILGFVTFL. The other negative control consisted of untreated 
cells. The cells were then stained with MA2.1 (an HLA-A2 antibody) as described in section 
2.14.2. HLA-A2 expression was quantified as % increase according to the formula: % 
Increase= [(mean fluorescence with peptide -  mean fluorescence without peptide)/ mean 
fluorescence without peptide xlOO].
2.4 Blood origin and preparation
2.4.1 Blood donors
Healthy donors used in this project were both male and female members of laboratory staff 
aged between 20 and 60 years or anonymous buffy coats from Welsh Blood Service. Blood 
from the laboratory staff was taken with informed consent. Since donors were healthy 
volunteers, no ethical approval was required. CLL patients studied in this project were 
attending clinics at Llandough hospital and Heath hospital. These patients are part of a cohort 
not requiring treatment. Blood samples were collected with informed consent as part of an 
ongoing LRF funded project (Drs Pepper and Fegan), and ethical approval was in place. 
Most of the blood samples used to generate short term T cell cultures were stained for HLA- 
A*201 using HLA-A2 specific monoclonal antibodies.
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2.4.2 Isolation of peripheral blood mononuclear cells (PBMC)
Fresh human blood was collected into heparinised (10 units/ml) Falcon tubes. PBMC were 
isolated by Ficoll-Hypaque (Histopaque-1077, Sigma) density gradient centrifugation. Blood 
was layered gently onto Histopaque at a 1:1 ratio and centrifuged at 2000 rpm for 20 minutes 
without the use of a brake. PBMC formed a monolayer at the plasma/histopaque interface 
and were carefully harvested using sterile Pasteur pipettes and washed three times in serum- 
free RPMI 1640 media. The first wash was at 1800 rpm for 10 minutes and the next two at 
1200rpm for 5 minutes. If the pellet was contaminated with a large proportion of red blood 
cells, it was resuspended in 1 - 2 mls of red blood cell lysis buffer and incubated for 1 0  
minutes at 4°C. Viable cells were then counted by trypan-blue-exclusion and resuspended in 
an appropriate volume of media.
2.5 Primary PBMC IT  cell cultures
2.5.1 Short-term in vitro culture of PBMC/T cells with peptides
PBMC/T cells were cultured in a 24 well plate at 2-2.5xl0 6  cells/ml of AB-RPMI (1 ml/well) 
in presence of peptide. MART-1, positive peptide pool (PPP), and Bax peptides were used at 
a total concentration of lOpg/ml where indicated, lpg/m l of CD28 antibody and 0.5pg/ml 
CD49d antibody (Serotec) were also added to the wells. It has been shown that the use of 
these costimulatory antibodies enhanced peptide specific IFNy production (Waldrop et al., 
1998). On day 2-3, 1ml of AB-RPMI media supplemented with IL-2 (40u/ml) (Proleukin) 
was added to each well. On day 7, some of the PBMC cultures were tested for the presence 
of peptide-specific T cells in the IFNy ELISpot assay.
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2.5.2 Cryopreservation of PBMC
A fraction of PBMC was resuspended in freezing mix to give 2-10xl0 6  cells per ml 
depending on the intended use, and 1ml aliquots were dispensed per cryovial. These were 
then placed in a Nalgene 5100 cryo freezing container (Merck Laboratory Supplies) for at 
least 24 hours at -70°C and then transferred to liquid nitrogen. Frozen PBMC were later used 
as APC to restimulate T cells in culture or in the IFNy ELISpot assay.
2.5.3 Restimulation of PBMC/T cell cultures
PBMC/T cell cultures were re-stimulated with the appropriate peptides every week. The 
cultured PBMC were harvested, counted, and re-plated at 1.5-2x106  cells/well in 0.5ml of 
AB-RPMI media supplemented with 40 U/ml IL-2. Autologous cryopreserved PBMC were 
used as APC. These cells were irradiated in FCS-RPMI at 3,000 rads, washed in serum-free 
RPMI and then added to wells in 0.5ml AB-RPMI at a ratio of 2 irradiated-APC: 1 cultured 
PBMC/T cells. Peptide or peptide pools were then added to the wells at lOpg/ml. After 2-3 
days, 1ml of AB-RPMI supplemented with IL-2 (40u/ml) and IL-7 (lOng/ml) (R&D systems) 
was added to each well. PBMC/T cell cultures were re-stimulated during 2-4 weeks where 
indicated.
2.5.4 Enrichment of CD8+ T cells from PBMC using specific microbeads
CD 8 + T cells were enriched using magnetic microbeads specific for CD 8  (30-50x106 input 
cells). Cells were washed in PBS and spun twice at 1500rpm in a 15ml Falcon tube. 
Supernatant was removed with a pipette and pellets were resuspended in 80pl cold MACs 
buffer and 20pl anti-CD8  microbeads (MACs, Miltenyi) per 107  cells. Cells were incubated 
for 15 minutes at 4°C in a rotator. Pellets were then washed (in 20x the incubation volume) 
with cold MACs buffer and spun at 1300rpm for 10 minutes. Supernatant was removed and
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cells resuspended in 500pl cold MACs buffer. This was then loaded onto a magnetic MS 
column (Miltenyi) pre-washed with 500pl MACs buffer. Unlabelled cells passed through the 
column, which was washed 3 times with 500pl MACs buffer. These cells were collected as 
the CD 8  depleted fraction. To collect the CD 8 -enriched fraction, the column was removed 
from the magnetic field and 1ml MACs buffer was applied to the column. A syringe plunger 
was then used to force the buffer and bead-labelled cells through. An aliquot of the pre-sort, 
positive and negative fraction was taken for purity analysis by flow cytometry. CD 8 + T cells 
were cultured as described in section 2.5.1.
2.6 Detection of peptide-specific T cells
2.6.1 IFNy ELISpot assay
ELISpot wells were set up either in triplicate or duplicate. Most experiments included wells 
containing T cells alone, T cells + APC, T cells + APC + peptide, T cells+mitogens (positive 
control). Firstly, mouse anti-human IFNy antibody 1-DIK (Mabtech) was diluted to lOpg/ml 
with PBS, and 50pl was added to each well of an ELISpot plate (Millipore). Plates were 
either incubated overnight at 4°C, or for 3 hours at 37°C. Plates were washed thoroughly 5 
times with 150pl PBS/well, before blocking with lOOpl of FCS-RPMI media for 1 hour at 
room temperature. The responder cells (either cultured PBMC or T cells) were added to the 
wells in 50pl of AB-RPMI media. The number of cells/well ranged from Ix l0 3 - lx l0 5. The 
APC (PBMC/T2) were then added in 50pl of AB-RPMI media to the appropriate wells at a 
ratio 1 APC: 1 responder. The peptide was added to appropriate wells in 50pl of AB-RPMI 
media. T cells + phytohaemagglutinin (PHA) (Biostat) 2pg/ml, ionomycin (Calbiochem) 
1.5pg/ml, phorbol myristate acetate (PMA) (Calbiochem) lOOng/ml and Concavalin A 
(Sigma) 20pg/ml were added to the positive control wells. Control wells that did not require
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peptide/APC received 50-100pl of the media alone, so that the total volume is 150pl. The 
plate was then wrapped in silver foil and incubated at 37°C for 16-18 hours.
Plates were washed 3 times with 150pl PBS and then incubated with lOOpl sterile water for 
10 minutes at room temperature, therefore lysing the remaining bound cells. The plate was 
then washed a further 2 times with 150pl/well PBS. The secondary biotinylated antibody 7- 
B6-1 -Biotin (Mabtech) was diluted 1:1000 with PBS. This was added at 50pl/well and 
incubated in the dark at room temperature for 2 hours. The plate was washed 5 times with 
PBS, and 50pl of Streptavadin-Alkaline phosphatase (diluted 1:1000 with PBS) was added to 
each well. The plates were incubated for 2 hours in the dark at room temperature, followed 
by washing 5 times with PBS.
Developing solution was made freshly using 25xAP colour development buffer (Bio-Rad), 
AP conjugate substrate A and B solutions (Bio-Rad), and sterile water. The solution was 
added at 50pl/well and left to develop in the dark between 10 to 50 minutes, until the spots 
were clearly visible. To stop the developing reaction, tap water was used to wash the plates 4 
times. Plates where then air dried in the dark before counting.
Spots were counted by eye using a stereomicroscope (magnification 3.2x) (Leica MZ6 ) and 
some were also counted using an automated ELISpot counting system (AID ELISpot reader, 
Cadama Medical) to confirm results. A response was considered positive if the mean number 
of spots from the test wells (T cells + APC + peptide) was greater than 20 spots/1 xlO 5 cells, 
after subtraction of the background response from control wells (T cells + APC). This 
criterion is used in order to reduce the possibility of detecting false positives.
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Unstimulated 
T cells
T cells +APC T cells+APC 
+ Peptide
Background Response Peptide Response
Positive ELlSpot Response = Peptide response -  Background response
Figure 2.1 Detection of peptide specific T cells by IFNy ELlSpot assay.
ELISpot wells were set up in triplicate with T cells, + APC, and + APC + peptide. Each spot 
represents an IFNy-secreting T cell. Background response (non-specific IFNy secretion by T cells 
and/or APC) must be subtracted from Peptide response (specific IFNy secretion by T cells 
recognising peptide + background response) in order to determine the peptide specific response. The 
ELISpot well images shown above were captured using an AID ELISpot reader. (Positive ELISpot 
response = > 20 spots/1 xlO5 cells)
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2.6.2 IFNy-Intracellular Cytokine Staining (ICS) analysis
T cells were plated out in 0.5ml AB-RPMI at 5x10s cells/well in a 48 well culture plate. 
APC were added to the wells in 0.5ml AB-RPMI at 0.5-1 x l0 6 /well, and the cells were 
incubated at 37°C with or without peptide (lOpg/ml). lp l of golgi plug (BD) was added to 
each well after 90 minutes incubation and cells were further cultured for 11-13 hours. After 
incubation, cells were harvested into 15ml Falcon tubes and washed twice with PBS. Cell 
pellets were then labelled with 5pl antibody anti-CD 8  and incubated for 20 minutes at 4°C. 
Cells were washed twice with cold ICS sample buffer and centrifuged at 4°C for 4 minutes at 
1500rpm. The supernatant was carefully removed and each cell pellet was resuspended in 
250pl of Cytoperm/Cytofix reagent (BD) and incubated at 4°C in the dark for 20 minutes. 
Cells were washed twice with lx  perm/wash solution (BD), with the supernatant being 
carefully removed by pipette to avoid cell loss. The cell pellets were resuspended in 50pl 
perm/wash + 2pl of mouse anti-human IFNy antibody (Caltag/Invitrogen) and incubated in 
the dark for 30 minutes at 4°C. Cells were then washed twice with perm/wash. The cells were 
resuspended in 200pl of ICS sample buffer and analysed by flow cytometry.
2.6.3 CD 107 assay
A CD 107 assay was carried out to identify and enrich Bax specific T cells following peptide 
stimulation. This assay allows the direct detection of degranulation by activated T cells. 
CD 107 is present in the membrane of cytotoxic granules. During T cell degranulation the 
granule fuses with the T cell plasma membrane and CD 107 can be detected on the cell 
surface. If the effector cells were frozen, they were thawed the day before and plated out at 
l-2 x l0 6  / well in AB-RPMI containing lOng/ml IL-7. Targets were pulsed with peptide or 
left unpulsed (control) for lhour in serum-free media at 37°C. 1x10s T cells were incubated 
in lOOpl AB-RPMI with lOOpl containing target cells in a 96 well plate, normally at 1:2
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ratio, otherwise stated in the results. The CD107a-FITC antibody was added to each well at 
2pl/ml and golgi stop (BD) was added at lp l/  well (diluted 1:5 in serum-free media). Cells 
were spun at 1300rpm for 2 minutes to increase cell to cell contact and incubated at 37°C for 
4 hours, after which they were harvested and washed (in FACS buffer) before analysing by 
flow cytometry.
2.6.4 CD137 assay
A CD 137 assay was also carried out to identify and enrich Bax specific T cells after peptide 
stimulation. This assay allows the detection of antigen-specific activated CD8 + T cells. 
CD 137 is a member of TNRF family that is expressed on activated T cells and helps T cells 
to proliferate and survive (Wolfl et al., 2007). If the effector cells were frozen, they were 
thawed the day before and plated out at l-2 x l0 6  / well in AB-RPMI containing lOng/ml IL-7. 
Targets were pulsed with peptide or left unpulsed (control) for 1 hour in serum-free media at 
37QC. 1x10s T cells were incubated in 500pl AB-RPMI with 500pl containing target cells in 
a 24 well plate at 1:1 ratio. Cells were spun at 1300rpm for 2 minutes to increase cell to cell 
contact and incubated at 37°C for 24 hours. The cells were then harvested and washed (in 
FACS buffer) and incubated with anti-human CD137-FITC and CD 8 -PE before analysing by 
flow cytometry.
2.7 Expansion of T cells using an allogenic feeder system
This expansion method was used to generate large numbers of T cell lines (antigen- 
independent protocol). T cells with numbers up to lx lO 6  were seeded into a T25 tissue 
culture flask with 25mls of AB-RPMI supplemented with 20 U/ml IL-2, 0.5pg/ml PHA, and 
lOxlO6  irradiated allogenous PBMC feeders (from 3 donors). The flask was placed into a 
37°C incubator tilted at 45°, so as to enhance cell-cell contact. On day 5 of the expansion,
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half the media was replaced with the same volume of AB-RPMI media supplemented with 20 
U/ml IL-2. Cells were resuspended and incubated for a further 2 days in upright position. 
Cells were then harvested, counted and rested in fresh AB-RPMI supplemented with 20U/ml 
IL-2 at 2x l0 6  cells/well in 24 well plates. Every 2-3 days when media turned yellow, half the 
media was replaced with AB-RPMI + 100 U/ml IL-2. The cells were then used in 
experiments or frozen until further use.
2.8 Enrichment of peptide specific T cells using CD 107 or CD 137 assay
Activation of CD8 + T cells after encounter with APC pulsed with Bax peptide pool was 
determined by cell surface expression of CD 107a or CD 137 as previously described in 
section 2.6.3 and 2.6.4. All samples were stained with an anti-CD8 -PE antibody. The T cell 
cultures were then washed once with warm PBS and resuspended in 0.5ml AB-RPMI. A 
CD 8 + CD107a+ or CD8 + CD137+ population containing peptide specific T cells was sorted 
using a MoFlo cell sorter (Dako). The cells were then expanded and used in further 
experiments or frozen until being used.
2.9 Enrichment of IFNy-secreting T cells using magnetic beads
Firstly, target cells (T2 cells) were irradiated the day before the enrichment and left in the 
fridge overnight. Cells were washed and added in presence of peptide/peptide pool (lOpg/ml) 
on top of T cells at 106  cells/lOOpl in 96 well plates. Cells were incubated for 4 hours at 
37QC. After incubation, a dead cell removal kit (Miltenyi Biotec) was used prior to the cell 
separation in order to reduce any dead cell contamination in the sample. Cells were harvested 
into a 15ml falcon tube and centrifuged. Supernatant was completely removed and the cell 
pellet was resuspended in lOOpl of Dead Cell Removal Microbeads /107  total cells, mixed 
well and incubated for 15 minutes at room temperature. Meanwhile, a MS column was
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prepared by rising with 500pl lx  Binding buffer. Cell were washed and resuspended in 500pl 
lx  Binding buffer. The live cells passed through the column, which was rinsed 4 times with 
500pl lxBinding buffer. Effluent was collected as the live cell fraction.
The cells were washed twice with lOmls of cold MACs buffer, and centrifuge at 1300rpm for 
10 minutes. The pellet was incubated on ice for 5 minutes with 80pl cold serum-free RPMI
n
and 20pl of IFNy catch reagent/10 cells. This catch reagent is a mouse anti-human IFNy 
antibody conjugated to a mouse anti-human CD45 antibody. Therefore, all leukocytes are 
labelled with an antibody capable of binding secreted IFNy. The cells were then diluted with 
warm AB media according to the expected number of IFNy secreting cells (<5% : l-2 x l0 6  
cells/ml; 5-20%: l-2 x l0 5 cells/ml), thus restarting the IFNy secretion process. Cells were 
incubated at 37°C for 45 minutes whilst being gently rotated using a MACsmix tube rotator 
(Miltenyi). During this period, the secreted IFNy was captured onto the surface of the cell 
that produced it. The IFNy secretion was terminated by topping up the tube with cold MACs 
buffer and placing the falcon on ice for 2 minutes. Cells were centrifuged and the pellet was 
resuspended in 80pl of cold MACs buffer, 20pl of IFNy detection antibody (/107 cells). After 
10 minutes incubation on ice, lOmls of cold MACs buffer was added to the tube and the cells 
were centrifuged. A small aliquot was taken for later analysis by flow cytometry. Supernatant 
was removed and the pellet was resuspended in 80pl cold MACs buffer and 20pl of anti-PE 
magnetic beads, mixed thoroughly and incubated at 4°C for 15 minutes. Cells were washed in 
lOmls of cold MACs buffer and the pellet was resuspended in 500pl cold MACs buffer. The 
remaining cells were loaded onto a prepared MS magnetic column (Miltenyi). The unlabelled 
and labelled fractions were collected as described in section 2.5.4, with one additional step in 
which the positive fraction was then reloaded onto a second MS column to ensure a high 
purity of IFNy-secreting cells in the enriched population.
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Aliquots of the pre and post enrichment fractions were analysed by flow cytometry. 7-AAD 
was added to the appropriate samples to allow exclusion of dead cells by negative gating 
during flow cytometric analysis.
2.10 Generating peptide-specific T cell lines
2.10.1 Culture of enriched peptide-specific T cell population
Enriched peptide-specific T cells using CD 107, CD 137 or IFNy protocol, were expanded 
using the antigen-independent protocol as described in section 2.7. After expansion, the T 
cells were allowed to rest in fresh AB-RPMI supplemented with 20U to lOOU/ml IL-2 at 
2x l0 6  cells / well in 24 well plates.
2.10.2 Generation of T cell lines from peptide specific T cells under limiting 
dilution conditions
The IFNy enriched cells were cultured under limiting dilution conditions. The T cells were 
diluted such that 1, or 10 cells/well and added in 50pl AB-RPMI to the 60 innermost wells of 
96 well, round-bottomed culture plates. Six plates were seeded with 1 cell/well, one plate 
with lOcells / well, and half a plate only with feeders. 50pl of a cloning mix was added to the 
appropriate wells. The cloning mix in each well consists of AB-RPMI, 40U/ml IL-2, 2pg/ml 
PH A, 5x l0 4  irradiated allogenic PBMC (from 3 donors). On day 7, cells were fed with lOOpl 
of fresh AB-RPMI + 40U/ml IL-2. On day 14, lOOpl was removed from each well and 
replaced with lOOpl cloning mix with a final concentration of 20U/ml IL-2, lpg/m l PHA, 
and 5x l0 4  irradiated autologous PBMC (from 3 donors). Feeding and re-stimulating were 
alternated for 2 further weeks. T cell lines that had grown to a large pellet size, were plated 
out into new plates, split 1:2 or 1:3 and fed with AB-RPMI + IL-2 (20 IU/ml). After 3-4
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weeks, these cultures had grown sufficiently to be tested for recognition of Bax peptides by 
ELISpot.
2.10.3 Selection of peptide-specific T-cell lines from cloning plates
The T cell lines isolated from the cloning protocol in the previous section were tested for 
recognition of the Bax pool in an IFNy ELISpot assay. Because the precise number of T cells 
in each well was not known, 4 different culture wells were harvested and counted and an 
average of l.OxlO5  cells/well was calculated. 50pl of each well, including on average 2- 
3.0x104  cells, was taken from each line and added to each of two wells of an ELISpot plate. 
T2 cells were used as APC and these were added at 3xl0 4  cells/well in 50pl AB-RPMI. Due 
to the number of responder cells, only 2  wells were set up, one of which was a control for 
spontaneous IFNy secretion (T-cell +T2) and the other contained Bax pool (T-cell + T2+Bax 
pool). Bax pool was added (at a final concentration of lpg/ml) in 50pl AB-RPMI media to 
one well, and 50pl of AB-RPMI media alone was added to the control well.
The most specific lines were selected according to the estimated number of spots in the 
peptide well (excluding lines that generated high background in control wells) and the size of 
the cell pellet in each culture well. These T cell lines were then expanded using the protocol 
described in section 2.7.
2.11 Chromium-51 (51Cr) release cytotoxicity assays
Functional assays to determine Bax specific CTL killing of cancer cell lines were carried out 
by 51 Cr release cytotoxicity assay. The target cells were labelled with 5 1 Cr, which is released 
if the cell is killed by CTL. Some assays were carried out using target cells that had been pre­
treated with IFNy or proteasome inhibitors (described in sections 2.12 and 2.13).
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Effector cells used in this assay, were either from T cells in culture or from cryopreserved 
stocks, which were thawed and incubated overnight at a density of 2x l06cells per well in a 24 
well plate in 10% AB media containing lOng/ml IL-7. On the day of assay, target cells were 
washed and labelled with 5 1 Cr (Perkin Elmer) (500pCi/107 cells of a 5mCi/ml stock) for 
lhour at 37°C. The cells were then washed, resuspended in 1ml FCS-RPMI. Peptide was 
added normally at lOpg/ml to the appropriate target, but this varied for peptide dose response 
experiments. All targets were incubated for 1 hour at 37°C to allow peptide binding and 
unincorporated 51 Cr to leach into the media.
Meanwhile, effector cells were harvested, resuspended in FCS-RPMI media and counted. 
The number of cells determined the top Effector:Target (E:T) ratio, but a top E:T ratio varied 
according to the experiment. The effectors were plated out and double diluted in a 96 well 
plate so as to give a range of E:T ratios and lOOpl/well.
After leaching, target cells were washed and resuspended at l-2 x l0 5 cells/ 10ml in FCS- 
RPMI. 1000 - 2000 targets/lOOpl was added to the wells of a 96 well plate which already 
contained effector cells in triplicate. Control wells containing only target cells in FCS-RPMI 
(minimum: spontaneous release) and wells containing targets with 5% Triton-XlOO (Sigma) 
(maximum release) were also set up. Assay was incubated at 37°C for 4 hours.
After the 4 hour incubation, 20pl of supernatant from each well was harvested and 
transferred to flexible 96 well counting plates (Wallac). 150pl of scintillation fluid 
(Optiphase scint, Wallac) was added to each well. The amount of 51Cr released was 
determined by measuring beta particle events per minute (Beta-plate counter, Wallac).
% specific lysis was calculated as follows:
(experimental release -  spontaneous release)
(maximum release -  spontaneous release) x 1 0 0 .
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2.11.1 Cold-target competition assay
For competition assays, an E:T ratio of 40:1 or 50:1 was used. Along with the labeled targets 
(T2, T2+Bax p613, tumour cell), nonlabeled T2, T2 + irrelevant peptide, T2 + Bax p613 and 
the same tumour cell type were included into the cytotoxicity assay at a competitor (cold 
target): target (hot target) (C:T) ratios of 20:1, 10:1, 5:1. Control lysis in the absence of 
competitor cells was also determined.
Firstly, the competitors T2 were pulsed with Bax p613 or Flu M l peptide at lOpg/ml for 1 
hour. Meanwhile, the hot targets were labeled with 51Cr and pulsed with peptide as described 
in the previous session. While hot targets are leaching, the competitors were washed and 
seeded at different C:T ratios. These cells were double diluted in a 96 well plate so as to give 
the chosen C:T ratios stated above and 50pl/well of FCS-RPMI. Effectors (with a fixed ratio 
of 25:1 or 50:1) were added on top of the competitors in lOOpl/well.
After leaching, hot target cells were washed and resuspended at l-2 x l0 5  cells/ 5ml in FCS- 
RPMI. 1000 - 2000 targets/50pl was added to the wells of a 96 well plate which already 
contained competitor and effector cells in triplicate. Control wells for spontaneous and total 
release containing only hot target cells with or without competitors were set up. The rest of 
this assay was carried using the method described before.
2.11.2 Antibody-blocking assay
HLA-restriction of CTL-mediated killing was achieved by incubating the targets with HLA-
specific antibodies for 30 minutes at 37°C before addition of a fixed number of effector cells.
T2 and T2+peptide were included as controls. The targets were labeled with 51 Cr as previous
described. After labeling and leaching, the targets were plated out in 50pl/well with different
volumes (25, 50 or lOOpl) of Ma2.1 antibody for HLA-A2.1, L243 antibody for HLA-DR
(negative control) and anti-HLA-A23/24 antibody at a concentration of lOpg/ml or 20pg/ml.
89
Chapter 2: Materials & Methods
After 30 minutes incubation, the effector cells were added to the wells in 50pl/well (normally 
an E:T of 40:1 or 50:1). The rest of the assay was performed as described before.
2.12 IFNy treatment of target cells
Target cells were split 48 hours prior to assay and 200units/ml of IFNy (Roche) was added to 
the flasks. After 48 hours, the cells were harvested and used as targets in cytotoxic assays.
2.13 Treatment of cells with proteasome inhibitors
C/osto-Lactacytin p-lactone (Calbiochem) or bortezomib, also known as Velcade, 
(Millenium) were used as proteasome inhibitors. Established cell lines were split 48 hours 
prior to assay, and then 18 hours before the assay proteasome inhibitor was added to the 
flasks. For PBMC cultures, cells were incubated overnight with proteasome inhibitor in 15ml 
falcon at a concentration of approximately 2 x l0 6 /ml. Thereafter, the cells were harvested, 
counted and used in further experiments.
2.14 Flow cytometric analysis and monoclonal antibodies
Cells were analysed using a BD FACSCalibur flow cytometer or a BD FACSCanto II 
cytometer (Becton Dickinson & Co) and analysis was performed using CellQuest Pro 
analysis software or FlowJo analysis software. Analysis of PBMC by flow cytometry 
involved the construction of a live lymphocyte gate which was based upon the forward and 
side scatter profiles of these cells. For immunophenotyping, compensation was done 
automatically using an anti-Mouse Ig/Negative control compensation particles set and 
FACSDiva software (BD). Three drops of CompBeads anti-mouse Ig and CompBeads 
negative control were added per 700pl of FACS buffer, from which lOOpl was transferred
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into FACS tubes. Fluorochrome-conjugated monoclonal abs (with the same concentration 
added to the cell samples) were added per tube and incubated for 5 minutes at room 
temperature in the dark. After this incubation, 900pl of FACS buffer was added to each tube. 
These were then used as single-colour compensation controls. On the dot plot for each 
single-stained control, a gate corresponding to a single population was set up and the 
negative and positive populations on a histogram were adjusted. Compensation was then 
automatically calculated using FACSDiva software for each tube based on the corresponding 
single-stained control.
2.14.1 Monoclonal antibodies
The monoclonal antibodies used in this study are shown in Table 2.5 and 2.6. Table 2.6 
shows the panels of antibodies used for the immunophenotyping study in the last chapter of 
results.
Table 2.5 Monoclonal antibodies
CD3-PE Serotec Mouse IgGl, clone UCHT1
CD4-PE Serotec Mouse IgGl, clone RPA-T4
CD8 -FITC Serotec Mouse IgGl, clone LT8
CD8 -PE Serotec Mouse IgGl, clone LT8
CD19-FITC Serotec Mouse IgGl, clone LT19
CD107a-FITC BD Mouse IgGl, clone H4A3
CD137-FITC Serotec Mouse IgGl, clone 4B4-1
HLA-A2 (Ma2.1) ATCC HB-54: B lymphocyte hybridoma; Mouse IgG2
HLA-DR (L243) ATCC HB-55: B lymphocyte hybridoma; Mouse IgG2a
HLA-A2-FITC Serotec Mouse IgG2b, clone BB7.2
HLA-A23/24 One Lambda Mouse IgG2b
IFNy-FITC Caltag Mouse IgGl, clone B27
TCR VP 2 Serotec Mouse IgGl, Clone MPB2D5
TCR VP 3 Serotec Mouse IgGM, Clone CH92
TCR VP 5.1 Serotec Mouse IgG2a, Clone IMMU157
TCR Vp 5.2 Serotec Mouse IgGl, Clone 36213
TCR Vp 7 Serotec Mouse IgG2a, Clone ZOE
TCR VP 8 Serotec Mouse IgG2a, Clone 56C5
TCR VP 9 Serotec Mouse IgG2a, Clone FIN9
TCR VP 11 Serotec Mouse IgG2a, Clone C21
TCR VP 12 Serotec Mouse IgG2a, Clone VER2.3.2
TCR VP 13.1 Serotec Mouse IgG2b, Clone IMMU222
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TCR V3 13.6 Serotec Mouse IgGl, Clone JU-74
TCR V3 14 Serotec Mouse IgGl, Clone CAS1.1.3
TCR VP 16 Serotec Mouse IgGl, Clone TAMAYA1.2
TCR VP 17 Serotec Mouse IgGl, Clone E17.5F3
TCR VP 18 Serotec Mouse IgGl, Clone BA62
TCR VP 20 Serotec Mouse IgGl, Clone ELL1.4
TCR VP 22 Serotec Mouse IgGl, Clone IMMU546
TRC VP 23 Serotec Mouse IgGl, Clone AF-23
FITC/PE (negative) Dako Mouse IgGl/FITC;Mouse IgG2a/RPE
FITC/PE (negative) Serotec Mouse IgGl/FITC;Mouse IgGl/RPE
FITC Dako Rabbit a-mouse IgG
Table 2.6 Panels of monoclonal antibodies for immunophenotyping
Panels Fluorochrome Supplier Description Volume added/1 0 6(m.1)
HHHHHHHHI
CD56 FITC Serotec Mouse IgG2a, clone MEM-188 5
CD200 PE Serotec Mouse IgGl, clone OX-104 1 0
CD5 PE-Cy5.5 Invitrogen Mouse IgGl, clone CD5-5D7 5
CD19 PE-Cy7 Ebioscience Mouse IgGl, clone HIB19 1 0
CD16 APC Serotec Mouse IgGl, clone 3G8 2.5
CD8 APC-Cy7 Invitrogen Mouse IgGl, clone SKI 5
CD4 Pacific Blue BD Mouse IgGl, clone RPA-T4 2.5
CD3 AmCyan BD Mouse IgGl, clone SK7 2.5
T cell 
‘ subsets
CD57 FITC Serotec Mouse IgM, clone TB01 5
CCR7 PE R&D systems Mouse IgG2a, clone 150503 1 0
CD28 percp-cy.5.5 BD Mouse IgGl, clone L293 1 0
CD27 PE-CY7 Ebioscience Mouse IgGl, clone 0323 1 0
CD45RO APC Invitrogen Mouse IgG2a, clone UCHL1 2.5
CD8 APC-CY7 Invitrogen Mouse IgGl, clone SKI 5
CD4 Pacific Blue BD Mouse IgGl, clone RPA-T4 2.5
CD3 AmCyan BD Mouse IgGl, clone SK7 2.5
CD279 FITC Serotec/BD Mouse IgGl, clone MIH4 1 0
CD200R PE Serotec Mouse IgGl, clone OX-108 1 0
CD19 PE-Cy7 Ebioscience Mouse IgGl, clone HIB19 5
TCRy5 APC BD Mouse IgGl, clone B1 1 0
CD8 APC-CY7 Invitrogen Mouse IgGl, clone SKI 5
CD4 Pacific Blue BD Mouse IgGl, clone RPA-T4 2.5
CD3 AmCyan BD Mouse IgGl, clone SK7 2.5
Foxp3 FITC Ebioscience Rat IgG2a, clone PCH101 1 0
CD25 PE Miltenyi Biotec Mouse IgG2b, clone 4E3 8
CD45RA APC BD Mouse IgG2b, clone HI100 1 0
CD4 Pacific Blue BD Mouse IgGl, clone RPA-T4 2.5
CD3 AmCyan BD Mouse IgGl, clone SK7 2.5
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2.14.2 Single colour immunofluorescence staining
Cells were pelleted in wells of a 96 well round bottomed plate or in FACS tubes at l-2 x l0 5  
cells/ well or tube. The pellets were washed twice with lOOpl cold FACS buffer (or 500pl if 
tubes) and centrifuged at 2000rpm at 4°C for 2 minutes. Supernatant was removed and the 
appropriate cells were resuspended in 2-3pl of commercially available antibody, or 20pl of 
the supernatants L243 and Ma2.1. Cells were incubated for 15-30 minutes at 4°C in the dark. 
Cells were washed with lOOpl cold FACS buffer (or 500pl if tubes) and centrifuged at 
2000rpm for 2 minutes at 4°C. Supernatant was removed and the wash process repeated 
twice. The cells were resuspended in FACS buffer and were either fixed with 
paraformaldehyde (PAF) or analysed immediately. For fixation, cells were resuspended in 
lOOpl FACS buffer + lOOpl 4% PAF, giving a final concentration of 2% PAF, and incubated 
at 4°C in the dark until analysis could be performed. Where un-conjugated antibodies were 
used, cells were subsequently incubated with the secondary rabbit anti-mouse-FITC antibody 
(Dako). Cells were incubated for 15-30 minutes at 4°C in the dark, before being washed 2 
times with FACS buffer. Cells were then either fixed or analysed immediately. Negative 
control wells were included in all experiments. For directly conjugated antibodies a mouse 
IgG-FITC/PE (Dako) negative control was used. The control for un-conjugated antibodies 
was incubation with the rabbit a-mouse-FITC alone. Unstained cells were also included as 
additional controls.
2.14.3 Multicolour immunofluorescence staining
The method varied according to whether the primary antibodies were conjugated or not. For 
directed conjugated antibodies (except for Tregs panel), staining was performed in a single 
step by adding conjugated antibodies to pelleted cells for 15-30 minutes at 4°C in the dark, 
before being washed twice with FACS buffer. Cells were then either fixed or analysed
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immediately. In the immunophenotypic study, usually 1-I.5xl0 6  cells were used per tube and 
were analysed immediately after staining without fixation. The antibodies that were used for 
immunophenotyping (see Table 2.6) were optimized by using neat, Vi dilution and Va dilution 
of the recommended concentration by the manufacturer. The panels were also optimized by 
replacing antibodies that did not work together.
In the absence of a FITC-conjugated antibody, rabbit anti-mouse FITC antibody was added 
to cells after washing off the unconjugated primary antibody. The cells were incubated for 
15-30 minutes at 4°C in the dark and washed twice with FACS buffer. The directed 
conjugated antibody was then added for 15-30 minutes at 4°C in the dark. The cells were 
again washed twice and then either fixed or analysed immediately.
2.14.4 Human Foxp3 staining
For Tregs panel, cells were stained using a FITC anti-human Foxp3 staining set
(eBioscience) that preferentially stains CD4+CD25+. Cells were resuspended at
lx l0 6 /100pl/tube in FACS buffer and stained for 30 minutes on ice with the surface cell
markers: CD25-PE, CD45RA-APC, CD4-Pacific blue, and CD3-AmCyan (see Table 2.6).
Cells were washed twice with 500pl cold FACS buffer. Fix/perm buffer was made by
diluting the fixation/permeabilization concentrate ( 1  part) into the fixation/ permeabilization
diluent (3 parts). The cells were resuspended in 500pl of fix/perm buffer and incubated for
40-60 minutes on ice. This step fixes the cells. Meanwhile, perm wash buffer was made by
diluting the lOx permeabilization buffer in distilled water to a lx  solution. The cells were
washed with l-2ml of perm wash buffer and centrifuge twice at 1500 rpm for 5 minutes. The
cells were resuspended in 30pl of perm wash buffer with 2% normal rat serum and incubated
for 15 minutes on ice. This step permeabilises the cells. Without washing, lOpl of Foxp3-
FITC was added to the cells and incubated for 30 minutes on ice in the dark. After
incubation, the cells were washed and centrifuged twice with perm wash buffer. The cells
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were washed again with FACS buffer, resuspended in approximately 250 pi FACS buffer 
and analysed immediately.
2.15 Western blotting
Detection of Bax protein in cells was carried out by Western blotting. This technique 
involves the separation of proteins (based on MW) by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transfer onto a polyvinylidine 
difluoride (PVDF) support membrane followed by immunostaining.
2.15.1 Buffers
2x gel sample buffer: 0.1M Tris/HCl (pH 6 .8 ), 4% SDS, 20% glycerol, 0.1 % bromophenol 
blue, 0.4M sodium 2-mercaptoethanesulfonate (MESNA) (Sigma) made up to 100ml of 
distilled water.
Running buffer: 50mls of 20x NuPAGE MOPS (Invitrogen), 950mls distilled water, made up 
to 1L.
Blotting buffer: 30g Tris, 144g Glycine, 2L methanol, 8 L distilled water.
Casein blocking solution (IBT): 0.2% I-Block, 0.1% Tween-20, 0.002% sodium azide made 
up in PBS.
Alkaline Phosphatse (AP) buffer: 11ml Diethylamine (Tropix-Applied Biosystems), 80ml 
distilled water, pH corrected to 9.5 before adding 0.2g MgCL2 . Made up to 100ml with 
distilled water.
MESNA stripper: 6.25ml 1M Tris pH 6 .8 , 0.82g MESNA, 2.0g SDS, made up to 100ml of 
distilled water.
2.15.2 Generation of total cell lysates
Cells were counted on a haemocytometer and resuspended in 50 pi lx  PBS per 5x l0 5 - lx l0 6  
cells. An equal volume of 2x gel sample buffer was added. Cells were then frozen at -20-C.
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Prior to use samples were sonicated for 1-2 minutes on continuous setting (W0385 sonicator, 
Heatsystems-Ultrasonics Inc.), and then heated at 100 °C for 5 minutes.
2.15.3 SDS-PAGE
Equal amounts of cell lysates (10-20pl) were loaded onto pre-cast polyacrylamide gels 
(NuPAGE 4%-12% Bis-Tris gels 10 wells 1.5mM, Invitrogen) and subjected to SDS-PAGE 
using the Invitrogen XCell system (Invitrogen). Invitrogen Xcell Surelock Mini-cell was 
filled with 800-900mls of lx  Running buffer. The gel was removed from storage buffer, 
comb was taken out and adhesive strip removed from foot of gel. Wells were washed 2-3 
times with running buffer, ensuring that all air bubbles were removed. Gels were inserted 
into the tank with wells facing inwards and locked into placed. 1 0 -2 0 pi of samples and lOpl 
pre-stained marker (See blue plus2, Invitrogen) were loaded with gel loading pipette tips. 
The tank was connected to power supply and run at 200volts for approximately 50- 
60minutes. Once the gels have finished running, the gels were removed from the gel cassettes 
using the Gel knife.
2.15.4 Transfer onto PVDF membranes
PVDF membranes, cut to size, were soaked in methanol for 1 minute, and then in blotting
buffer. Pads and filter papers were soaked in blotting buffer. The gels were removed from
cassette using a piece of pre-wet filter paper to assist gel handling. The gel/membrane
sandwich was assembled by layering, if only one gel, 2  pads on the cathode core of the blot
module, then filter paper, gel, membrane, filter paper, 2 pads. If two gels, the assembly was
done by layering 2  pads, filter paper, first gel, membrane, filter paper, 1  pad, filter paper,
second gel, membrane, filter paper, 2 pads. This transfer stack was placed into Invitrogen
Xcell II blot module, taking care to avoid air bubbles between gel and membrane. Blotting
buffer was added to the central chamber, enough to just cover the gel/membrane sandwich.
Water was added to the outside chamber to help diffuse any heat generated during transfer.
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The tank was connected to power supply and run at 30v 250mA, if one gel, for 60 minutes, 
and, if two, for 80 minutes.
2.15.5 Immunodetection of protein on PVDF blots
After transfer, the membranes were washed with 0.2% PBS-Tween-20 for 10 minutes on a 
rocking platform. The blots were blocked for a minimum of 1 hour using IBT. The 
membranes were removed from the blocking reagent and cut into two. The top part was 
incubated overnight with anti-human Actin (mW 42kDa, Sigma) and bottom part with 
monoclonal anti-human Bax (mW 21kDa, R&D systems). Bax antibody was made up as a 
1/1000 dilution in IBT, and Actin was made up as 1/10000 dilution.
The membranes were removed from primary antibody and washed in PBS-Tween 3 times for 
a period of 10 minutes. After washing, the membranes were probed for 1 hour with the 
secondary antibody, made up as a 1/10000 dilution in IBT. Goat anti-rabbit IgG-AP antibody 
and goat anti-mouse IgG-AP antibody were used as secondary antibodies for Actin and Bax 
detection, respectively. The membranes were removed from secondary antibody and washed 
3 times for 10 minutes. The membranes were incubated with AP buffer for 5 minutes, and 
subsequently incubated with 500pl of substrate CDP-star (ready-to-use, Tropix-Applied 
Biosystems) to enable detection of the protein of interest using chemiluminescence. In a 
darkroom the blots were exposed to photographic film (Kodak, GE-Healthcare Life sciences) 
in an autoradiography cassette and developed using a Compact X4 automated developer 
(Xograph Imaging Systems).
2.16 Statistical analysis
All statistical analysis were performed with Graphpad Prism software. Non-parametric 
Mann-Whitney test was used for comparison of two independent groups.
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Chapter 3
Generation of CD8+ T cell Responses against Bax derived 
peptides in healthy donors
The central hypothesis for this thesis predicted that T cells specific for Bax would be 
able to recognise and kill human tumour cells. To test this prediction, T cells against Bax 
were required. However, there had been no previous reports that Bax could be immunogenic. 
In an attempt to define novel peptide epitopes from Bax protein that prime specific CTL, a 
reverse immunology approach was used (Figure 3.1). First, candidate peptides were predicted 
using computer algorithms and Bax derived peptides were synthesized. Binding of HLA-A2 
predicted peptides was analysed in a T2 binding assay. This study was primarily focused on 
HLA-A2 because it is widely expressed (30-50%) in the Caucasian population. However, 
peptides predicted to bind other HLA types were included in an effort to increase the 
possibility of generating a Bax specific T cell response, as T cells might not be restricted to 
HLA-A2 but to other HLA. Subsequently, Bax derived peptides were used to stimulate 
primary CD8 + T cells from the peripheral blood of HLA-A2 donors. In order to generate 
short-term peptide specific cultures, CD 8 + T cells were cultured for 2-4 weeks in the 
presence of IL-2 and a Bax peptide pool, using autologous PBMC as APCs. T cell 
immunogenicity for the Bax-derived peptides was tested after 2 and 4 weeks of stimulation 
using IFNy ELISpot assays.
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BAX protein (192 a.a)
MDGSGEQPRGGGPTSSEQIMKTGALLLQGFIQDRAGRMGGEAPELALDPVPQDASTKKLSECLKRIGDELDSNMELQRMIAAVDTDSPREVFFR
VAADMFS0GNFNWGRWALFYFASKLVLKALCTKVPEURTIMGWTLDFLRERLLGW1QDQGGWDGLLSYFGTPTWQTVTIFVAGVLTASLTIWKK
^  Used computer algorithms to predict candidate peptides
C andidate pep tides
cm  cz i cz] cm  izzi \m  cm cm  i z z i  cm tm
^  Bax-derived peptides synthesised
Peptide binding assa y
^  Tested HLA-A2 peptides for MHC binding using T2 cells 
In vitro priming of T cells with Bax pep tid es
U sed HLA-A2 healthy donors to test immunogenicity o f peptides: 
Stimulated CD8+ T cells with autologous PBMC + Bax peptide pool
> r
IFNy ELISpot a ssa y
^  D etected Bax specific IFNy-secreting T cells 
E nrichm ent of Bax specific  T cells
^  U sed CD107 a ssay  or IFNy secretion a ssa y
G eneration of highly specific  T cell lines I c lo n es  for BAX pep tid es
^  Expanded T cells using the antigen-independent protocol
T est ag a in s t tum our cells
Figure 3.1 General plan for the generation of Bax specific T cells.
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3.1 Defining CD8+ T cell responses against Bax pool 1-15
3.1.1 Peptide binding to HLA-A2 on the T2 cell line
There are several steps that determine processing and presentation of peptides to T 
cells. These include degradation of proteins by the proteasome, transport of peptides by TAP 
and binding of peptide to MHC class I molecules. A binding assay using the T2 cell line was 
used to analyse peptide binding to human HLA-A2. The T2 cell line is TAP deficient and 
cannot load endogenous peptide onto HLA-A2 molecules, prior to transport to the cell 
surface. This results in the production of unstable “empty” HLA-A2 molecules and therefore 
low expression of HLA-A2 at the surface of the T2 cells. HLA-A2 molecules on the T2 cells 
can be stabilised by addition of appropriate exogenous peptide, which results in an increase in 
HLA-A2 expression. The increased number of HLA-A2/peptide complexes are detectable on 
the cell surface by flow cytometry (Nijman et al., 1993). Therefore, upregulation of HLA-A2 
expression is an indication of peptide binding, which is assessed in relation to a negative 
control (no peptide sample).
Fifteen candidate epitopes (9- to 10-mers) were selected from Bax on the basis of 
scores generated by two computer algorithms (BIMAS and SYFPEITHI) (see Table 2.3). Ten 
were predicted to bind to HLA-A2, three to HLA-A3, and two to HLA-B7. However, when 
the binding of the predicted HLA-A2 peptides was tested in T2 binding assays, only 3 out of 
10 peptides showed measurable binding capacity to HLA-A2 molecules (Figure 3.2). These 
results do not exactly correlate with the scores from the computer algorithms as some of the 
highest scored peptides (e.g. Bax 2, 6  and 9) do not bind at all or bind weakly (Bax 1) to 
HLA-A2. Bax 5 (ALCTKVPEL) was the strongest HLA-A2 binding peptide, with 123% 
increase in HLA-A2 expression, followed by Bax 3 (IMGWTLDFL) with 106% increase.
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Figure 3.2 Binding of candidate peptides from Bax (pool 1-15) to HLA-A2. Binding was 
determined by flow cytometric measurement of HLA-A2 expression on the TAP-deficient T2 cell 
line. Peptides were added into wells containing T2 cells and, after overnight culture, cells were stained 
with an anti-HLA-A2.1 monoclonal antibody. Peptides that bind to HLA-A2 up-regulate HLA-A2 
expression. HLA-A2 expression was quantified as percentage increase, according to the formula: % 
Increase= [(mean fluorescence with peptide -  mean fluorescence without peptide) / mean fluorescence 
without peptide xlOO]. The positive control is a known HLA-A2 binding peptide, Flu M l58.66 
(GILGFVFTL), from Influenza A matrix 1 protein. This graph shows the results from triplicate 
experiments.
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These peptides exhibited a binding capacity that was comparable to the positive 
peptide control (163%), Flu M l 5 8 -6 6 , which is a well-known strong HLA-A2 binding peptide. 
In contrast, Bax 1 (KLSECLKRI) exhibited 52% upregulation of HLA-A2, indicating that 
this peptide is a weaker binding peptide. Therefore, three Bax peptides were potential 
candidate epitopes for T cells based on HLA-A2 binding.
3.1.2 Donor responses
The previous results identified three candidate peptides that could bind to HLA-A2. 
However, to maximise the possibility of obtaining T cell responses, the entire peptide pool 
(containing the 15 peptides) was used to stimulate T cells. This was done for two reasons: T2 
binding is not an absolute guarantee of immunogenicity and there is the possibility to 
generate non-HLA-A2 restricted responses. Twelve healthy volunteers were tested for T cell 
responses to Bax pool 1-15. Six of the twelve donors (donors 1, 4, 7, 8, 9 and 11) responded 
to Bax peptides, with responses ranging from 24 to 139 spots/105 cells. Bax specific 
responses in healthy donors are illustrated in Figure 3.3.
Three restimulation steps were necessary as only weak responses (24 to 37 spots) 
were detected in three donors after two weeks stimulation (Donor 4, 7 and 8). However, due 
to limited number of cells from donors 7 and 8, no further stimulations were possible. Donor 
1, 9, and 11 responded to Bax after 4 weeks stimulation. The frequency of Bax-specific T 
cells was greatest for donors 1 and 11, with an average number of spots of 131 and 139 per 
105 cells, respectively. However, only T cells from donor 1 could be grown and used in 
further experiments.
The remaining six donors (donors 2, 3, 5, 6, 10 and 12) did not elicit a Bax specific T 
cell response after 2 or 4 weeks but were capable of responding to mitogens (PHA, PMA, 
concavalin, ionomycin) in an ELISpot assay (>200 spots) (data not shown).
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Figure 3.3 Bax T cell responses from healthy donors after 2 to 4 weeks of stimulation (Bax pool
1-15). CD8+ T cells were purified using immunomagnetic beads and cultured with irradiated 
autologous PBMC and the Bax pool 1-15. Cultures were restimulated weekly with the Bax pool. After
2-4 weeks of culture, the number of Bax specific T cells was determined by using an IFNy ELISpot 
assay. The dashed line represents the 20 spot cut-off for a positive result and the standard deviation is 
also shown. Background responses have been subtracted from the data. SFC= Spot Forming Cells.
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As previously stated, a positive response was detected from donor 1 after 4 weeks of 
stimulation with Bax peptides. T cells from this donor were restimulated for seven more days 
with the Bax peptide pool using irradiated autologous PBMC as APCs. This additional period 
of restimulation was included in an attempt to further increase specificity for the Bax 
peptides. This T cell culture was shown to maintain specificity, with an average of 150 
spots/105 cells (Figure 3.4), however, cell numbers were low. In an attempt to generate larger 
numbers of T cells for further experiments, the resulting T cells were expanded using the 
antigen-independent protocol (section 2.7). This protocol produced a 48-fold increase in cell 
number (24xl06 from 5xl05 cells), but simultaneously there was a decrease in CD8+ T cells 
from 98% to 19%. In order to validate the immunogenicity of Bax epitopes, attempts were 
made to generate long term, stable CD8+ T cell lines, as described in the next section.
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Figure 3.4 Bax T cell response from donor 1 after 5 weeks of stimulation. CD8+ T cells from 
donor 1 were purified using immunomagnetic beads and cultured with irradiated autologous PBMC 
and the Bax pool 1-15. Culture was restimulated weekly with the Bax pool and autologous PBMC. 
After 5 weeks of culture, the number of Bax specific T cells was determined by using an IFNy 
ELISpot assay. Background response has not been subtracted. Average and standard deviation of 
triplicate wells are shown. SFC= Spot Forming Cells.
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3.2 Generation of a Bax-specific polyclonal T cell line using CD 107 assay
In an attempt to isolate Bax-specific T cells, a CD 107 activation assay was used 
because this assay had the advantage that it did not require knowledge of epitope specificity, 
and it allowed direct sorting of CD8+ cytotoxic T cells. During T cell killing, cytotoxic 
granules, which express LAMPs (CD 107a, CD 107b and CD63), are transported to cell 
membrane, releasing cytotoxic mediators, such as perforin and granzymes, into the immune 
synapse between the effector T cell and the target. These LAMPs are transiently exposed on 
the cell surface during degranulation. The CD 107 assay allows direct detection of 
degranulation of activated T cells by flow cytometric measurement of CD 107 surface 
expression. Several groups have used CD 107 assay to identify antigen-specific CD8+ T cells 
(Betts et al. , 2003; Rubio et al., 2003). Rubio et al. (2003) were able to directly identify and 
isolate viable populations of tumour-cytotoxic T cells from patient blood using CD 107a as a 
marker after tumour stimulation.
Therefore, CD8+ T cells from donor 1 (after 5 weeks stimulation) were tested for their 
ability to secrete lytic granules in response to Bax peptides using the CD 107 assay. This 
assay was used to identify and isolate polyclonal T cells specific for Bax peptides by flow 
sorting. It was possible to detect 1.6% CD107a+CD8+ T cells specific for Bax (Figure 3.5), 
with almost no detection when T cells were left unstimulated (0.04%) or stimulated with just 
the APC T2 alone (0.09%) (data not shown). Subsequently, 1.5xl04 CD107a+CD8+T cells 
were flow sorted (MoFlo) and propagated using the antigen-independent expansion protocol 
(section 2.7). An enriched T cell population against Bax was generated (lOxlO6 cells), 
showing an enrichment to 32.9% CD107a+CD8+ T cells against Bax peptides (Figure 3.5), 
which is hereon referred to as the JSB line. In addition, either 1 cell/well or 10 cells/well were 
plated into the wells of 96 well plates using the MoFlo cell sorter (10 plates with 1 cell/well 
and 2 plates with 10 cells/well) (section 2.10.2). However, these cells proved difficult to grow 
and no further tests were done.
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Figure 3.5 The approach used to derive a Bax peptide specific T cell line (JSB line) by surface 
expression of CD 107a. Activation of CD8+ T cells after encounter with APC pulsed with Bax 
peptide pool 1-15 was determined by cell surface expression of CD107a. Flow sorting (MoFlo cell 
sorter) was used to generate a CD 107a+CD8+enriched population (1.5xl04). This sorted population 
was expanded using the antigen-independent expansion protocol (lOxlO6) before testing again for 
CD107a expression. This gave an enrichment from 1.6% to 32.9% for CD107a+CD8+ cells following 
peptide stimulation.
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3.2.1 Mapping epitopes from Bax pool 1-15 responses using the JSB line
Bax specific T cells from JSB were originally detected on the basis of IFNy secretion 
(ELISpot). To test whether the CD 107 assay had also enriched for IFNy-secreting T cells, 
ELISpot assays were performed to assess the frequency of Bax specific T cells, and to 
precisely map the peptide epitopes.
The JSB line was tested with the entire Bax peptide pool and 3 split pools (Bax pl-p5, 
p6-pl0, and p i 1-15). A positive response against whole Bax peptide pool was detected (200 
spots/105 cells), which was narrowed down to split pool Bax 1-5 (Figure 3.6A). The response 
against this split pool was mapped to Bax p i, p3 and p5 (Figure 3.6B). Bax p i and p5 
responses were relatively weak (49 spots/105 cells and 52 spots/105 cells) when compared 
with Bax p3 (209spots/105 cells). The Bax p3 response was approximately equal to that of 
Bax peptide pool response, suggesting it was a dominant epitope in the Bax peptide pool. 
This demonstrated that the three potential peptides that up-regulated HLA-A2 on T2 cells 
(shown in section 3.1.1) were immunogenic to CD8+ T cells.
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Figure 3.6 Mapping the Bax response from the JSB line to split pools and individual peptides.
The JSB line was tested by IFNy ELISpot against the whole Bax pool, and split pools: Bax 1-5, Bax 
6-10, and Baxl 1-15 (A). The JSB line was again tested by ELISpot against the whole Bax pool, split 
pool Bax 1-5 and individual peptides Bax p i, p2, p3, p4 and p5 (B). Background responses were 
subtracted from this data. The dashed line represents the 20 spot cut-off for a positive result and the 
standard deviation is also shown. SFC= Spot Forming Cells.
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3.2.2 Loss of Bax peptide specificity through repeated expansions of the JSB line
In order to characterize Bax specific T cell responses in detail, a major aim was to 
generate a highly specific T cell line that could be maintained in culture. However, repeated 
attempts to expand T cell numbers using the antigen-independent protocol produced low 
yields of T cells (2xl06/ expansion), with poor viability (< 50% viable). In addition, the 
repeated expansion attempts led to a loss of peptide specificity as determined by the CD 107 
assay. The percentage of CD107+CD8+ T cells specific for Bax decreased from 30% to 17%, 
10% and 3% after subsequent rounds of expansion (Figure 3.7).
Other enrichments of Bax specific T cells from this donor were done by CD107-FITC 
and flow sorting or FITC magnetic beads (Miltenyi Biotec), but these T cells also proved to 
be difficult to grow and to sustain high specificity to Bax (data not shown). Some of the 
frozen JSB cells from the initial expansion were later used with a new method of selection, 
which is discussed in section 3.6.
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Figure 3.7 Demonstration of Bax specificity loss of the JSB line after repeated expansions using 
CD107 assay. The JSB line was expanded using the antigen-independent protocol. Specificity was 
determined by surface expression of CD107a after incubation of the JSB line with T2 cells in presence 
o f the Bax peptide pool. T cells were gated based upon their forward and side scatter profile. Flow 
cytometric analysis was done using CellQuest software.
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3.3 Defining CD8+ T cell responses against Bax pool 601-23
As described in section 3.2, the JSB line that was generated by flow sorting using 
CD 107a expression did not retain specificity and proved difficult to grow. No T cells specific 
for Bax from other donors could be isolated and further characterised due to limited numbers 
and relative low frequency of T cells. There is a possibility that the selection process for the 
original set of fifteen peptides could have missed potential epitopes. Nevertheless, three 
peptides were shown to be immunogenic to human CD8+ T cells and therefore putative 
epitopes worthy of further investigation. A new set of peptides, which included those three 
peptides, and 20 more candidate epitopes were identified from the Bax protein (Bax pool 
601-23). Fourteen peptides were predicted to bind to HLA-A2, one to HLA-A3, one to HLA- 
B7, two to HLA-A1, two to HLA-B8 and three to HLA-B44. The first step was to identify if 
the peptides were immunogenic to human T cells. T cell immunogenicity for Bax derived 
peptides was tested using an in vitro approach as previously done for the first Bax pool. 
ELISpot assays were carried out to detect Bax reactive IFN-y-secreting T cells. Table 3.1 
shows both sets of Bax pools (Bax pool 1-15 and Bax pool 601-23).
112
Chapter 3: Results
Table 3.1 Bax pool 1-15 (A) and Bax pool 601-23 (B) 
A B
Res idue  HI  \  
Pos i t i on
Sentience
ALFYFASKL
WIQDQGGWV
6 PVPQDASTK 49 A3
7 VLKALCTKV 121 A2
8 IMKTGALLL 19 A2
9 ALFYFASKLV 112 A2
10 VVYNAFSLRV 209 A2
11 KLVLKALCTK 119 A3
12 VVALFYFASK 110 A3
13 VPQDASTKKL 50 B7
14 KPPHPHHRAL 163 B7
15 LVLKALCTKV 120 A2
Highlighted rows correspond to the peptides that 
were used in both Bax peptide pools
601 RMGGEAPEL 37 A2
602 QIMKTGALL 18 A2
603 LLSYFGTPT 161 A2
604 LLQGFIQDRA 26 A2
605 GLLSYFGTPT 160 A2
606 FVAGVLTASL 176 A2
607 ELQRMIAAV 75 A2
608 ALDPVPQDA 46 A2
609 LLLQFIQDR 25 A2
610 TIMGWTLDFL 135 A2
611 FLRERLLGWI 143 A2
615 DELDSNMEL 68 B44
616 MELQRMIAA 74 B44
617 SEQIMKTGAL 16 B44
618 CLKRIGDEL 62 B8
619 ASKLVLKAL 117 B8
620 GGWDGLLSY 156 Al
621 DTDSPREVF 84 Al
622 VALFYFASK 111 A3
623 SPREVFFRV 87 B7
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3.3.1 Peptide binding to HLA-A2 on the T2 cell line
Twenty new candidate epitopes were selected from Bax on the basis of a computer 
score, using three to six computer algorithms (Table 2.4). Fourteen were predicted to bind to 
HLA-A2 and were therefore used in a T2 binding assay. From the fourteen potential HLA-A2 
binding peptides, only the three original peptides that were considered immunogenic in the 
previous pool showed measurable binding capacity to HLA-A2 molecules (Figure 3.8). 
Again, Bax p614 (ALCTKVPEL = Bax p5 from old pool) was the strongest HLA-A2 binding 
peptide (150%) followed by Bax p613 (IMGWTLDFL = Bax p3) with 115% increase, which 
showed a binding capacity comparable to the positive peptide control (161%), Flu M l 5 8 -6 6 * 
Bax p612 (KLSECLKRI= Bax pi) exhibited a lower up-regulation than the other two 
peptides as previously shown. These three peptides were predicted to bind to HLA-A2 by 6/6 
computer algorithms, but one peptide (Bax 601) that was also predicted by 6/6 computer 
algorithms did not actually bind to HLA-A2 according to this assay. Thus, based on the 
criteria of strong peptide binding, Bax peptides p614, p613 and p612 would be predicted to 
be likely T cell epitopes.
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Figure 3.8 Binding of candidate peptides from Bax (pool 601-23) to HLA-A2.
Binding was determined by flow cytometric measurement of HLA-A2 expression on the TAP- 
deficient T2 cell line. Peptides were added to wells containing T2 cells and, after overnight culture, 
cells were stained with anti-HLA-A2.1. Peptides that bind to HLA-A2 up-regulate HLA-A2 
expression. HLA-A2 expression was quantified as a percentage increase according to the formula: % 
Increase= [(mean fluorescence with peptide -  mean fluorescence without peptide)/ mean fluorescence 
without peptide xl00]. The positive control is a known HLA-A2 binding peptide, Flu M l58-66 
(GILGFVFTL), from Influenza A matrix 1 protein. HLA-A2- Bax peptides 615 to 623 were also 
tested as negative controls and no HLA-A2 up-regulation was seen for these (data not shown). This 
graph shows the results from triplicate experiments.
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3.3.2 Donor responses
Five healthy volunteers were tested for T cell responses to Bax pool 601-23. As donor 
11 showed a positive response for Bax pool 1-15 (Figure 3.3), cells from this donor were also 
tested against Bax pool 601-23. Unfortunately, the donor for JSB line was not available to 
donate more blood, so it was not possible to test this donor with the Bax peptide pool 601-23.
Positive but variable Bax T cell responses (23 to 160 spots/ 105 cells) were detected 
from all of the five donors after 4 weeks of stimulation with peptide. However, none of 
donors elicited a Bax specific T cell response after 2 weeks of stimulation (Figure 3.9). Donor 
11 showed the highest Bax specific T cell response with an average count of 160 spots, 
followed by donors 13 and 15 with 130 and 99 spots, respectively. Donor 14 and 16 
responded weakly to Bax peptides, with an average number of 32 and 23 spots, respectively. 
All of the donors were capable of responding to mitogens (PHA, PMA, concavalin, 
ionomycin), positive control in ELISpot (>200 spots/105 cells) (data not shown).
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Figure 3.9 Bax T cell responses from healthy donors after 2 to 4 weeks of stimulation (Bax pool 
601-23). CD8+ T cells were purified using immunomagnetic beads and cultured with irradiated 
autologous PBMC and Bax pool 601-23. Cultures were restimulated weekly with the Bax pool. After 
2-4 weeks of culture, the number of Bax specific T cells was determined using an IFNy ELISpot 
assay. The dashed line represents the 20 spot cut-off for a positive result and the standard deviation is 
also shown. Background responses have been subtracted from data. SFC= Spot Forming Cells.
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3.4 Testing different protocols for the detection of peptide specific T cells
As demonstrated in sections 3.1.2 and 3.3.2, it was possible to generate short-term Bax 
peptide specific CD8+ T cell cultures. However, initial attempts to produce highly enriched 
peptide specific T cell lines and clones from these low frequency cultures failed. So, it was 
crucial to develop a consistent method for detecting and purifying peptide specific T cell lines 
and clones.
To address this, a test was made using Melan-A/MART-1 peptide because it is a model 
system for naive T cell responses against HLA-A2 tumour antigens. It is possible to detect 
responses against Melan-A/MART-1 in a large proportion of healthy HLA-A2 donors (Pittet 
et al., 1999). T cells were cultured as explained in section 2.5. Briefly, T cells were 
stimulated with peptide on days 0 and 7, and grown until day 14. The cultures were then 
tested for specificity using several different detection systems. T2 or autologous frozen 
PBMC were used as APC.
Several studies have shown that CD107 (Betts et al., 2003; Rubio et al., 2003), CD137 
(Wolfl et a l ,  2007) and IFNy (Brosterhus et al., 1999; Campbell, 2003; Oelke et a l ,  2000) 
can be used to detect and isolate antigen-specific T cells. Therefore, all these methods were 
compared for detection of MART-1-specific T cells, in order to determine the optimum 
method for selection of Bax-specific T cells. The CD 107 assay detects antigen-specific T 
cells by measurement of the surface expression of CD 107a as a marker for degranulation of 
activated T cells (see section 3.2). The CD 137 assay measures CD 137 expression on 
specifically activated CD8+ T cells. CD 137 (4-IBB) is a member of the TNFR-family with 
costimulatory function that promotes T cell proliferation and T cell survival. Antigen specific 
IFNy secretion by CD8+ T cells was also investigated by ELISpot assay and flow cytometry 
based ICS.
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Figure 3.10 illustrates all the methods used for detection of peptide-specific T cells. The 
ELISpot assay demonstrated a positive response against MART-1 peptide with an average of 
290 spots/105 cells after subtracting background, which gives approximately 0.3% of positive 
cells against MART-1 (Figure 3.10A). As for the CD 107 assay, no peptide-specific T cells 
were detected with this method as the percentage of CD107a+CD8+ T cells was similar when 
incubated with only T2 or with T2 + peptide (-1%) (Figure 3.10B). The CD137 assay 
showed 0.3% CD137+CD8+ T cells against MART-1 after background subtraction (2.3% T 
cells + T2; 2.6% T cells + T2 + MART-1) (Figure 3.10C). Finally, it was possible to detect a 
higher percentage of MART-1 specific T cells (1.5% after subtracting background) when 
using IFNy ICS. Further to this, it was also noticeable that the expression intensity of IFNy+ 
peptide specific T cells was several fold higher than T cells + T2 without peptide, or CD 137+ 
T cells (Figure 3.10D). This suggests that it should be easier to distinguish activated versus 
non-activated T cells for cell sorting purposes.
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Figure 3.10 Comparison of methods for detection of MART-1 specific T cells. An ELISpot assay 
was set up in triplicate wells with T cells alone, T cells+APC, T cells+APC+MART-1. Background 
response has not been subtracted (A). Flow cytometric analysis o f % CD107a+CD8+cells (B), 
%CD137+CD8+ (C) % IFNy-secreting CD8+ (D) within the lymphocyte gate after incubation with 
T2 with or without peptide. All samples were stained with an anti-CD8-PE antibody. T cells were 
gated based upon their forward and side scatter profile. Dead cells were excluded from analysis of d) 
plots using negative gating, based on 7-AAD staining. Flow cytometric analysis was done using 
CellQuest software.
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3.5 Generation of T cell lines against Bax pool 601-23 using IFNy secretion assay
An approach was developed in order to isolate T cell lines and clones (Figure 3.11). 
This involved immunomagnetic enrichment of peptide-specific T cells based on IFNy 
secretion (section 2.9). This approach was used because initial screening of Bax specific T 
cells involved detection of IFNy-secreting T cells (ELISpot), and IFNy secretion provided the 
best results by flow cytometry (Figure 3.10)
3.5.1 Enrichment of IFNy-secreting cells from donor 11 using magnetic-based cell
sorting
Donor 11 showed the strongest peptide response in an ELISpot after 4 weeks, thus T 
cells from this donor were used to characterise the Bax specific responses in detail. T cells 
from donor 11 were expanded using the antigen-independent protocol to provide sufficient 
numbers for enrichment. ELISpot results showed a similar response against Bax as in pre­
expansion (155 spots/105 cells) (data not shown). T cells (4xl06) were activated with APC 
and Bax pool 601-23 prior to detection and enrichment of IFNy-secreting T cells. Pre-sorted 
and post-sorted cells were taken for analysis to assess the enrichment of the IFNy+ T cells 
(Figure 3.12).
Analysis of the pre-sort cells showed that 6.45% were IFNy-i- CD8+ T cells reactive to 
Bax pool. Bax specific IFNy-secreting cells were enriched to 87.36% of CD8+T cells. This 
also showed that the CD8 negative T cells were lost with the enrichment. Furthermore, the 
mean fluorescence intensity (MFI) of the IFNy+ cells in the post-sort fraction was several 
fold higher than in the pre-sort fraction, suggesting that this method preferentially selects for 
cells that secrete high levels of IFNy. The implementation of a magnetic-based cell sorting 
technique permitted the isolation of 1.2xl05 enriched Bax-specific CD8+ T cells from a 
starting population of 4x106 cells. These enriched cells were then used in the generation of T 
cell lines containing high frequencies of Bax-specific T cells.
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Enrichment of Bax-specific T cells from donor 11 
based on IFNy secretion and magnetic sorting
Enriched T cells (1.2x10s)
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Figure 3.11 Overview of the process by which Bax-specific T cell lines were generated from 
donor 11.
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Figure 3.12 Enrichment of IFNy-secreting Bax-specific T cells from donor 11 using a magnetic 
bead cell sorting system. After re-stimulation of T cells from donor 11 with Bax pool 601-23 and 
irradiated T2 for 4hours, the IFNy-secreting cells were stained with anti-IFNy-PE antibody and were 
enriched using anti-PE magnetic beads. Cells were also stained with an anti-CD8-FITC antibody. The 
pre-sort (A) and post-sort (B) fractions were analysed by flow cytometry. T cells were gated based 
upon their forward and side scatter profile, and dead cells were excluded from analysis using negative 
gating, based on 7-AAD staining. The percentage of each quadrant is shown. Flow cytometric 
analysis was done using FlowJo software.
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3.5.2 Generation of KSI line through the antigen-independent expansion of IFNy- 
enriched T cells
To increase the likelihood of generating a highly specific T cell line from the enriched 
cells, two different methods were utilized: expansion using the antigen-independent protocol 
(section 2.7) and cloning under limiting dilution conditions in 96 well plates (section 2.10.2). 
The first method involved the antigen-independent expansion of 7.8x104 enriched cells. This 
was seen as a necessary precaution in case no other T cell lines or clones were generated from 
the limiting dilution cultures. From this expansion, 8x l06 cells were recovered and these are 
referred to as KSI line. These cells were re-expanded to secure a large stock of these cells. 
Further characterisation of this T cell line is shown in the next chapter.
3.5.3 Generation of Bax-specific KSI 10B7 T cells using the limiting dilution 
protocol
To generate Bax specific T cell lines, the IFNy-enriched cells were plated at varying 
concentrations into seven 96 well cloning plates (section 2.10.2). After 3-4 weeks, 90-100 
cultures had grown sufficiently to have at least two replicate wells. In total, 60 cultures were 
grown from plates with 10 cells/well and 40 cultures from 1 cell/well. These were tested by 
ELISpot assay with the Bax pool 601-23 to indicate the specificity of each culture (section 
2.10.3). The purpose of the ELISpot was to help selection of the most specific cultures for 
further study. From these results (Figure 3.13) it can be seen that the vast majority of cultures 
recognised Bax peptides, although with varying magnitudes of response. Cultures B7 from 10 
cells/well plates (Figure 3.13A), 3B2 and 4E9 from 1 cell/well plates (Figure 3.13B) provided 
the strongest responses. The spot counts for the 3 cultures selected for expansion were above 
200 spots and B7 culture gave the strongest response against Bax (644 spots).
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Figure 3.13 T cell lines (100 in total) generated using limiting dilution culture conditions were 
screened for recognition of Bax pool by ELISpot assay. To help estimate the average cell number 
in the cultures, 4 different cultures were counted. The cell counts ranged from 5xl04 to 1.5x10s, with 
a mean average of 1.0x10s cells/well. On average 2-3 xlO4 cells/well from each culture were plated 
out with 3xl04 T2 cells in the presence and absence of Bax pool 601-23 (10pg/ml) in an ELISpot 
plate. There was only one well for each condition. 60 lines were generated from 10 cells/well plates 
(A) and 40 lines generated from 1 cell/wel (B). The actual frequency of Bax-specific T cells in each 
line could not be determined in this experiment as the exact number of cells added per well was 
unknown. The lines selected for expansion are highlighted (*). Background responses (+T2 without 
peptide) have been subtracted.
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Cells from each culture were further propagated using the antigen-independent 
expansion protocol. For unknown reasons, cultures 3B2 and 4E9 did not expand well, and 
there were insufficient cells for further characterisation. Therefore, only B7 culture was used 
for further characterisation (described in the next chapter), which is hereon referred as KSI 
10B7.
3.6 Generation of T cell lines from JSB cells using IFNy secretion assay
Since this enrichment protocol allowed the successful generation of lines from a low 
frequency population, the JSB line that was previously generated by CD107 sorting (section 
3.2) was “re-sorted” based on IFNy secretion. These enriched T cells were then used to 
produce several T cell lines using the approach described previously for Donor 11 in Figure 
3.11.
3.6.1 Enrichment of IFNy-secreting cells from JSB cells using magnetic-based cell
sorting
Bax p i, p3 and p5 were found to be immunogenic to JSB line (Figure 3.6) and so to 
increase the chance of getting more specific T cells, only these three peptides were used to 
activate T cells prior to sorting. Analysis of the pre-sort cells showed that 11.22% of JSB 
cells were reactive to Bax peptides, as measured by dual expression of CD8 and IFNy. Bax 
specific IFNy-secreting CD8+ T cells were enriched to 92.18% after sorting (Figure 3.14). An 
IFNy+ CD8 T cell population with a lower expression intensity was also detected in the 
presort (11%) but virtually eliminated after sorting. The MFI of the IFNy+ cells in the post­
sort fraction was several fold higher than in the pre-sort fraction, implying again that cells 
secreting high levels of cytokine are preferentially selected by this method. This technique 
permitted the isolation of l.OxlO4 enriched Bax-specific CD8+ T cells.
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Figure 3.14 Enrichment of IFNy-secreting Bax-specific T cells from JSB line using a magnetic 
bead cell sorting system. After re-stimulation o f JSB line with Bax peptides p i, p3 and p5 and 
irradiated T2 for 4 hours, the IFNy-secreting cells were stained with anti-IFNy-PE antibody and were 
enriched using anti-PE magnetic beads. Cells were also stained with an anti-CD8-FITC antibody. The 
pre-sort (A) and post-sort (B) fractions were analysed by flow cytometry. T cells were gated based 
upon their forward and side scatter profile, and dead cells were excluded from analysis using negative 
gating, based on 7-AAD staining. The percentage o f each quadrant is shown. Flow cytometric 
analysis was done using FlowJo software.
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3.6.2 Generation of JSBI line through the antigen-independent expansion
As done for the generation of KSI line, some of the enriched cells were expanded 
using the antigen-independent protocol as a precaution in case no cells were grown from the 
limiting dilution cultures. In this case, because of the lower number of enriched cells, only 
9.3x103 cells were expanded using the antigen-independent protocol. After two rounds of 
expansion, a large stock of these cells (18xl06) was obtained and these are referred to as JSBI 
line. Further characterisation of this T cell line is described in the next chapter.
3.6.3 Generation of Bax-specific JSBI 10B6 T cells using the limiting dilution 
protocol
The IFNy-enriched cells were also cultured under limiting dilution conditions in seven 
96 well cloning plates as described in section 2.10.2. After 4-5 weeks, only ten cultures had 
grown sufficiently to have at least two replicate wells. Five T cell cultures were grown from 
plates with 10 cells/well added and five cultures from 1 cell/well. However, it must be taken 
into consideration that the cells from this donor were known to be difficult to grow from 
previous experiments when the T cells were sorted using CD 107 (section 3.2.2).
These cultures were tested by ELISpot with Bax peptides p i, p3 and p5 to confirm 
the specificity of each culture (Figure 3.15). Almost all the cultures recognised Bax peptides, 
although with varying magnitudes of response. 10E6 and 3E6 cultures were selected for 
expansion, with spot counts of 480 and 200, respectively. Unfortunately, only 10E6 line was 
able to grow to sufficient number for further characterisation, which hereon is called JSBI 
10E6. Further characterisation of JSBI 10E6 will be discussed in the following chapter.
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Figure 3.15 T cell lines (10 in total) generated using limiting dilution culture conditions were 
screened for recognition of Bax peptides by ELISpot assay. On average 2-3.0xl04 cells/well from 
each culture were plated out with 3xl04 T2 cells in the presence and absence of Bax peptides pi, p3 
and p5 (10pg/ml). There was only one well for each condition. Five lines were generated from 
lOcells/well plates and five lines generated from lcell/wel. The actual frequency of Bax-specific T 
cells in each line could not be determined in this experiment as the exact number of cells added per 
well was unknown. The lines selected for expansion are highlighted (*). Background responses (+T2 
without peptide) have been subtracted.
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3.7 Discussion
In the first stage of this study, the ability of Bax-derived peptides to generate peptide- 
specific CD8+ T cells in healthy donors was investigated. This involved a reverse 
immunology approach, which consisted of candidate peptide selection based on computer 
algorithms, peptide binding assays to determine the actual binding of the predicted peptides 
to MHC molecules, in vitro stimulation of CD8+ T cells from healthy donors, generation of 
highly peptide specific T cell lines and clones, and ultimately testing the generated T cells 
towards tumour target cells endogenously expressing the antigen (discussed in chapter 4). A 
large number of CD8+ T cell epitopes have been identified from several human tumour 
antigens using this approach, such as hTERT (Minev et al., 2000), PSCA (Kiessling et a l ,  
2002),. STEAP (Rodeberg etal., 2005), and survivin (Reker et a l ,  2004).
Alternatively, a direct immunology approach could have been used in this study, 
which investigates the specificity of T cells that recognise tumour cells in order to define the 
epitope. The tumour-reactive T cells are used to screen cDNA libraries prepared from 
autologous tumour cells for expression of a potential antigen. This approach allowed the 
identification of the first tumour antigen MAGE-1 (van der Bruggen et a l ,  1991). Another 
alternative approach, which also starts from T cell function, uses biochemical methods to 
purify naturally occurring peptides associated with MHC molecules on the tumour cells. 
After acid elution from the MHC molecules, these are fractionated by high-performance 
liquid chromatography (HPLC), and the fraction that is recognised by T cells is then analysed 
by mass spectrometry to identify the peptide epitopes (Cox et a l ,  1994). However, this 
approach requires large numbers of cells (109 to 1010) and highly sensitive analytical 
techniques due to the low number of tumour-specific peptides among thousands of other 
peptides. Such approaches have been most successful in identifying melanoma-associated 
antigens (Cox et a l ,  1994; van der Bruggen et a l ,  1991). Nevertheless, it has been 
complicated to employ this method for the identification of other cancer antigens because it is
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difficult to isolate and grow tumour cell lines from most of other types of cancers, and large 
numbers of long-term stable T cell clones or lines for screening are required, which 
frequently cannot be achieved. Thus, the reverse immunology approach seemed to be the 
most appropriate and straightforward for the present study.
Initially, 15 candidate peptides were identified from Bax protein using two computer- 
based algorithms. Three peptides (Bax p i, p3 and p5) were shown to bind to HLA-A2 
molecules in a T2 binding assay. Binding to HLA is a pre-requisite for T cell recognition. 
Efficient peptide binding to MHC class I is necessary for immunogenicity. However, 
immunogenicity is not assured by efficient peptide binding to MHC molecules, suggesting 
that other factors are involved (Feltkamp et al., 1994). Furthermore, predictive algorithms are 
not 100% precise as not all high-scoring peptides bind to MHC molecules (e.g. Bax 2, 6 and 
9) and some low-scoring peptides are epitopes.
Correlation between actual peptide binding and immunogenicity is not perfect. 
Peptides that bind with high affinity are not always epitopes, and peptides that bind with low 
affinity sometimes are epitopes, e.g. hTERT peptide with low affinity to HLA-A2 
(Hernandez et al., 2002). Peptide-MHC complex stability and immunogenicity are more 
closely correlated than peptide affinity and immunogenicity. Immunogenic peptides are 
characterised by a low dissociation rate, indicating that they induce stable MHC-peptide 
complexes. Peptides (including low or intermediate affinity peptides) that display low 
dissociation rates are immunogenic, while peptides with a high dissociation rate are probably 
non-immunogenic (van der Burg et al., 1996). So, in order to increase the chance of finding 
immunogenic peptides, a Bax pool containing all predicted peptides was tested for its ability 
to trigger primary CD8+ T cells from the peripheral blood of HLA-A2 healthy donors. This 
study was focussed on HLA-A2 restricted T cell responses because the frequency of this 
allele in the Caucasian population (30-50%) and the availability of well-characterized 
reagents.
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Twelve healthy donors were tested by ELISpot for T cell responses against Bax pool 
1-15. Overall, six donors responded to Bax peptides with variable responses after two to four 
weeks of stimulation. Three restimulation steps were included in the in vitro culture protocol, 
so as to increase the frequency of peptide-specific T cells. This indicated the likelihood that 
these were naive T cell responses. Several studies have demonstrated that healthy donors can 
be used to evaluate the immunogenicity of peptides from well-known antigens, such as PSA 
(Correale et al., 1997; Elkord et al., 2005) , STEAP (Rodeberg et al., 2005), PTHrP (Yao et 
al., 2004), survivin (Schmitz et al., 2000) and hTERT (Hernandez et al., 2002; Minev et al., 
2000). For example, two hTERT peptides induced peptide-specific CTLs in 7-9 out of 10 
healthy donors (Minev et al., 2000). The data obtained here is comparable to those findings, 
by demonstrating that T cell precursors for self-antigens circulate in the peripheral blood of 
healthy donors.
It was possible that the selection of the peptides of Bax pool 1-15 using only two 
algorithms could have missed potential epitopes. Therefore, a new set of peptides was 
identified from Bax protein using three to six algorithms. Interestingly, the HLA-A2 binding 
peptides that were shown to be immunogenic in Bax pool 1-15, were also ranked highly by 
the additional algorithms. However, these algorithms did not predict any further peptides that 
were capable of binding to HLA-A2 in T2 binding assays. Therefore, epitope prediction 
efficiency was not increased by using additional algorithms.
Screening healthy donors for T cell responses using the Bax peptide pool 601-23 
produced similar results to Bax peptides 1-15. A donor (donor 11) that had strong response 
against Bax pool 1-15, also had a strong response against Bax pool 601-23. Neither the 
magnitude nor the kinetics of the responses improved with the new 601-23 Bax peptide set. 
However, the data obtained here indicated that at least one peptide derived from Bax should
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be immunogenic to human CD8+ T cells and that T cell precursors reactive to Bax are 
present in the peripheral blood of healthy donors.
The IFNy ELISpot assay was used to detect low frequency peptide specific T cells in 
culture. This assay has been extensively used in the laboratory to monitor HPV specific 
responses in peripheral blood of healthy donors and patients (Gallagher & Man, 2007; Smith 
et al., 2005). The ELISpot assay is a simple, reliable, cost effective and very sensitive 
technique, permitting enumeration of antigen-specific T cells at frequencies lower than 1 in 
10,000 (Helms et al., 2000). This assay is particularly useful when dealing with low cell 
numbers for analysis (Shacklett etal., 2003). The ELISpot is less expensive, uses less number 
of cells for analysis than ICS. Furthermore, this assay is more suitable to use when detecting 
low frequency T cell responses than ICS due to its lower detection limit (Karlsson et al., 
2003). The criteria used in this thesis to define a positive response of >20 spots per 1x10s 
cells after subtraction of background is either similar or more stringent than that used by 
several other groups (Currier et al., 2002; Godard et al., 2004; Karlsson et al., 2003)
The initial experiments using the Bax pool 1-15 allowed limited characterisation of T 
cells from a single donor (Donor 1). The first attempt to generate long term, stable CD8+ 
Tcell lines/clones involved using the CD 107 assay combined with high speed flow cell 
sorting. It allowed the demonstration that at least three of the HLA-A2 binding peptides were 
candidate T cell epitopes. However, it proved difficult to derive T cell lines or clones for 
further characterisation, and to address the central hypothesis.
Repeated expansions of JSB cells using the antigen-independent protocol produced
low yields of T cells with poor viability and led to a loss of peptide specificity as verified by
CD 107 assay. This loss of Bax specificity could have occurred for a number of reasons. The
antigen-independent expansion protocol uses non-specific stimuli (IL-2 and PHA) which
support multiple rounds of T cell proliferation. During this process, there is the possibility
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that the non-specific T cell population (which also included CD4+ T cells) expanded to a 
greater degree compared to the Bax-specific T cells. The CD107-based sorting may 
compromise cell viability to some extent, in part through the toxicity of the reagent GolgiStop 
(BD). An alternative explanation for poor viability or functionality of the T cells could be that 
the flow cell sort conditions are too harsh for these T cells. Given that cells are submitted to 
considerable stress by acceleration in the nozzle, vibration, illumination, decompression, 
charging and deflection. It is likely that some damage occurs to the sorted T cells. Besides 
that, the flow sorting procedure is laborious and requires a trained technician to run the 
apparatus.
Rubio et a l  (2003) were able to identify and isolate viable populations of tumour 
cytolytic T cells from blood using CD107a and flow cell sorting. However, for this current 
study (and other studies in the laboratory) it was not possible to corroborate their findings. 
Therefore, it was necessary to develop a consistent method for detecting and purifying low- 
frequency peptide specific T cell lines and clones. Several methods have been reported for 
this purpose, including CD107 (Betts et a l ,  2003; Rubio et a l ,  2003), CD137 (Wolfl et a l ,  
2007) and IFNy secretion (Brosterhus et a l ,  1999; Oelke et a l ,  2000) assays. These methods 
were compared using MART-1 peptide as model antigen and only IFNy secretion 
demonstrated a distinct population of peptide-specific T cells.
The IFNy secretion assay has an advantage over CD 107 assay by not requiring the 
addition of GolgiStop, which may partly affect the viability of cells. Furthermore, unlike 
high-speed flow cell sorting, there was little physical stress during MACs sorting, favouring 
the recovery of viable cells. This assay allows the identification and isolation of viable 
cytokine-secreting cells with very low frequencies (down to 0.0001%) by MACs (Campbell, 
2003). However, it is not suitable for isolation of high frequency of antigen-specific T cells, 
as the culture medium can become saturated with cytokine and all cells will be non- 
specifically labelled. This method requires a restimulation step with antigen to produce IFNy
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secretion. Due to the downregulation of TCR after antigen stimulation, the enriched T cell 
fraction cannot be tested directly after selection and needs a further culture period to permit 
re-expression of the TCR. This IFNy based enrichment has been used by a number of groups 
to isolate antigen-specific T cells (Brosterhus et a l ,  1999; Campbell, 2003; Oelke et a l ,
2000). It has also been used successfully in the laboratory to generate CD4+ T cell 
lines/clones highly specific to a HPV peptide (Gallagher & Man, 2007).
Besides the methods explained above, soluble MHC-peptide tetramers have been 
widely used to enumerate and isolate antigen specific T cells, for example in melanoma and 
HIV patients (Dunbar et a l ,  1998; Lee et a l ,  1999; Yee et a l ,  2002). The use of 
commercially made tetramers to enrich Bax specific T cells was not an option due to the high 
cost of production to engineer several different peptide-MHC complexes. On the other hand, 
the IFNy based enrichment was selected for use because it is a rapid, cost-effective, and 
relatively simple technique that does not require knowledge of peptide epitopes. Moreover, 
the advantage of this technique is that it would select T cells based on their effector function, 
whereas tetramer staining does not reveal information about the functionality of the T cells 
and not all tetramer positive cells secrete IFNy.
The IFN-y based enrichment method had a higher success rate in isolating highly Bax 
specific T cell populations than the previous attempts made by other methods. This system 
has allowed the isolation of full repertoire of CD8+ T cells responding to Bax antigen in an 
epitope independent way by using the Bax pool 601-23. It has subsequently permitted the 
generation of T cell lines from two healthy donors. Lines containing high frequencies of Bax 
specific T cells were generated by culturing cells under limiting dilution conditions. 
However, only polyclonal/oligoclonal T cell populations were isolated suggesting that culture 
conditions used here may not be sufficient to allow growth of single cells. The conditions 
could have been improved by using other types of media supplemented with IL-2 and perhaps 
other cytokines that support the in vitro expansion of T cells, such as IL-7 and IL15.
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Nevertheless, the derivation of stable T cell lines allows testing of the hypothesis, and the 
further characterisation of these lines will be described in the next chapter.
To sum up, this chapter has so far provided evidence for the recognition of Bax 
protein as an antigen by human CD8+ T cells from healthy donors. Overall, the approach 
used here has proved to be an efficient method for detecting immunogenicity of Bax peptides, 
and has thus provided basis for further analysis of Bax T cell responses. Consequently, 
implementing the technology of selecting T cells with low frequency based on their 
IFNy secretion resulted in the successful purification of Bax-specific T cells. The present 
study also implies that this system could be applied to other candidate tumour antigens or rare 
T cell populations. Figure 3.16 shows a summary of the in vitro approach used to generate 
Bax-specific T cell lines.
For Bax antigen to be considered a tumour antigen, functional assays need to be 
performed that conclusively show specific tumour recognition by the Bax-specific T cells in a 
MHC-restricted manner. This will be addressed in the next chapter.
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T cell stimulation with Bax peptides
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Enrichment of Bax-specific T cells 
(IFNy secretion assay) 
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Polyclonal /Oligoclonal Bax-specific T cell lines
Antigen-independent expansion
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Culture under limiting dilution conditions 
+ expansion of positive cells 
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Figure 3.16 Summary of the in vitro approach used to generate Bax-specific T cell lines
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Chapter 4
Characterisation of CTL generated against Bax derived peptides
In the chapter 3, several T cell lines were generated against Bax peptides from two 
HLA-A2+ healthy donors using the IFNy secretion assay and magnetic sorting. This part of 
this study was focussed on the detailed characterisation of those Bax-specific T cells. In 
particular, the epitope specificity, clonality by TCR Vp usage, avidity and tumour cell 
specificity of the T cells were determined.
4.1 Characterisation of Bax-specific T cells derived from the JSB line
As explained in section 3.6, two different strategies were used to generate highly 
specific T cell lines. First, the JSBI line was generated by expanding 9.3x103 of the IFNy- 
enriched T cells from the JSB line using the antigen-independent protocol (section 3.6.2). 
Second, JSBI 10E6 was generated by culturing the enriched T cells under limiting dilution 
conditions in 96 well plates (section 3.6.3).
4.1.1 Epitope recognition by JSBI line using an ELISpot assay
A mixture of Bax peptides p i (KLSECLKRI), p3 (IMGWTLDFL) and p5 
(ALCTKVPEL) were used to enrich peptide-specific T cells and create the JSBI line (section
3.6.1). However, it was not known whether the antigen-independent expansion was able to 
maintain the peptide specificity of the T cells. This was tested by using an ELISpot assay, and 
demonstrated that specificity against the pool and each individual peptide was maintained 
(Figure 4.1). The peptide IMGWTLDFL (Bax p3) response was similar to the pool response 
(392 spots /2xl04 cells), with weaker responses against p i and p5. Overall, this indicates the 
JSBI line is polyclonal, but has a dominant reactivity against the peptide IMGWTLDFL (Bax 
p3).
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4.1.2 Epitope recognition by JSBI 10E6 using an ELISpot assay
JSBI 10E6 was also generated using the mixture of Bax p i, p3 and p5 peptides. To 
evaluate whether JSBI 10E6, which was cultured under limiting dilution conditions, had an 
enhanced specificity, it was also tested using ELISpot assays. JSBI 10E6 has different pattern 
of specificity and a higher magnitude of response than JSBI line (Figure 4.2). A dominant 
reactivity was seen against peptide IMGWTLDFL (Bax p3), as for the JSBI line, there was 
only a subdominant response against p3. Therefore, in this case culturing T cells under 
limiting dilution conditions had narrowed down the range of peptide specificities and 
enhanced the frequency of Bax p3-specific T cells.
4.1.3 Analysis of the TCR Vp chains used by Bax-specific polyclonal T cell lines
The purpose of this experiment was to assess the number of different clonal T cell 
populations in each line, and whether the difference in peptide specificities between JSBI and 
JSBI 10E6 correlated with TCR Vp usage. There are over 20 different groups of the TCR Vp 
chain family that can be detected serologically. A panel of 19 PE-conjugated antibodies 
recognising different TCR Vp chains was used to stain the T cell lines, which were 
subsequently analysed by flow cytometry.
TCR analysis of the JSBI line demonstrated that 85% of T cells expressed TCR 
V pi4, 12% TCR V pl2  and 2.4% TCR Vp3 (Figure 4.3A). Analysis of JSBI 10E6 was shown 
to be predominately TCR V pi4+  T cells (98.4%) (Figure 4.3C). The TCR Vp usage was 
compared with the parental T cells (JSB line), from which both were generated. The JSB line 
(generated using a CD107 assay, section 3.2) was shown to express five different TCR Vp, 
which are Vp3 (23.3%), Vp7 (12.5%), V p i4  (45%), V p i6  (7.5%), and V pi7  (6.7%) (Figure 
4.3C).
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Figure 4.1 Epitope recognition by JSBI line using an ELISpot assay. The JSBI line was tested by 
IFNy ELISpot against Bax pi (KLSECLKRI), p3 (IMGWTLDFL) and p5 (ALCTKVPEL) pooled 
together and individually. The JSBI line T cells were plated out at 2xl04 cells/well in triplicate and 
incubated either alone, with T2 or with T2 + Bax peptides (10pg/ml) at a ratio of 1:1. An average of 
411 spots/2xl04 cells was positive for the mixture of peptides. An average response of 392 spots was 
detected against Bax p3. Average responses against Bax pi and Bax p5 were 72 and 64 spots, 
respectively. Background responses have been subtracted from the data and the standard deviation is 
shown.
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Figure 4.2 Epitope recognition by JSBI 10E6 using an ELISpot assay. The JSBI 10E6 was tested 
by IFNy ELISpot against Bax pi (KLSECLKRI), p3 (IMGWTLDFL) and p5 (ALCTKVPEL) pooled 
together and individually. The JSBI 10E6 T cells were plated out at 2xl04 cells/well in triplicate and 
incubated either alone, with T2 or with T2 + Bax peptides (lOpg/ml) at a ratio of 1:1. An average of 
411 spots/2xl04 was positive for the mixture of peptides. A response of 107 spots was detected 
against Bax p5 and no response was detected against Bax pi. Background responses have been 
subtracted from the data and the standard deviation is shown except for Bax p3. Due to the numerous 
spots per well, only an estimation was made with approximately 600 spots / well containing Bax p3 
and no standard deviation is shown for this result.
140
Chapter 4: Results
(A)
100-,
90-
80-
tn 70-0)o 60-+
CO
Q 50-
O 40-gS
30-
20-
10-
5.1 5.2 5.3 11 12 13.1 13.6 14
TCR vp chain
18 20 22 23
(B)
100 
90 
80 
70 
60 
50 H 
40 
30- 
2 0 -  
1 0 -  
0
(C)
5.1 5.2 5.3 11 12 13.1 13.6 14
TCR vp chain
23 24
100
9 0 -
8 0 -
7 0 -
0)o 6 0 -+co
O 5 0 -
O 4 0 -V?
3 0 -
2 0 -
1 0 -
o -l n n
5.1 5.2 5.3 11 12 13.1 13.6 14
T C R vp cha i n
16 17 18 20 22 23 24
Figure 4.3 Staining of Bax-specific T cell lines (from donor 1) for TCR Vp expression. The JSBI 
line (A), JSBI 10E6 (B), and the parental T cells (JSB line, CD107 sorted) (C) were co-stained with a 
CD8-FITC antibody and 19 different TCR Vp chain-PE antibodies. Data shown represents the 
percentage of CD8+ cells expressing each Vp chain. T cells were gated, based on their forward and 
side scatter profile. Data was analysed using CellQuest software.
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Overall, these results indicate that a narrow range of TCR Vp chains were used by the 
T cell lines. Furthermore, the percentage of cells expressing TCR V pl4  increased as the T 
cell lines became more specific for Bax peptides. Therefore, it seemed likely that TCR V p i4  
was involved in Bax peptide recognition.
4.1.4 JSBI 10E6 is able to lyse peptide-pulsed targets
In order to assess whether JSBI 10E6 contains cytotoxic activity towards these Bax 
peptides, it was tested against peptide-pulsed T2 target cells using a 51 Cr release assay. JSBI 
10E6 demonstrated peptide-specific killing against T2 cells pulsed with Bax pool pl/p3/p5 
(Figure 4.4). These CTLs only recognised T2 cells loaded with Bax pool (70%) whereas they 
did not lyse unpulsed T2 (5%).
142
Chapter 4: Results
100
80
72
60
T2 + B A X 1/ 3/5
40
20
50.0 25.0 12.5 3.16.3 1.6 0.8 0.4
E T
Figure 4.4 Ability of JSBI 10E6 to lyse target pulsed with Bax peptides. JSBI 10E6 was assayed 
against T2 which were pulsed with Bax pl/p3/p5 (■ )  or unpulsed (♦ ) .  Peptide-pulsed targets were 
pulsed with peptides at lOpg/ml for 1 hour at 37°C after 51Cr-labelling. Cytotoxicity was measured in 
a 4 hours 5ICr release assay at various Effector:Target (E:T) ratios. Results are expressed as mean of 
triplicate samples. A positive result is considered > 20% lysis.
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4.2 Characterisation of Bax-specific T cell lines derived from donor 11 using Bax pool 
601-23
Because initial attempts to generate T cell lines/clones failed with donor 1 (section
3.2.2), T cells from donor 11 were also used to maximise the likelihood of successful 
generation of Bax-specific T cell lines/clones. Similar to donor 1 (JSB), two different 
strategies were used to generate highly specific T cell lines from donor 11 using Bax pool 
601-23 (section 3.5). The KSI line was generated by expanding 7.8xl04of the IFNy-enriched 
T cells using the antigen-independent protocol (section 3.5.2). Second, KSI 10B7 was 
generated by culturing the enriched T cells under limiting dilution conditions (section 3.5.3).
4.2.1 Mapping epitopes from Bax peptide pool 601-23 responses using KSI line
Bax peptide pool 601-23 was used to enrich peptide-specific T cells and create the 
KSI line. In order to map the peptide specificity, the KSI line was tested by ELISpot with the 
whole Bax pool 601-23 and three smaller sub pools. As every peptide pool turned out 
positive (data not shown), individual peptides were tested. Figure 4.5 illustrates the 
identification of potential epitopes recognised by the KSI line. Seven peptides from Bax pool 
601-23 were recognised from Bax pool by the KSI line. Peptide responses of > 100 spots 
were detected against Bax p603, p610, 613, and p614. A weaker response (< 100 spots) was 
also detected against Bax p605, p611, and p615, with 42, 50, and 61 spots / 2x l04 cells 
respectively. Surprisingly, the KSI line derived from donor 11 (HLA-A2, A24, B44, B60, 
Bw4, Bw6, Cw5, Cw20) was able to elicit a detectable response to Bax p615, which is 
predicted to bind to B44 (61 spots /2xl04 cells), using T2 cell line (HLA-A2) as APC. In 
general, these results demonstrated that the KSI line contained T cells with multiple peptide 
specifities. This suggests that for donor 11, at least 7 peptides within the Bax pool (23 
peptides) were immunogenic.
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Figure 4.5 Mapping the Bax 601-23 response from KSI line to individual peptides. The KSI line 
generated from the enriched Bax-specific T cells was tested by IFNy ELISpot against the Bax pool 
601-23 and individual peptides. The KSI line T cells were plated out at 2xl04 cells/well in triplicate 
and incubated either alone, with T2 or with T2 + Bax pool 1-23 (10pg/ml) or individual peptides at a 
ratio of 1:1. Background responses have been subtracted from the data and the standard deviation is 
shown. The number of spots detected (per 2xl04 cells) for each peptide ranged from 42 to 200 after 
background subtraction.The spots/well for Bax pool were too numerous to count accurately, but 470 
spots were estimated for against Bax 601-23.
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4.2.2 Mapping epitopes from Bax peptide pool 601-23 responses using KSI 10B7
The KSI 10B7 was generated under limiting dilution conditions. Therefore, it was of 
interest to determine whether it had a more restricted peptide specificity than the KSI line. T 
cells were tested by ELISpot to map epitopes, first using three split pools (Bax p601-609, Bax 
p610-615 and Bax p616-623) to narrow down the response, followed by individual peptides 
to allow identification of potential epitopes. KSI 10B7 was able to strongly respond to split 
pool Bax p610-615 (Figure 4.6), but as spots / well in the ELISpot assay were too numerous 
to count accurately, only an estimation of the number of spots was made with approximately 
600 spots. A comparable response to Bax pool 601-623 and split pool Bax p610-15 was 
detected against Bax p610 and p613. Again, the spots / well were too numerous to give an 
accurate count, therefore the number of spots were considered to be in the region of > 600 
spots. Interestingly, these two peptides are almost identical: Bax p610 is a 10-mer 
(TIMGWTLDFL) and Bax p613 is a 9-mer (IMGWTLDFL). These results showed that KSI 
10B7 response is constrained to these two related peptides, and suggests that the limiting 
dilution culture had narrowed down the range of peptide specificities.
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Individual peptides
Figure 4.6 M apping the Bax 601-23 response from  KSI 10B7 to split pools and individual 
peptides. KSI 10B7 generated from the enriched Bax-specific T cells was tested by IFNy ELISpot 
against the Bax pool 601-23, split pools (Bax p601-609, Bax p610-615 and Bax p616-623) and 
individual peptides from the positive split pool (Bax p610, p611, p612, p613, p614 and p615). The 
KSI 10B7 T cells were plated out at 2x l04 cells/well in triplicate and incubated either alone, with T2 
or with T2 + peptides at a ratio of 1:1. Background responses have been subtracted from the data. The 
positive responses were approximately > 600 spots (*). No standard deviation is shown because no 
accurate count of number of spots was possible.
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4.2.3 Analysis of the TCR Vp chains used by Bax-specific polyclonal T cell lines
As mentioned in section 4.1.3, the purpose of this experiment was to identify the 
number of different T cell populations each line contained and to determine whether the 
enrichment for particular peptide specificities correlate with TCR Vp usage. Donor 11 pre­
sort T cells (section 3.3.2), from which Bax specific T cell lines were derived, were initially 
tested in to determine what proportion of the TCR Vp chains for this donor could be 
identified using these antibodies. The percentage of CD8+ T cells expressing each TCR Vp 
chain is shown in figure 4.7A. This panel of TCR Vp antibodies was able to identify the Vp 
chain usage of 46% of CD8+ cells, with 54% of the TCR Vp chains not being detected for 
this donor.
In subsequent experiments the Vp usage of the KSI line and KSI 10B7 was examined. 
The KSI line revealed similar percentages of CD8+ T cells expressing each TCR Vp chain to 
the pre-sorted T cells (Figure 4.7B). On the other hand, analysis of KSI 10B7 showed that 
66.4% of the T cells expressed TCR VP5.1 and 29.9% expressed TCR V p i7  (Figure 4.7C). 
This data indicates that KSI 10B7 is oligoclonal, containing two main T cell populations, a 
Vp5.1+ and a V pl7+  population. By contrast, in the KSI line, only 1.8% of gated cells were 
TCR Vp5.1+ and 5.3% were TCR V pi7+.
Based on these results, the approach used for KSI 10B7 did lead to selective 
enrichment of Bax specific T cells. Furthermore, it seemed likely that TCR Vp5.1 or V p i7  
was involved in Bax p610 and Bax p613 recognition. Because of the interesting results 
obtained with KSI 10B7, these cells were further sorted according to their TCR Vp chains, 
described in the next section.
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Figure 4.7 Staining of Bax-specific T cell lines (from donor 11) for TCR Vp expression. Donor 1 
pre-sorted T cells (from which the Bax specific T cell lines were generated) (A), KSI line (B), and 
KSI 10B7 (C) were co-stained with a CD8-FITC antibody and 19 different TCR V|3 chain-PE 
antibodies. Data shown represents the percentage of CD8+ cells expressing each Vp chain. T-cells 
were gated, based on their forward and side scatter profile. Data was analysed using CellQuest 
software.
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4.2.4 KSI line and KSI 10B7 are able to lyse target cells pulsed with Bax pool
601-23
It was not known whether both the KSI line and KSI 10B7 had cytotoxic activity 
against the Bax peptides. Therefore, these T cell lines were tested against T2 target cells 
pulsed with Bax pool 601-23 in a 51Cr release assay. The KSI line was able to kill Bax-pulsed 
T2 cells (65% lysis at E:T 25:1), but not unpulsed T2 (10%) (Figure 4.8). KSI 10B7 
effectively lysed T2 pulsed with Bax pool 601-23 (92% lysis at E:T 50:1), whereas no 
cytotoxicity was observed against unpulsed T2 (0.1%). These T cells demonstrated a higher 
lytic activity against Bax peptides than the KSI line, at multiple E:T ratios (Figure 4.9).
It was demonstrated that these generated T cell lines increased their specificity against 
Bax peptides after enrichment, particularly when cultured under limiting dilution conditions. 
These initial results indicate that Bax are immunogenic and able to induce a cytotoxic 
response to peptide-loaded target cells. Since KSI 10B7 showed the highest lytic activity 
against peptide-pulsed targets compared to the other T cell lines, only KSI 10B7 was used in 
subsequent experiments. A summary of Bax-specific T cell lines generated in this study is 
shown in table 4.1
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Figure 4.8 Ability of the KSI line to lyse target pulsed with Bax pool 601-23. The KSI line was 
assayed against T2 which were pulsed with Bax pool 601-23 (■ )  or unpulsed (♦ ) .  Peptide-pulsed 
targets were pulsed with peptides at lOpg/ml for 1 hour at 37°C after 3lCr-labeIling. Cytotoxicity was 
measured in a 4 hours 5lCr release assay at various Effector:Target (E:T) ratios. Results are expressed 
as mean o f triplicate samples. A positive result is considered > 20% lysis.
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Figure 4.9 Ability of KSI 10B7 to lyse target pulsed with Bax pool 601-23. KSI 10B7 was assayed 
against T2 which were pulsed with Bax pool 601-23 (■ )  or unpulsed (♦ ) .  Peptide-pulsed targets were 
pulsed with peptides at lOpg/ml for 1 hour at 37°C after 5'Cr-label ling. Cytotoxicity was measured in 
a 4 hours 5,Cr release assay at various Effector:Target (E:T) ratios. Results are expressed as mean of 
triplicate sample. A positive result is considered > 20% lysis.
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Table 4.1 Summary of Bax-specific T cell lines generated in this study
JSBI line JSBI 10E6 KSI line KSI 10B7
Peptide specificity
IMGWTLDFL
ALCTKVPEL
KLSECLKRI
IMGWTLDFL
ALCTKVPEL
LLSYFGTPT
IMGWTLDFL
TIMGWTLDFL
ALCTKVPEL
GLLSYFGTPT
FLRERLLGWI
DELDSNMEL
IMGWTLDFL
TIMGWTLDFL
TCR vP 
(>i%)
3 (2.4%) 
12 (12%) 
14 (85%)
14 (98.4%)
3 (2.7%), 5.1 (1.8%), 
7 (2.4%), 8 (4.3%),
12 (1.5%), 13.1 
(2.3%), 13.6 (2.1%), 
14(6.3%), 17(5.3%), 
18 (5%), 20 (2.6%), 
22 (3.3%)
5.1 (66.4%) 
17 (29.9%)
Cytotoxicity 
(T2+Bax) 
E:T 50:1
Not tested 70% 65% 92%
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4.3 Generation of TCR VP5.1+ and VP17+ T cells from KSI 10B7
Characterisation of KSI 10B7 revealed the presence of two distinct T cell populations, 
one expressing TCR Vp5.1 and the other expressing TCR V pl7 . In order to effectively 
investigate Bax peptide recognition by these sub-populations, they were separated using high 
speed flow sorting. To generate a TCR Vp5.1+ and V pl7+  T cell populations, KSI 10B7 T 
cells were stained with a TCR V pl7-PE antibody and sorted based upon positive (Vpl7+) 
and negative (Vpl7-) PE staining using a MoFlo cell sorter. After sorting cells were cultured 
overnight in media containing IL-2 before expanding using the antigen-independent protocol. 
Expansions yielded >15xl06 cells for both T cell populations. Flow cytometric analysis 
revealed the KSI Vp5.1+ T cells were 98.37% positive for Vp5.1 expression and the KSI 
VP17+ T cells were 99.1% positive for V p l7  (Figure 4.10).
Both enriched populations were tested in a 51 Cr release assay against T2 pulsed with 
either Bax p610 or Bax p613 to confirm whether TCR Vp5.1 or V p i7  were involved in the 
recognition of these peptides. Figure 4.12 demonstrated that KSI V pi7+  T cells, but not KSI 
Vp5.1+ T cells, were able to recognise target pulsed with Bax p613 or p610 (Figure 4.11). 
Therefore, only KSI V pl7+  T cells (hereon referred as KSIVB17) were used for further 
experiments.
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100
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Figure 4.10 G eneration of the TCRVP5.1+ and TC R V pi7+  T cells from KSI 10B7. KSI 10B7 
was shown to consist o f 70.15% TCR V(35.1+ CD8+ T cells and 29.85% TCR V pi7+  CD8+ T cells 
(left panel). To generate a TCR Vp5.1+ line and a TCR V pl7+  line, 5x106 KSI 10B7 T cells were 
incubated with an anti-TCR Vpl7-PE antibody. Cells were sorted based upon positive and negative 
PE staining using a MoFlo cell sorter. 3.6xl06 TCR Vp5.1+ cells and lx l0 6TCR V pl7+  T cells were 
recovered after sorting. The cells obtained were expanded using the antigen-independent protocol. 
The purity o f both lines was assessed by flow cytometry using an anti-TCR Vpl7-PE antibody (right 
panel) and histograms depict the percentage o f the lines expressing TCR V pl7. Flow cytometric 
analysis was done using Flowjo software.
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Figure 4.11 KSI V]317+ T cells are able to lyse targets pulsed with Bax p610 or p613. KSI VP17+ 
T cells (A) and KSI V|35.1+ T cells (B) were assayed against T2 which were pulsed with Bax p610 
(■ ), Bax p613 ( A) or unpulsed (♦).Peptide-pulsed targets were pulsed with peptides at lOpg/ml for 1 
hour at 37°C after 51Cr-labelling. Cytotoxicity was measured in a 4 hours 51Cr release assay at various 
EffectonTarget (E:T) ratios. Results are expressed as mean of triplicate samples. A positive result is 
considered > 20% lysis.
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4.4 Avidity of KSIVB17 CTL for Bax p610 and p613
The strength of interaction between the TCR of KSIVB17 clone and Bax p613 (9- 
mer) or Bax p610 (10-mer) peptides was not known. The avidity of a T cell population can be 
identified by the concentration of antigen required to elicit a T cell response. Therefore, this 
was evaluated by performing peptide dose-response titration curves in 51 Cr release assays. 
KSIVB17 was able to recognise Bax p613 with a higher avidity than Bax p610 at an E:T 10:1 
(Figure 4.12). The Bax p613 concentration required for half-maximal lysis of target cell was 
2.4ng/ml (2nM) compared with Baxp610, which was 15ng/ml (13.7nM) (Figure 4.12A). 
There was a possibility that T cells were recognising a contaminant within the peptide 
preparations, because the purity of both peptides was <70% (p613 68% pure; p610 51% 
pure). Therefore, new peptides with purity >90% were synthesised and tested in a peptide 
titration experiment. This confirmed that KSIVB17 is able to recognise both peptides when 
used at higher peptide concentrations, and confirmed that the T cells have higher avidity for 
Bax p613 than Bax p610. The concentration of Bax p613 (96.4% pure) required for half- 
maximal lysis was 0.6ng/ml (0.5nM), while Bax p610 (95.7% pure) was 12 ng/ml (10.9nM) 
(Figure 4.12B).
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Figure 4.12 Peptide dose-response for KSIVB17 recognition of Bax p613 and Bax p610 -pulsed 
target cells. KSIVB17 was assayed against 51Cr-labelled T2 cells pulsed with varying concentrations 
o f Bax p613 ( A ) and Bax p610 (■ )  from lOpg/ml to O.lng/ml for 1 hour at 37°C after 51Cr-labelling. 
(A) Peptide titration for Bax p613 with purity o f 68% and Bax p610 with purity o f 51%. (B) Peptide 
titration for Bax p613 with purity o f 96.4% and Bax p610 with purity o f 95.7%. Both the results 
shown are at an effector:target ratio of 10:1. Results are expressed as mean o f triplicate samples. The 
molecular weights (Mw) of Bax p613 (IM G W TLD FL) and Bax p610 (T IM G W TLD FL) were 
calculated from their amino acid sequences (1096 and 1196 respectively) and from this, the Molarity 
o f each peptide concentration was determined (lOpg/ml equals 8.36pM for Bax p613 and 9.13pM for 
Bax p610). The EC50 value was calculated using the curve fitted to the data.
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4.5 Recognition of tumour cells by KSIVB17 CTL
The KSIVB17 clone specific for Bax was then tested for its ability to lyse a range of 
HLA-A2+ tumour cells. This was conducted to test the hypothesis that abnormal proteasomal 
degradation of Bax protein in cancer cells results in the generation of peptide capable of 
binding to MHC class I molecules. A prediction of this hypothesis is that T cells specific for 
Bax peptides should be able to recognise and kill cancer cells.
4.5.1 PCa cell lines
It has been shown that abnormal Bax degradation by the ubiquitin/proteasome 
pathway occurs in PCa (Li & Dou, 2000). Therefore, two HLA-A2+ PCa cell lines (LNCaP 
and CA-HPV10) were tested for CTL recognition. The KSIVB17 clone did not kill LNCaP 
(16%) or CA-HPV10 (10%), but it killed Bax pulsed T2 cells (93%) (Figure 4.13).
Because IFNy can enhance the expression of MHC class I molecules and upregulate 
the expression of many proteins involved in the generation of antigenic peptides (Evans et al. ,
2001), the possibility that IFNy could restore the recognition of these PCa cell lines by 
KSIVB17 was investigated. Furthermore, previous studies have shown that sub-lethal doses 
of irradiation can upregulate MHC class I, tumour-associated molecules and enhanced 
antigen-specific killing of tumour cells by CTL (Garnett et al. , 2004). Therefore, it was also 
examined whether exposure of both targets to a sub-lethal dose of irradiation (1000 rads) 
could sensitize these targets to Bax-specific T cells. However, no substantial increase in 
killing by KSIVB17 was seen when LNCaP and CA-HPV10 were IFNy treated (1% and 
19%, respectively) or irradiated (21% and 17%, respectively).
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Figure 4.13 KSIVB17 clone does not lyse HLA-A2+ PCa cell lines LNCaP and CA-HPV10.
KSIVB17 was assayed against 51Cr-labelled LNCaP (A) and CA-HPV10 (B) that were either 
untreated ( * ) ,  treated with 200 units/ml of IFNy for 48 hours ( - ) or irradiated at 1000 rads 72 hours 
prior to the assay (♦). Peptide pulsed T2 ( A ) and unpulsed T2 (■ )  were added as controls. 
Cytotoxicity was measured in a 51Cr release assay at various EffectoriTarget (E:T) ratios. Results are 
expressed as mean of triplicate samples. The dashed line represents the 20% lysis cut-off for a 
positive result.
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4.5.2 Lymphoid malignancies
The KSIVB17 clone was tested for its ability to recognise primary human malignant 
CLL cells (HLA-A2+) as it has been reported that Bax is abnormally degraded by the 
ubiquitin/proteasome pathway in CLL patients (Agrawal et al., 2008; Liu et a l ,  2008). 51Cr 
release assays were tried with CLL cells, but it was difficult to properly label primary cells 
with 51 Cr, therefore they were tested in an ELISpot instead. PBMC of seven HLA-A2+ CLL 
patients were used, with two HLA-A2- CLL patients used as negative controls. The 
KSIVB17 clone was able to recognise 6/7 HLA-A2+ CLL samples, but not the HLA-A2- 
controls (13 and 18 spots/105 cells). Positive responses varied in magnitude from 25 to 186 
spots/105 cells (Figure 4.14). This result indicates CLL cells can process and present Bax 
peptides for T cell recognition.
To investigate whether the KSIVB17 clone can recognise other haematological 
malignant cells, several B cell malignant cell lines were tested in a 51Cr release assay, 
including BJAB (EBV negative cell line similar to Burkitt’s lymphoma), BV173 (B cell 
precursor leukemia cell line), and DG75 (EBV negative B cell lymphoma cell line). Daudi 
with defects in HLA class I (lacking p2m) was tested as a negative control. The KSIVB17 
clone was not able to lyse any of these cell lines (Figure 4.15).
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Figure 4.14 KSIVB17 clone recognises HLA-A2+ CLL cells using ELISpot assay. KSIVB17 
clone was tested in an IFNy ELISpot against 7 HLA-A2+ CLL patient samples and 2 HLA-A2- CLL 
samples (negative controls 8 and 9). T cells were plated out at 2x104 cells/well in triplicate and 
incubated with CLL cells at a ratio of 1:3. Results are shown as SFC/ 105 cells. Background responses 
(CLL alone) have been subtracted from the data. The dashed line represents the 20 spot cut-off for a 
positive result.
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Figure 4.15 KSIVB17 clone does not lyse HLA-A2+ lymphoid malignant cell lines. KSIVB17 
was assayed against 51Cr-labelled BJAB (* ) ,  BV173 ( * ) ,  DG175 (♦), and Daudi (negative control) 
(■ ). Cytotoxicity was measured in a 5lCr release assay at various Effector:Target (E:T) ratios. Results 
are expressed as mean of triplicate samples. The dashed line represents the 20% lysis cut-off for a 
positive result.
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4.5.3 HPV-transformed cervical cancer cell lines
HPV is associated with the development of cervical cancer. HPV16 is the most 
common high risk type HPV type associated with cervical cancer, which is detected in over 
50% of all cervical cancer cases worldwide, followed by HPV18 at 10-20%, with HPV31, 45, 
52 and 58 also being associated depending on the ethnic group studied (Bosch et al., 1995). 
E6 and E7 are the major transforming proteins in HPV and are thought to modify cell cycle so 
as to maintain the differentiating host keratinocyte in a state that facilitates viral DNA 
replication and uncontrolled cell proliferation (Ruesch & Laimins, 1998). E6 protein 
contributes to oncogenesis in part by interacting with or inactivating proteins involved in 
apoptosis, such as Bak (Thomas & Banks, 1998). Both Bax mRNA and protein stability have 
been shown to be reduced in human differentiating keratinocytes by the expression of HPV16 
E6. This study also revealed that E6 can enhance Bax degradation and inhibit Bax-induced 
apoptosis in stable and transiently expressing cells (Magal e t a l ,  2005).
Therefore, the KSIVB17 clone was tested for recognition of HLA-A2+ cervical cancer 
cell lines. Three HPV16 E6 + cell lines, CaSki, SiHa-A2 and C33A-HPV16, and a HPV45 
E6+ cell line MS751 were tested in 51Cr release assays. HLA-A2+ HPV- C33A cell line was 
included as a negative control. This clone was able to kill CaSki (32%), MS751 (50%), but not 
SiHa-A2 (16%) at a E:T ratio of 40:1 (Figure 4.16A). KSIVB17 also lysed C33A-HPV16 
(55%), but not the HPV negative cell line C33A (17%) at a E:T ratio of 50:1 (Figure 4.16B), 
suggesting that T cell recognition of these cell lines is related to HPV expression.
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Figure 4.16 KSIVB17 CTL recognition of HPV-transformed cervical cancer cell lines. KSIVB17 
was assayed against 51Cr-Iabelled Caski (HPV16+) (♦ ), MS751 (HPV45+) ( A ) ,  SiHa-A2 (HPV16+) 
(■ )  (A); C33A-HPV16 (♦ ) and C33A (HPV-) (■ )  (B). Cytotoxicity was measured in a 5lCr release 
assay at various EffectonTarget (E:T) ratios. Results are expressed as mean of triplicate samples. The 
dashed line represents the 20% lysis cut-off for a positive result.
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4.5.4 Osteosarcoma cell lines
Osteosarcoma is the most common type of malignant bone cancer, mainly occurring 
in children and adolescents. Poor prognosis tumours have been associated with apoptosis 
resistance. A decrease in Bax has been observed in osteosarcoma tumours with poor 
histologic response to chemotherapy (Mintz et al., 2005). The KSIVB17 clone was tested 
against three HLA-A2+ osteosarcoma cell lines, TK143 (also known as 143b), Saos-2, and 
U20S. The T cell clone effectively lysed TK143 (62%) and to a lesser extent Saos-2 (28%) 
and U 20S (32%) at an E:T ratio of 40:1 (Figure 4.17).
4.5.5 Other cancer cell types
The ability of KSIVB17 clone to interact with other cancer cell types was also tested 
to investigate its broad specificity. Three HLA-A2+ cancer cell lines were used in 51Cr 
release assays: a hepatocellular carcinoma cell line (HepG2), a melanoma cell line 
(SK29mel), and a breast cancer cell line (MDA231). KSIVB17 was capable of killing HepG2 
(32%), but not SK29mel (18%) nor MDA231 (2%) (Figure 4.18).
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Figure 4.17 KSIVB17 CTL recognition of HLA-A2+ osteosarcoma cell lines. KSIVB17 was 
assayed against 51Cr-labelled TK143 ( * ) ,  Saos-2 (♦ ), and U 20S (■ ). Cytotoxicity was measured in 
a 51Cr release assay at various Effector:Target (E:T) ratios. Results are expressed as mean of triplicate 
samples. The dashed line represents the 20% lysis cut-off for a positive result.
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Figure 4.18 KSIVB17 clone lyses a hepatocellular cell line but not a breast cancer or melanoma 
cell lines. KSIVB17 was assayed against5'Cr-labelled MDA231 ( A), HepG2 (♦ ), and SK29mel (■ ). 
Cytotoxicity was measured in a 51Cr release assay at various Effector:Target (E:T) ratios. Results are 
expressed as mean of triplicate samples. The dashed line represents the 20% lysis cut-off for a 
positive result.
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4.5.6 Negative controls
Since Bax protein is also expressed in normal, non-transformed cells, there is the 
potential that Bax peptides could be processed and presented for T cell recognition on these 
cells as well. Therefore, the KSIVB17 clone was tested on autologous and allogeneic healthy 
PHA blasts and allogeneic healthy skin fibroblasts in 51 Cr release assays. KSIVB17 did not 
induce specific lysis of either autologous or allogeneic PHA blasts (Figure 4.19). 
Furthermore, no specific lysis by KSIVB17 was observed against two HLA-A2+ allogeneic 
healthy skin fibroblasts (Figure 4.20). NK cell-like activity was also excluded by the failure 
of KSIVB17 T cells to specifically lyse K562 cells, which are easily killed by NK cells 
(Figure 4.20). Specific killing was seen only against Bax-pulsed T2 cells (Figure 4.19 and 
4.20). These results confirm that specific killing by KSIVB17 is directed to tumour cells and 
not healthy cells.
4.5.7 Summary of targets
The KSIVB17 clone was able to recognise primary human CLL cells, kill HPV- 
transformed cervical cancer cell lines CaSki, MS751 and C33A-HPV16, osteosarcoma cell 
lines TK143, Saos-2 and U20S, and a hepatocellular cell line HepG2. A summary of the 
target cells tested in 51 Cr release assays and their respective lysis is shown in Table 4.2.
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Figure 4.19 KSIVB17 clone does not lyse healthy PHA blasts. KSIVB17 was assayed against 51Cr- 
labelled T2+Bax (♦), autologous PHA blasts (■ ), allogeneic HLA-A2+ PHA blasts ( A ), and 
allogeneic HLA-A2- PHA blasts (x). PHA blasts were generated by culturing PBMC with PHA 
(lOpg/ml) for 3-5 days. Cytotoxicity was measured in a 51Cr release assay at various Effector:Target 
(E:T) ratios. Results are expressed as mean of triplicate samples. The dashed line represents the 20% 
lysis cut-off for a positive result.
100
80
K 5 6 2
T 2 + B a x
H ealthy fib rob lasts G W  A 2 +  
H ealthy fib rob lasts S B  A 2 +
60
40
20
0 =
50.0 25.0 12.5 6.3 3.1 1.6 0.8 0.4
E:T
Figure 4.20 KSIVB17 clone does not lyse healthy skin fibroblasts and K562 cell line. KSIVB17 
was assayed against 51Cr-labelled T2+Bax (■ ), K562-A2 (♦ ), and allogeneic HLA-A2+ healthy 
fibroblasts GW ( A), and SB (*). Cytotoxicity was measured in a 51Cr release assay at various 
Effector:Target (E:T) ratios. Results are expressed as mean of triplicate samples. The dashed line 
represents the 20% lysis cut-off for a positive result.
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Table 4.2 Summary of target cells tested in 51Cr release assays and their respective lysis.
Target cells % Lysis
LNCaP 15%
CA-HPV10 10%
SiHa-A2 16%
CaSki 38%
MS751 46%
C33A-HPV16 47%
C33A 16%
TK143 61%
Saos-2 23%
U20S 28%
HepG2 22%
HLA-A2+ skin fibroblasts GW 4%
HLA-A2+ skin fibroblasts GW 1%
Autologous PHA blasts 9%
Allogeneic HLA-A2+ PHA blasts 8%
Allogeneic HLA-A2- PHA blasts 12%
BJAB 11%
BV173 12%
Daudi 7%
DG175 18%
SK29mel 17%
MDA231 2%
K562 1%
The % lysis shown is an average of at least duplicate experiments at an 
E:T ratio o f40-50:1. The results considered as positive killing (>20%lysis) 
are in bold.
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4.6 Specificity of KSIVB17 clone
It was possible that the lysis of tumour cell lines by the KSIVB17 clone was not 
mediated by the Bax peptide-specific T cells. For example, it was possible that KSIVB17 
was not clonal, and contained multiple sub-populations of TCR V(317+ T cells. Some of 
these sub-populations could be Bax peptide specific but unable to kill tumour cells. In that 
case, the killing of the tumour cells is mediated by a separate sub-population that is tumour 
reactive but not Bax specific. Therefore cold target competition experiments were done to 
confirm that the CTLs that lyse the tumour cells are the same as those that recognise Bax 
peptides. Unlabeled tumour cells or T2 cells alone, pulsed with Bax p613 or with an 
irrelevant peptide (cold targets) were included in 51 Cr release assays at different ratios. 
Addition of unlabelled cold targets TK143 and T2 cells pulsed with Bax p613 decreased the 
CTL activity against labelled (hot) TK143 targets in a cold:hot target ratio-dependent 
manner, whereas unlabelled T2 alone or pulsed with flu M l showed no effect on cytotoxic 
lysis (Figure 4.21). The lysis of hot TK143 decreased from 77% to 33% when T2+Bax p613 
or TK143 were added at a cold : hot target (C:T) ratio of 20:1. In addition, it was 
demonstrated that the KSIVB17 CTLs do not lyse T2 pulsed with an irrelevant peptide (Flu 
M l) (data not shown), confirming that KSIVB17 specificity is against Bax (Figure 4.21).
Cold target inhibition of Bax-induced CTL cytotoxicity was also observed using the 
target MS751. Addition of unlabelled MS751 or T2 pulsed with Bax p613 decreased the CTL 
activity against MS751 from 36% to 13 and 10%, respectively (Figure 4.22). Collectively, 
these experiments confirm that killing of tumour cells is mediated by Bax peptide-specific T 
cells.
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Figure 4.21 Antigen specificity of KSIVB17 clone against TK143. Antigen specificity was 
confirmed by cold target inhibition experiments. The KSIVB17 clone was tested in the presence of 
unlabelled cold targets: TK143 (■), T2 alone (♦) or pulsed with the cognate (Bax p613) (A) or an 
irrelevant peptide (Flu Ml) (* )  at various coldrhot target ratios (5:1, 10:1 and 20:1) and incubated 
with 5,Cr labelled TK143 (hot target). The KSIVB17 clone was also tested against 51Cr labelled 
T2+Flu M 1 without any addition of cold targets. No specific killing (4%) was found against T2+ Flu 
M 1 (data not shown). Cytotoxicity was measured in a 5,Cr release assay. Results shown are at an E:T 
ratio of 50:1 and are expressed as mean of triplicate samples.
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Figure 4.22 Antigen specificity of KSIVB17 clone against MS751. Antigen specificity was 
confirmed by cold target inhibition experiments. The KSIVB17 clone was tested in the presence of 
unlabelled cold targets: MS751 (■), T2 alone ( * )  or pulsed with the cognate (Bax p613) ( A) or an 
irrelevant peptide (Flu M l) (♦) at various cold:hot target ratios (5:1, 10:1 and 20:1) and incubated 
with 5,Cr labelled MS751 (hot target). Cytotoxicity was measured in a 51Cr release assay. Results 
shown are at an E:T ratio of 40:1 and are expressed as mean of triplicate samples.
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The hypothesis being tested predicts that Bax peptides are being presented by HLA- 
A2 on the tumour cells. Since these tumour cells were allogeneic, it was possible that the 
lysis of the tumour cells was due to alloreactivity rather than HLA-A2 restricted recognition. 
Therefore MHC restriction of the tumour cell recognition was tested by blocking experiments 
using an anti- HLA-A2 antibody (Ma2.1) and two negative controls, anti-HLA-DR (L243) 
and anti-HLA-A23/24 antibody. T2 pulsed Bax p613 and TK143 were tested in present of 
MA2.1 and L243 antibodies. MS751 was tested with the HLA-A23/24 antibody as a negative 
control because both donor 11 and this tumour cell line are HLA-A24+. As shown in Figure 
4.23, incubation of peptide-pulsed T2 or TK143 with MA2.1 resulted in the inhibition of the 
target cell lysis, whereas incubation with L243 had no effect. A similar result was seen with 
MS751. Lysis of MS751 by KSIVB17 was inhibited by Ma2.1, but not by the anti-HLA- 
23/24 antibody (Figure 4.24). These results confirm that Bax peptide specific CTL response 
is restricted to HLA-A2, and that lysis of tumour cells is also restricted to HLA-A2.
Together, the cold target competition and antibody blocking results, suggest that the 
KSIVB17 T cell clone is recognising Bax peptide presented by HLA-A2 on the tumour cells.
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Figure 4.23 Anti-HLA-A2 antibody inhibition of TK143 and Bax-pulsed T2 lysis by KSIVB17 
clone. HLA-A2 restriction was confirmed by antibody blocking experiments. This was done by 
incubating the 51Cr labelled TK143 and T2 pulsed with p613 with or without different dilutions of 
HLA-specific antibodies (Ma2.1 :HLA-A2 and L243:HLA-DR) for 30 minutes before adding 
KSIVB17 cells. Lysis of Bax p613-pulsed T2 + Ma2.1 antibody (A), Bax p613-pulsed T2 + L243 
antibody (♦), TK143 + Ma2.1 antibody (■ ) and TK.143 + L243 antibody are shown. 
Cytotoxicity was measured in a 5,Cr release assay. Results shown are at an E:T ratio of 40:1 and are 
expressed as mean of triplicate samples.
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Figure 4.24 Anti-HLA-A2 antibody inhibition of MS751 lysis by KSIVB17 clone. HLA-A2 
restriction was confirmed by antibody blocking experiments. This was done by incubating the 51Cr 
labelled MS751 with or without different dilutions of HLA-specific antibodies (Ma2.1 and anti-HLA- 
23/24) for 30 minutes before adding KSIVB17 cells. Lysis of MS751 + Ma2.1 antibody (A) and 
MS751 + anti-HLA-23/24 antibody (♦) are shown. Cytotoxicity was measured in a 51Cr release assay. 
Results shown are at an E:T ratio of 40:1 and are expressed as mean of triplicate samples.
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4.7 The effect of proteasome inhibition on MHC class I presentation of Bax peptides to 
KSIVB17 clone
Another prediction of the hypothesis is that blocking proteasome function will 
prevent generation of Bax peptides on cancer cells. To test this, a proteasome inhibitor called 
bortezomib (also known as Velcade, PS-341) was used. Bortezomib is a reversible inhibitor 
of both standard proteasomes and immunoproteasomes (Voorhees & Orlowski, 2006).
The tumour cell lines with the highest percentage of killing by the KSIVB17 were 
tested (MS751, TK143 and C33A-HPV16) (see Table 4.1). T2 pulsed with Bax p613 was 
used as a negative control as presentation of exogenous peptide should not be affected by 
proteasomal inhibition. The lysis of all the tumour cell lines was partially inhibited by 
bortezomib, suggesting that proteasome plays a role in the generation of the Bax p613 
epitope in these tumour cells. Lysis of T2 with exogenous peptide was not affected by the 
treatment with proteasome inhibitor (Figure 4.25). MS751 was then further tested in the 
presence of different concentrations of bortezomib (Figure 4.26). Inhibition of MS751 lysis 
was seen with all the concentrations of the proteasome inhibitor tested, but this inhibition 
was reversed by adding exogenous peptide (Bax p613). This suggests that endogenous Bax 
peptides can be generated by the proteasome pathway in tumour cells lines.
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Figure 4.25 Bortezomib inhibits presentation of endogenous Bax epitopes in tumour cell lines.
KSIVB17 clone was assayed against 51Cr-labelled T2 pulsed with Bax p613, MS751, TK143 and 
C33A-HPV16 which were either untreated (white bars) or treated with 0.1 pM of bortezomib (grey 
bars) overnight at 37QC. Cytotoxicity was measured in a 51Cr release assay. Results shown are at an 
E:T ratio of 30:1 and are expressed as the mean of triplicate samples.
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Figure 4.26 Presentation of endogenous Bax epitopes in MS751 is blocked with various 
concentrations of the proteasome inhibitor Bortezomib. KSIVB17 clone was assayed against51 Cr- 
labelled MS751 untreated (white bar) or treated with various concentrations of bortezomib 
(pM) overnight at 37QC. As a control, MS751 was treated with 0.1 pM of velcade and pulsed with Bax 
p613 (stripy bar). Cytotoxicity was measured in a 51 Cr release assay. Results shown are at an E:T 
ratio of 30:1 and are expressed as the mean of triplicate samples. The dashed line represents the 20% 
lysis cut-off for a positive result.
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4.8 Discussion
In the first part of this chapter, characterisation of the T cell lines confirmed that it 
was possible to generate stable populations of T cells specific for Bax peptides from low 
frequency starting populations. It was shown that these T cell lines increased their specificity 
against Bax peptides after immunomagnetic enrichment. Based on the epitope mapping 
experiments and analysis of TCR VP usage, culturing cells under limiting dilution conditions 
clearly selected T cells with particular TCRs and specificity towards restricted epitopes.
Both the JSBI line and JSBI 10E6 were predominantly TCR V pi4+  and recognise 
Bax p3 (IMGWTLDFL) as a dominant epitope. However, the JSBI 10E6 were 98.5% TCR 
V pl4+  and had a higher magnitude of response against Bax p3, confirming that the culturing 
T cells under limiting dilution conditions was a superior approach to selectively enrich 
peptide-specific T cells. This also indicated that the TCR V p l4  was likely to be involved in 
the recognition of Bax p3 in this donor.
KSI 10B7, which was generated from a different donor (donorll), was found to be an
oligoclonal T cell line, containing two main T cell populations: a Vp5.1+ and a V pl7+
population. It was able to recognise the same Bax peptide IMGWTLDFL (Bax p613) from
Bax 601-23 pool, but interestingly it also reacted against a related peptide, the 10-mer
TIMGWTLDFL (Bax p610) at higher peptide concentrations. In contrast, KSI line had
similar percentages of TCR Vp chains to the T cells from pre-sort and contained multiple
antigen-specific reactivities. A way to further study the KSI line is to sort this polyclonal T
cell line using individual peptides rather than entire Bax 601-23 pool and culture them under
limiting dilution conditions, thus narrowing down the selection of highly specific T cells
responding to individual peptides. But this would be a very labour intensive approach.
Results from this donor suggested that 7-8 Bax peptides were immunogenic to T cells.
Interestingly, the KSI line was able to recognise Bax p615 that is predicted to bind to HLA-
B44. T2 cells were used as APC in ELIspot assays, and these express HLA-A2 and have
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extremely low expression of HLA-B5. The recognition of p615 could be explained by T cells 
from donor 11 presenting Bax p615 to each other (HLA type of donor 11: HLA-A2, A24, 
B44, B60, Bw4, Bw6, Cw5, Cw20). Alternatively, this could be due to cross-reactive binding 
of p615 to HLA-B5+. It would be interesting to test the immunogenicity of this peptide with 
T cells from HLA-A2-, HLA-B44+ or HLA-B5+individuals.
JSBI 10E6, KSI line, KSI 10B7 (and KSIVB17) were further shown to be cytotoxic 
against T2 cells pulsed with exogenous Bax peptides, and thus proven that these T cells have 
lytic efficacy towards Bax peptides. The avidity of the KSIVB17 (TCR V pl7+  clone) for 
both Bax p613 and p610 was determined from peptide dose-response assays. The first set of 
results showed that KSIVB17 had higher avidity for Bax p613 than Bax p610. As shown in 
the Chapter 3, Bax p613 showed a measurable binding capacity to HLA-A2 (115% increase 
of HLA-A2 expression) whereas Bax p610 showed only a 5% increase of HLA-A2 
expression, indicating that Bax p613 is a stronger binder to HLA-A2 (see Figure 3.8). Several 
studies have shown that T cell clones can recognise multiple peptides (Hagerty & Allen, 
1995; Loftus et al., 1996). Since the sequences of two peptides are almost identical, it is 
possible that T cells can cross-react on the two peptides because they present a similar 
structure to the TCR once they are complexed to HLA-A2. The stronger response against Bax 
p613 may be caused by its higher affinity towards HLA-A2, resulting in more stable 
peptide:MHC complex. Another explanation for recognition of both peptides is that there are 
two TCR V pl7+  subpopulations, one recognising the Bax p610 and the other Bax p613. This 
possibility could be tested by sequencing of the TCR chains using PCR, and thus would 
confirm whether only one TCR V pl7+  population exists.
The possibility of KSIVB17 recognising a common contaminant was considered 
because the purity of both synthetic peptides was <70%. This possibility seems unlikely 
because new peptides with purity >90% were also being recognised and with higher avidity 
than the unpurified peptides. However, since the purity is not 100%, there is always a slight
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chance that KSIVB17 could be recognising p613 only, but this is a contaminant of Bax p610. 
The results using pure peptides confirmed that KSIVB17 had higher avidity for Bax p613 
(0.5nM for half-maximal lysis) than Bax p610 (10.9nM). This is higher than the figures 
obtained for T cells against other HLA-A2 associated epitopes, such as gplOO (946) peptide 
(1 to lOpM) (Cox et al. , 1994) and HPV 16 E7 11-20 peptide (lOpM) (Youde et al., 2000). 
However, it is similar or lower than the concentrations required for half-maximal lysis of 
some other HLA-A2-associated peptide epitopes such as WT1-derived peptide WT126 
(lOnM) (Bellantuono et al., 2002), Melan-A/Martl A27L analogue (0.4 to 113nM) (Palermo 
et al., 2001), NY-ESO-1 157-165 (50nM) (Chen et al., 2000) and MUC-1 derived peptides 
(10 to lOOnM) (Brossart et al., 1999). Thus, it can be said the avidity of KSIVB17 clone for 
Bax p610 is low and for Bax p613 is intermediate, comparable to the avidity of some other 
well-known tumour CTLs capable of recognizing endogenously processed tumour antigens.
The KSIVB17 clone was able to lyse targets pulsed with Bax peptides and recognise 
HLA-A2+ tumour cells of various types, including CLL, HPV transformed cervical, 
osteosarcoma, and hepatocellular carcinoma cells. Based on these results, it appears these 
cancer cells are effective in processing and presenting the same endogenous Bax peptides. 
However, these results need to be confirmed with T cell clones from other donors. Formal 
validation of Bax being processed and presented will require elution of naturally occurring 
peptides associated with MHC molecules from the tumour cells and their analysis by mass 
spectrometry.
Killing of tumour cells by the KSIVB17 clone was antigen-specific and HLA-A2 
restricted as shown by a number of control experiments, including cold-target competition 
and monoclonal antibody blocking experiments. The lack of killing of the K562 cells 
indicated that the cytotoxic activity against tumour cells was not NK cell mediated.
Bax-specific responses mediated by KSIVB17 were seen against HLA-A2+ primary 
CLL cells and no HLA-A2- CLL cells using an ELISpot. These observations indicate that the
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primary CLL cells can naturally process and display immunogenic peptides derived from 
Bax, and thus induce functional responses by Bax-specific T cells. The findings that 
abnormal degradation of Bax occurs in CLL cells (Agrawal et al. , 2008; Liu et al. , 2008) and 
Bax-specific T cell responses were detected against CLL cells seem to support the hypothesis 
proposed in this study. However, to further address this hypothesis, it will be required to 
evaluate T cell responses against Bax in CLL patients. In contrast to several solid tumours, 
there are only relatively few tumour-associated antigens that have been identified for CLL 
and thus defining new tumour antigens with a role in cancer is desirable. Bax is an attractive 
tumour antigen for CLL because of its reduced expression is linked to resistance to 
chemotherapy and apoptosis of tumour cells, thereby playing a crucial role in cancer 
progression. Interestingly, other lymphoid malignant cell lines were not killed by the Bax- 
specific T cells, indicating that the Bax-specific T cells may have a particular specificity 
towards CLL and not to the other lymphoid malignancies.
Although it has been shown that abnormal degradation of Bax occurs in advanced 
PCa patients (Li & Dou, 2000), PCa cell lines (LNCaP, HPV10) were not lysed by the Bax- 
specific T cells. The study carried out by Li and Dou (2000) used PCa tissue samples and not 
tumour cell lines. Therefore, to support the hypothesis proposed here, tumour cells from 
biopsy samples of PCa patients would have been ideal to test for KSIVB17 recognition, but 
unfortunately, no PCa samples were available for this study. Breast cancer (MDA231) and 
melanoma (SK29mel) were also not lysed by the KSIVB17 clone. It is possible that Bax p613 
and Baxp610 epitopes are not naturally processed and presented on the cell surface of these 
tumour cells or they might be present but at too low a level for detection by the CTLs.
Interestingly, the KSIVB17 clone was able to lyse HPV-transformed cervical cancer 
cell lines, Caski (HPV16), C33A-HPV16 and MS751 (HPV45), but not a HPV negative 
cervical cancer cell line C33A. The Bax specific cytotoxic responses towards HPV positive 
cervical tumour cells suggest that these responses are related with HPV expression as the
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HPV negative C33A was not killed. HPV16 E6 expression has been shown to shorten the 
half-life of Bax protein in differentiating keratinocytes. In addition, expression of E6 has been 
demonstrated to enhance Bax degradation and inhibit Bax-induced apoptosis in stable and 
transiently E6 expressing human cells (Magal et al., 2005). The results obtained here 
demonstrate that some HPV transformed cervical cancer cell lines can process and present 
Bax epitopes associated with MHC class I molecules for KSIVB17 recognition. It is possible 
that this is a result of HPV E6 expression.
However, KSIVB17 did not kill SiHa-A2 cells, which is an HPV 16 transformed cell 
line. Many of HPV16 E6 interacting proteins have been shown to be targets of E6 dependent 
ubiquitin-proteasomal degradation, including p53 (Scheffner & Whitaker, 2003). Previous 
studies demonstrated that SiHa cells have the highest steady-state levels of p53 because SiHa 
cells contain only one to two copies of HPV 16 per cell, compared with other HPV- 
transformed cell lines, such as CaSki cells containing 600 copies of HPV16 (Ding et al., 
2007; Scheffner et al., 1991). Therefore, it is possible that SiHa-A2 was not killed by 
KSIVB17 because the low copy number of HPV16 E6 meant that not enough Bax was being 
targeted for degradation and thus less Bax peptides were being generated and presented at the 
cell surface.
Unexpectedly, Bax-specific CTLs were also able to efficiently lyse osteosarcoma cell 
lines (TK143, U20S, Saos-2) and one hepatocellular cancer cell line (HepG2). It has been 
reported that reduced expression of Bax is associated with poor response to treatment and 
shorter survival in osteosarcoma and hepatocellular carcinoma patients, respectively (Garcia 
et al., 2002; Mintz et al., 2005). This underscores the essential role of Bax in tumour 
development and survival. However, these studies did not demonstrate whether Bax is 
degraded by the proteasome. Expression can be altered in many ways, including mutations 
and transcription. Therefore, it will be important to test whether proteasomal degradation of 
Bax occurs in all the different cancer cell lines recognised by KSIVB17.
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More importantly, the KSIVB17 clone did not lyse any of the healthy controls, 
including autologous and allogeneic PHA blasts, and allogeneic healthy skin fibroblasts. 
These results are in agreement with the proposed hypothesis. In healthy cells, Bax has a long 
half-life and predominantly localized in cytosol or loosely attached to outer mitochondrial 
membranes in an inactive form and may not be efficiently targeted by the proteasome. So, it 
is expected that there would not be substantial quantities of Bax-derived peptides for MHC 
class I binding. Possibly, the quantity of Bax peptides generated in normal cells is insufficient 
to mediate lysis by CTL. The preferential lysis of tumour cells but not normal cells by 
KSIVB17 might be related to the affinity of the T cells and higher presentation of Bax- 
derived peptides by tumour cells. Another explanation might be that normal cells present a 
different repertoire of T cell epitopes compared with tumour cells, and the Bax p613 and 
BaxpblO epitopes are not naturally processed and presented on the cell surface of normal 
cells. This leads to the assumption that there are differences in the processing and 
presentation of endogenous Bax peptides by tumour cells and normal cells. This could be 
confirmed by the elution of natural processed peptides complexed with MHC class I 
molecules from the tumour cells and normal cells, and analysis of their sequences by mass 
spectrometry.
Moreover, the proteasome pathway was shown to be involved in the generation of 
endogenous Bax peptides in tumour cells. This was demonstrated by inhibition of tumour cell 
lysis after treatment of tumour cells with proteasome inhibitor (bortezomib), even at 
relatively low concentrations. No inhibition of peptide pulsed target T2 cells was seen, ruling 
out any non-specific toxicity effect. Further experiments will include analysis of the effect of 
different doses of proteasomes inhibitor on T cell recognition of all the other tumour cells 
that were found to be recognised by the Bax-specific T cells.
A report carried out by Maia et al. (2005) has shown that Bax-5 (143a.a), an isoform
resulting from alternative splicing of Bax, can act as a potential tumour antigen in acute
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lymphoblastic leukemia. However, the functional significance of this isoform remains unclear 
(Akgul et al., 2004). The epitopes identified from Bax-8 (143a.a) by that group do not 
correspond to the epitopes from Bax-a (192 a.a) investigated here in this study. Bax-a is the 
best-characterised isoform and is essential in induction apoptosis (Akgul et a l ,  2004; 
Nechushtan et al., 1999; Wolter et al., 1997). To our knowledge, this is the first study that 
demonstrates Bax-a protein as a potential tumour antigen for various cancers of different 
origins and types.
Collectively, this study presents the first identification of antigenic peptide epitopes 
within the Bax protein based on its abnormal expression in cancer. The data reported herein 
provide evidence that Bax peptides are naturally processed by several tumour types and are 
presented in the context of HLA-A2 in sufficient quantities to allow recognition by Bax- 
specific T cells. It was demonstrated that two HLA-A2-binding epitopes (Bax p610 and Bax 
p613) derived from Bax can elicit epitope-specific CTL responses against tumour cells. In 
conclusion, these data revealed that peptides derived from the ubiquitously expressed Bax 
protein are immunogenic to human CD8+ T cells and support the concept that Bax could 
serve as a potential tumour antigen for immunotherapy of several human cancers.
Overall, the data presented in this chapter supports the hypothesis, but to strengthen 
these findings it would be necessary to show whether increased proteasomal degradation of 
Bax occurs in cancer cells. This will be addressed in the next chapter.
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Chapter 5
Analysis of Bax expression in cancer cells
In the last chapter, it was revealed that Bax peptides can be naturally processed and 
presented by several tumour types for recognition by Bax-specific T cells. Here, it will be 
investigated whether T cell reactivity correlates with Bax expression and its degradation in 
cancer cells. Based on the hypothesis, there should be an increased proteasomal degradation of 
Bax in cancer cells, but not normal cells, resulting in these being recognised by Bax-specific T 
cells. Therefore, Bax expression will be analysed in PCa cell lines, CLL patient samples, 
cervical cancer cell lines, osteosarcoma and normal (non-cancerous) cells by western blotting. 
In order to assess the expression of Bax protein and its degradation by proteasomes, the cells 
were treated with proteasome inhibitors.
In this study, two proteasome inhibitors were used, clasto-lactacystin and bortezomib. 
At the beginning of this project, the cells (PCa, CLL and healthy donors) were tested with 
clasto-lactacystin, but this proteasome inhibitor was changed later to bortezomib. Clasto- 
lactacystin is a specific, but metabolically unstable proteasome inhibitor, and thus is only used 
for studying proteasomal processes in vitro. While, Bortezomib is a specific proteasome 
inhibitor and the first proteasome inhibitor approved for human applications, including 
treatment of multiple myeloma and continues to be studied in various haematological 
malignancies and solid tumours (Voorhees & Orlowski, 2006).
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5.1 Bax expression in human PCa cell lines
Four PCa cell lines (see Table 2.1) were used to analyse steady-state Bax expression 
by western blotting. LNCaP is a metastatic androgen sensitive PCa cell line, CA-HPV10 is a 
less aggressive non-metastatic, androgen sensitive PCa cell line, and PC3 is androgen 
resistant, and derived from aggressive PCa. DU 145 (androgen resistant, metastatic cell line) 
was used as a negative control as it is a Bax null cell line. Analysis of these PCa cell lines 
demonstrated that there was a differential expression of Bax levels as detected by western 
blotting (Figure 5.1). Both CA-HPV10 and LNCaP showed increased full-length Bax protein 
(21 kda, Baxa) levels, compared to PC3. Lower levels of Bax expression in PC3 were 
revealed by western blotting. Proteasome inhibition slightly increased Bax expression in 
advanced PCa cell line PC-3 and CA-HPV10. However, no increase was seen in LNCaP after 
treatment. As expected, no Bax expression was detected in DU 145 (negative control).
5.2 Bax expression in CLL patients
Bax expression and its degradation were determined in fresh peripheral blood samples 
from 19 CLL patients, using the proteasome inhibitor clasto-lactacystin (2pM and lOpM). 
Figure 5.2 shows representative immunoblots of ten CLL patients. A slight upregulation of the 
full length Bax protein (21 kda) was detected in 11/19 CLL patients, after treatment with 
clasto-lactacystin. However, accumulation of a lower molecular weight form of Bax (18 kda) 
was clearly seen in most CLL patients (18/19) after clasto-lactacystin treatment. The degree of 
accumulation varied among these samples. Only one CLL patient (CLL 6) did not show 
detectable levels of this product after proteasome inhibition. The molecular weight of this 
lower molecular form of Bax corresponds to a truncated version of Bax (p i8 Bax) that is 
formed during apoptosis by calpain cleavage of the full-length form (p21 Bax) (Wood et al., 
1998). The results suggest that active proteasomal degradation of Bax p i8 cleavage product is 
occurring in most CLL patients.
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Figure 5.1 Expression of Bax in PCa cell lines in the presence or absence of the proteasome 
inhibitor, clasto-lactacystin. PCa cells (CA-HPV10, LNCaP, PC3, and DU 145) were treated with or 
without the proteasome inhibitor clasto-lactacystin (10 pM) overnight, followed by preparation of 
whole cell lysates. These were then analysed by western blotting for the expression of Bax. The blots 
were incubated with specific antibodies to Bax (21 kda) at 1/1000 dilution and Actin (42 kda; loading 
control) at 1/10000 dilution.
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Figure 5.2 Representative immunoblots showing expression of Bax in CLL cells in the presence 
or absence of the proteasome inhibitor, clasto-lactacystin. CLL cells were treated with or without 
clasto-lactacystin (2pM and 10 pM) overnight, followed by preparation of whole cell lysates. These 
were then analysed by western blotting for the expression of Bax. The blots were incubated with 
specific antibodies to Bax (21 kda and 18kda) at 1/1000 dilution and Actin (42 kda; loading control) at 
1/10000 dilution.
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5.3 Bax expression in cervical cancer cell lines
It has previously been reported that transfection of HPV16 E6 into human fibroblasts 
resulted in reduced Bax mRNA and protein expression. The reduction in protein appeared to 
be related to increased degradation of Bax (Magal et al., 2005). However, Bax expression in 
cervical cancer cell lines was not studied. Therefore, four cervical cancer cell lines CaSki 
(HPV 16 metastatic cell line), MS751 (HPV45 metastatic cell line), C33A-HPV16 and C33A 
(HPV negative cell line) were examined for their Bax expression and degradation by the 
proteasome, using the proteasome inhibitor bortezomib (Figure 5.3). Dose-dependent 
accumulation of Bax (21kda, Baxa) was seen in CaSki and MS751 treated with bortezomib. 
Interestingly, an additional protein of approximately 24kda was detected after proteasome 
inhibition particularly in MS751, and C33A-HPV16. It has been recently demonstrated that 
this protein corresponds to the isoform Baxp (Fu et al., 2009). As for C33A, no significant 
increase of Baxa and only a slight accumulation of Baxp were seen after treatment. These 
results indicate that both Bax isoforms are degraded by the proteasome in HPV-transformed 
cell lines. No cleavage to Bax p i8 form was observed in any of the cervical cancer cell lines.
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Figure 5 3  Expression of Bax in cervical cancer cell lines in the presence or absence of the 
proteasome inhibitor, bortezomib. Cervical cancer cell lines (CaSki, MS751, C33A-HPV16 and 
C33A) were treated with or without bortezomib (lpM  and 10 pM) overnight, followed by preparation 
o f whole cell lysates. These were then analysed by western blotting for the expression o f Bax. The 
blots were incubated with specific antibodies to Bax (24kda and 21kda) at 1/1000 dilution and Actin 
(42 kda; loading control) at 1/1000 dilution.
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5.4 Bax expression in osteosarcoma cell lines
Poor prognosis of patients has been associated with apoptosis resistance in 
osteosarcoma. A decrease in Bax has been observed in osteosarcoma tumours with poor 
histologic response to chemotherapy (Mintz et a l ,  2005). Bax degradation by the proteasome 
has been shown in one of the osteosarcoma cell lines, Saos-2 (Chang et al., 1998). However, 
Bax degradation in TK143 and U 20S has not been studied. Therefore, these two osteosarcoma 
cell lines were examined for Bax expression and its degradation using the proteasome 
inhibitor bortezomib. A dose-dependent increase in full-length Bax expression was observed 
in both U 20S and TK143 treated with bortezomib (Figure 5.4). Detection of Bax cleavage 
product (18 kda) was also seen in bortezomib-treated TK143, but not in treated U20S. 
Overall, this data show that Bax is degraded by the proteasome in these osteosarcoma cell 
lines.
5.5 Bax expression in normal (non-cancerous) cells
PBMC from nine healthy donors and PHA blasts generated from one healthy donor 
were examined for Bax expression and potential degradation by the proteasome (Figure 5.5). 
Full-length Bax (21 kda) expression did not seem to significantly increase with inhibition of 
the proteasome activity in all the donors. HD7 was the only one to show a slight increase of 
the full-length Bax protein after proteasome inhibition. Low levels of Bax cleavage product 
(p i8) were detected without treatment in PBMC of five donors (HD4, HD5, HD6, HD7 and 
HD9) and the PHA blasts. However, no accumulation of the cleavage product was seen in the 
majority of donors when treated with the proteasome inhibitor, with exception of PBMC from 
HD1, which showed a modest increase from a very low initial expression. Overall, this data 
indicates that Bax protein expression in these cells is usually not regulated by the proteasome 
pathway.
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Figure 5.4 Expression of Bax in osteosarcoma cell lines in the presence or absence of the 
proteasome inhibitor, bortezomib. Ostesarcoma cell lines (U 20S  and TK143) were treated with or 
without bortezomib (lpM  and 10 pM for U20S; 0.1 pM, lpM  and 10 pM for TK.143) overnight, 
followed by preparation of whole cell lysates. These were then analysed by western blotting for the 
expression of Bax. The blots were incubated with specific antibodies to Bax (21 kda and 18kda) at 
1/1000 dilution and Actin (42 kda; loading control) at 1/10000 dilution.
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Figure 5.5 Expression of Bax in normal cells in the presence or absence of the proteasome 
inhibitor, clasto-lactacystin. Fresh PBMC from nine healthy donors were treated with or without 
clasto-lactacystin (2pM and 10 pM) overnight. PHA blasts from a healthy donor were generated by 
culturing PBMC with PHA (10|ig/ml) for 3 days and treated with or without clasto-lactacystin (1|^M 
and 10fiM) overnight, followed by preparation o f whole cell lysates. These were then analysed by 
western blotting for the expression of Bax. The blots were incubated with specific antibodies to Bax 
(21 kda and 18kda) at 1/1000 dilution and Actin (42 kda; loading control) at 1/10000 dilution. HD = 
healthy donor.
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5.6 Discussion
In this chapter, Bax degradation by the ubiquitin-proteasome pathway was examined in 
different cell types. Bax is normally ubiquitously expressed but decreased expression has been 
observed in various cancer cells. It has been reported that Bax is short-lived in cancer cells and 
is abnormally degraded by the ubiquitin-proteasome system (Agrawal et al., 2008; Li & Dou, 
2000; Liu e ta l ,  2008).
Among the PCa cell lines tested, low levels of Bax expression were detected in PC3. 
Although only one cell line was studied, this is consistent with the concept that decreasing 
Bax expression is observed with increasing grade (severity) of cancer, shown by Li et a l  
(2000). However, it is difficult to compare the present results with this study, because tissue 
samples from PCa patients with advanced disease were used. Unfortunately, PC3 is HLA-A2 
negative, so it was not possible to test whether this potential degradation leads to T cell 
recognition. As for LNCaP, no accumulation of Bax expression was seen with proteasome 
inhibition. It can be suggested that Bax protein would not be degraded in these cells so would 
not be processed and presented to the T cells, hence explaining the lack of recognition by Bax 
specific T cells.
By contrast in CLL patients, the western blot data shows that proteasomal degradation 
of Bax is enhanced in most CLL cells. These findings are in accordance with previous studies 
(Agrawal et al., 2008; Liu et a l ,  2008). Bax is short-lived in malignant B cells and increased 
Bax degradation activity has been associated with poor prognosis in CLL and resistance to 
chemotherapy in lymphoid malignancies (Agrawal et al., 2008; Liu et al., 2008; Pepper et al., 
1997; Pepper et al., 1998). This Bax degradation activity was seen in CLL cells but not in 
normal lymphocytes. Correlation between increased apoptosis and accumulation of Bax 
following treatment with proteasome inhibitors indicates that increased proteasomal 
degradation of Bax contributes to resistance to apoptosis in cancer cells. The mechanism of 
Bax degradation is still not clear, but it has been recently suggested that Bax degradation
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occurs when Bax is translocated and undergoes conformational changes at the mitochondrial 
level, probably before its stable mitochondrial membrane insertion. The exposure of Bax 
hydrophobic domains during its conformational changes triggers ubiquitin recognition and 
proteasomal degradation (Yu e ta l ,  2008).
A Bax cleavage product (p i8) became detectable after treatment, with very low levels 
of p i8 being rescued by proteasome inhibition. It has been previously reported that cleavage 
of full-length Bax (p21) during apoptosis, to the p l8  form may enhance its cell death function 
(Cao et al., 2003; Wood & Newcomb, 2000). Although cleavage to p l8  Bax has been shown 
not to be necessary for Bax to initiate apoptosis, this cleavage product can accelerate apoptosis 
and displays a more potent ability to disrupt mitochondrial membrane integrity and promote 
cell death than p21 Bax (Cao et al., 2003; Wood & Newcomb, 2000). The selective 
degradation of the cleavage product by proteasome seen in CLL cells may thus be a way to 
silence this potent form of Bax, delaying or avoiding the apoptosis process. Conversely, some 
of the tumour cell lines tested (PCa, cervical cancer and U 20S cell lines) did not show 
detectable levels of the cleavage product with or without proteasome inhibition. This suggests 
that cleavage of Bax may not be a major mechanism to induce apoptosis in these cell lines.
Bax degradation by the proteasome was also detected in cervical cancer cell lines. 
Interestingly, increased levels of an additional band (24kda), corresponding to the isoform 
Baxp were found in MS751 and C33A-HPV16 after proteasomal inhibition, indicates that this 
isoform is also degraded by the proteasome. This is in agreement with recent findings showing 
that this isoform is tightly regulated by the ubiquitin proteasome pathway. This study also 
reported that Baxp is highly potent in inducing cytochrome c release from mitochondria and it 
can associate with Baxa (21kda) to promote its change to active conformation (Fu et al., 
2009)
It is possible that the degradation of Bax in cervical carcinoma cell lines is a 
consequence of HPV gene expression. Expression of E6 oncoprotein has been reported to
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induce Bax degradation and inhibit Bax-induced apoptosis (Magal et al., 2005). Furthermore, 
HPV E6 can target many cellular proteins including proteins involved in apoptosis, such as 
Bak, for ubiquitin-proteasomal degradation (Scheffner & Whitaker, 2003). The results in this 
thesis also support this concept. There was an accumulation of Baxa/Baxp in HPV E6+ cells 
after treatment with bortezomib, whereas only a sight increase of Baxp with the highest dose 
of bortezomib was seen in HPV negative C33A. It would be of interest to directly the effect of 
HPV E6 by transfecting it into cell lines that do not show any proteasomal degradation of Bax.
Osteosarcoma cells TK143 and U 20S also showed degradation of Bax by the 
proteasome. However, differential expression of Bax was detected between cell lines. TK143, 
but not U20S, showed detectable levels of cleavage product after treatment with proteasome 
inhibitor. Although Saos-2 was not tested in the present study, it has previously been reported 
by others that Bax is degraded by the ubiquitin-proteasome pathway in these cells (Chang et 
a l ,  1998).
Important evidence to support the concept of differential degradation of Bax between 
tumour cells and normal cells, was that there was no substantial accumulation of Bax in non­
transformed cells (PBMC and PHA blasts) after treatment with proteasome inhibitor. This is 
consistent with previous findings, demonstrating that malignant B cells, but not normal 
lymphocytes, have a defect in Bax stability (Agrawal et al., 2008). This group found an 
increased Bax degradation at the mitochondrial level in malignant cells, but not in normal 
peripheral blood lymphocytes, indicating that Bax in healthy cells is stable and has a long 
half-life. It was also suggested that ubiquitin recognizes the active form of Bax (Agrawal et 
al., 2008; Liu et al., 2008). A recent study proposed that the exposure of Bax hydrophobic 
domains during conformation change and translocation to the mitochondria triggers ubiquitin 
recognition and proteasome degradation in cancer cells (Yu et a l ,  2008). In healthy cells, Bax 
is stable and predominantly localized in cytosol or loosely attached to outer mitochondrial 
membranes in an inactive state (Nechushtan et al., 1999; Wolter et al., 1997). Therefore, Bax
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in healthy tissues does not appear to be efficiently targeted for proteasomal degradation. This 
is consistent with the hypothesis and explains why healthy cells are not recognized by Bax- 
specific T cells.
In this study, Bax stability was not tested and only a measurement of Bax protein level 
at a single time point was done using whole cell lysates. It will be useful to use cytosol and 
mitochondrial fractions, instead of whole cell lysates, as it will give information about the 
location of Bax in the different cancer cells and normal cells. Future experiments include the 
investigation of the stability of Bax and the rate of degradation using cycloheximide in these 
tumour cells compared with healthy cells (and other tumour cells). Cycloheximide inhibits 
protein synthesis and allows the measurement of degradation only. Therefore, this will provide 
information about the intrinsic ubiquitin/proteasome activity of these tumour cells and 
dynamic changes in Bax protein levels over time. It will also be essential to examine both Bax 
stability and T cell recognition for fresh tumour tissue compared to cell lines of solid cancers. 
Investigation of Bax degradation in other non-cancerous cells such as skin fibroblasts, will 
also be important.
In conclusion, Bax was found to be ubiquitously expressed as expected, but differential 
degradation by proteasomes was revealed between cell types. It was shown here that Bax 
degradation by proteasome occurs in cancer cells, but not in the healthy cells tested. This 
correlates with the T cell recognition data and supports the hypothesis. Overall, the results 
from this chapter and chapter 4 support the concept of Bax as a tumour antigen for several 
human cancers.
197
Chapter 6: Results
Chapter 6 
Generation of T cell Responses in CLL patients
The previous chapters have shown that Bax peptides were immunogenic in healthy 
donors, and could generate T cells able to recognise tumour cells. For Bax to be useful in 
immunotherapy, it is required that T cell responses can be generated in cancer patients. In this 
chapter, the general immune responsiveness in CLL patients will be evaluated. In order to 
know if it is possible to generate T cell responses in CLL patients, memory responses were 
tested against a mixture of recall antigens and primary T cell responses against MART-1 
peptide. MART-1 was used as a model antigen for naive T cell responses in a HLA-A2 
restricted system. Naive and memory T cell responses were characterized using samples from 
both healthy donors as a control, and CLL patients. Ultimately, T cell responses against the 
candidate tumour antigen Bax were investigated in CLL patients, particularly because Bax- 
specific T cells from a healthy donor were able to recognise CLL cells, indicating that Bax can 
be processed and presented by CLL cells.
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6.1 T cell responses against PPP
The capacity of T cells from CLL patients to respond against a mixture of recall 
antigens (PPP) was tested as a general indication of immune competence. PPP contained both 
CD8+ and CD4+ T cells epitopes from common recall antigens. The source of these antigens 
included EBV, CMV, influenza A and tetanus. This protocol has been used as a positive 
control for memory T cell responses in testing candidate therapeutic vaccines (Smith et al.,
2005).
PBMC from thirteen CLL patients and eleven healthy donors were used to assess 
memory T cell responses against PPP in vitro. T cell responses against PPP were detected in 
9/13 CLL patients, with a range of responses between 27 and 298 spots /105 cells (mean = 88 
spots + 24) (Figure 6.1). All the patients were capable of responding to mitogens (PHA, PM A, 
Concavalin A, ionomycin), which were used as a positive control in ELISpot (between 150- 
300 spots/105 cells) (data not shown). Unlike the CLL patients, memory T cell responses 
against PPP were detected in all eleven healthy donors, with responses ranging from 29 to 384 
spots /105 cells (mean = 177 spots + 37.3). It was also evident that responses in healthy donors 
were significant higher than in CLL patients (p = 0.0127) (summarized in Figure 6.2). Overall, 
this data shows that fewer CLL patients were able to respond to recall antigens and T cell 
responses were weaker when compared to healthy donors.
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Figure 6.1 M em ory T  cell responses against recall antigens in CLL patients. PBMC from CLL 
patients were cultured with a mixture of peptides from influenza, EBV, CMV and tetanus toxoid (PPP). 
After 7 days, T cells were harvested and IFNy-secreting T cells reactive against PPP were measured 
using an ELISpot assay. The dashed line represents the 20 spot cut-off for a positive response and the 
standard deviation is also shown. Background responses (+PBMC without peptide) have been 
subtracted from data.
200
Chapter 6: Results
400 n
P=0.0127
</> 3 0 0 -
<uo
inO
O
CL
CO
200 -
1 0 0 -
0
Healthy donors
‘A'a S ^
CLL patients
Figure 6.2 Memory T cell responses against recall antigens in CLL patients and healthy donors.
PBMC from either CLL patients or healthy donors were culture with PPP. After 7 days, T cells were 
harvested and IFNy-secreting T cells reactive against PPP were measured using an ELISpot assay. The 
dashed line represents the 20 spot cut-off for a positive response and the solid horizontal lines represent 
the mean. Background responses (+PBMC without peptide) have been subtracted from data. Statistical 
analysis (Mann Whitney test) was done using GraphPad Prism software.
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6.2 T cell responses against MART-1
MART-1 antigen is highly immunogenic and it has been shown that this antigen is 
capable of eliciting robust primary T cell responses in a large proportion of healthy HLA-A2+ 
donors (Pittet et a l ,  1999). Therefore, MART-1 was used to evaluate whether CLL patients 
were capable of mounting naive T cell responses. Five CLL patients in this study were HLA- 
A2+ and so tested in parallel for responses against MART-1 peptide (Patients 2, 7, 8, 10 and 
11). However, none of the HLA-A2+ patients generated positive MART-1 T cell responses 
(Figure 6.3A). Interestingly, CLL patients 7 and 11 were also not able to mount memory 
responses against recall antigens, whilst in patients 2, 8 and 10, it was possible to detect a 
weak PPP response (41-88 spots/105 cells) (Figure 6.1). PBMC from seven HLA-A2+ healthy 
donors were also stimulated with MART-1 peptide. Primary T cell responses could be detected 
in 4/7 healthy donors, with responses ranging from 89 to 168 spots/105 cells (Figure 6.3B).
Since in CLL patients, 80-95% of PBMC are CD 19+ B cells and only 1-15% are CD3+ 
T cells, it was also evaluated whether the low frequency of T cells in the PBMC was having an 
impact on the detection of T cell responses. CD8+ T cells were enriched (using 
immunomagnetic beads) from five HLA-A2+ CLL patients and healthy donors, and stimulated 
with autologous PBMC and MART-1 peptide for up to 3 weeks to determine if MART-1 T 
cell responses could be detected. However, a weak positive response against MART-1 peptide 
was detected in only one of the patients (34 spots/105) (Figure 6.4A), suggesting that other 
factors, besides the frequency of CD3+T cells influenced the priming of MART-1 T cells. In 
contrast, it was possible to detect T cell responses against MART-1 in 4/5 healthy donors 
(Figure 6.4B).
Overall, this data suggests that priming of naive CD8+ T cell responses is impaired in 
CLL patients, compared to healthy donors.
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Figure 6.3 Naive T cell responses against MART-1 peptide in CLL patients (A) and healthy 
donors (B). PBMC from either CLL patients or healthy donors were cultured with MART-1 peptide 
(ELAGIGILTV) for 7 days. T cells were harvested and IFNy-secreting T cells reactive against MART- 
1 were measured using an ELISpot assay. All subjects were typed as HLA-A2. The dashed line 
represents the 20 spot cut-off for a positive response. Background responses (+PBMC without peptide) 
have been subtracted from data.
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Figure 6.4 MART-1 T cell responses after 2-3 weeks of stimulation in CLL patients (A) and 
healthy donors (B). CD8+ T cells were purified using immunomagnetic beads and cultured with 
irradiated autologous PBMC and MART-1. Cultures were restimulated with MART-1 weekly. T cells 
were harvested after 2 to 3 weeks stimulation and IFNy-secreting T cells reactive against MART-1 
were measured using ELISpot assay. All subjects were typed as HLA-A2. The dashed line represents 
the 20 spot cut-off for a positive response. Background responses (+PBMC without peptide) have been 
subtracted from data.
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6.3 T cell responses against Bax peptides
Although it was previously revealed that CLL cells can be recognised by Bax-specific 
T cells from a healthy donor (section 4.5.2), it was not known whether the candidate tumour 
antigen Bax is effective in generating T cell responses in CLL patients. Therefore, T cell 
responses against Bax peptides were investigated in CLL (summarised in table 6.1). PBMC 
from two HLA-A2+ patients (CLL1 and CLL2) were stimulated with Bax pool 1-15 for up to 
4 weeks, but Bax specific T cell responses were not detected. Taking into account that 80-95% 
of CLL cells are B cells, CD8+ T cells from one HLA-A2+ patient (CLL3) were purified by 
flow sorting and cultured with irradiated autologous CLL cells in the presence of Bax pool 1- 
15 for one week. A positive T cell response against Bax peptides was detected after being 
stimulated for one week and expanded using the antigen-independent protocol (110 spots/105 
cells). However, Bax specific T cells from this patient were difficult to grow and no further 
characterisation of these T cells was done.
CD8+ T cell enrichment using flow sorting was time consuming 0  4 hours to purify 
only lxlO 6 cells), expensive and a low number of T cells was recovered after stimulation 
(2xl05). Therefore, CD8+ T cells from additional four HLA-A2+ CLL patients (CLL4, CLL5, 
CLL6 and CLL7) were enriched using immunomagnetic beads (MACs), as previously done 
for healthy donors. Cells were harvested after 1-3 weeks and tested in an ELISpot assay, 
depending on the numbers of CD8+ T cells after each stimulation. A weak response against 
Bax peptides was detected in one of these patients (21 spots/105 cells) after 1 week of 
stimulation with Bax pool. No additional stimulations with Bax pool were possible for this 
patient due to limited numbers of T cells.
Overall, these results indicate Bax peptide specific T cells can be detected occasionally 
in CLL patients but that it is difficult to generate robust T cell responses from the blood using 
current protocols.
205
Chapter 6: Results
Table 6.1 Summary of T cell responses against Bax in CLL patients
CLL1 No PBMC+ irradiated 4 weeks: < 20 spotsautologous PBMC
CLL2 No PBMC+ irradiated autologous PBMC 4 weeks: < 20 spots
CLL3 Flow sorting T cells + irradiated autologous PBMC 1 week: 110 spots
CLL4 MACs sorting T cells + irradiated autologous PBMC 2, 3 weeks: < 20 spots
CLL5 MACs sorting T cells + irradiated autologous PBMC 1 week: 22 spots
CLL6 MACs sorting T cells + irradiated autologous PBMC 2, 3 weeks: < 20 spots
CLL7 MACs sorting T cells + irradiated autologous PBMC 3 weeks : < 20 spots
Background responses (+PBMC without peptide) have been subtracted from data.
6.4 Discussion
The data from this in vitro study suggests that naive and, to a certain extent, memory T 
cell responses are compromised in CLL patients. It was particularly difficult to detect naive 
responses to MART-1 in HLA-A2+ CLL patients even when CD8+ T cells were purified. 
However, in 9/13 CLL patients tested in this study, T cell responses were detected against 
recall antigens without purification of T cells, indicating that functional memory T cells can be 
found in the peripheral blood of most patients. The frequency of responses against recall 
antigens was significant lower than in healthy donors, but it must be taken into consideration 
the immunosuppressive effect of leukaemic B cells, which were predominant in the cultures 
tested against PPP, accounting for 80-95% of PBMC in culture. Furthermore, the age of 
healthy donors tested was lower (30-60 years) compared to the age of the CLL cohort (>45 
years) and thus might have a slight influence on the detection of higher magnitude of 
responses in the healthy cohort. One major limitation of using CD8+ T cells from CLL patients 
is the starting numbers of T cells. Lower CD8+ T cell numbers were obtained from CLL
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patients since only 3 mis of blood samples were collected from patients compared with 50-100 
mis of blood from healthy donors. Furthermore, only 1-15% CD3+ T cells are found in the 
peripheral blood of CLL patients, resulting in just 2x105 to 1.5xl06 CD8+ T cells being 
recovered from each patient. Since repeat blood sample could not be obtained from the CLL 
patients, it was not possible to culture T cells for more than 3 weeks.
It is interesting to see that it is possible to detect memory T cell responses, as it implies 
that CLL cells, despite their reduced antigen presenting ability, can still be competent APCs in 
presenting recall antigens in vitro. This is in accordance with the concept that memory T cells 
are less dependent on co-stimulation for their activation compared with naive T cells (Croft et 
al., 1994). It has been reported that CLL patients have increased numbers of CMV-reactive T 
cells and that the T cell population is altered towards a cytotoxic phenotype in an effort to 
control persistent viral infections, including CMV (Mackus et al., 2003). Since PPP contained 
CMV peptides, it is possible that most of detectable T cell responses are against CMV. 
However, mapping PPP specific T cell responses to individual peptides, in conjunction with 
assessment of CMV serology would be needed to prove this.
It is well known that CLL cells express low levels of the adhesion and co-stimulatory 
molecules essential for functional APCs, therefore it is not completely unexpected that CLL 
cells failed to prime naive T cell responses against MART-1. There are other immune defects 
in CLL that can contribute to the failure in inducing activation and differentiation of tumour- 
specific T cells. These include abnormal maturation and function of DCs (Orsini et a l ,  2003), 
secretion of inhibitory cytokines and expression of inhibitory molecules such as CD200 by B 
cells, that actively suppress T cell activation, expansion and effector function (Kretz-Rommel 
et al., 2007; Pallasch et al., 2009). CLL cells can also manipulate the gene expression profile 
of T cells through cell-cell contact, inducing abnormal expression of genes involved in CD4+ 
T cell differentiation, and impaired production of cytolytic granzyme granules in CD8+ T cells
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(Gorgun et a l ,  2005). Furthermore, impairment of immune synapse formation between CLL 
cells and T cells, which in turn can prevent T cell activation, has also been demonstrated in 
CLL patients (Ramsay et al., 2008). The T cell themselves can also have abnormalities, which 
include inverted ratio of CD4:CD8 (Platsoucas et a l ,  1982; Totterman et a l ,  1989), reduced 
expression of CD28, £ chain of TCR complex, and CD40L, and reduced IL-2 (IL-2R) that 
collectively suggest impairment of ability to initiate an immune response, and maintenance 
and expansion of T cell responses to antigens (Rossmann et a l ,  2003). All of these defects are 
likely to contribute to the failure to generate a primary T cell response in CLL patients.
Only two CLL patients (CLL3 and CLL5) were able to respond to the candidate 
tumour antigen Bax. Although in CLL5 only a weak response was detected, it was possible to 
detect a positive response in CLL3 after only one week stimulation with Bax pool. This might 
imply that the Bax specific T cells responses in these patients are memory responses. 
However, without further characterisation of these T cells, this cannot be confirmed. 
Therefore, it will of great interest to generate a tetramer for Bax p610 and/or p613 as this will 
allow examination of Bax specific T cells directly ex vivo and allow assessment of memory 
markers. The Bax-specific T cell responses were not robust responses, but this was not 
surprising, since even T cell responses against a highly immunogenic tumour antigen like 
MART-1 are difficult to detect. Similar to MART-1, most of the patients were not able to 
respond to Bax, suggesting that the immunosuppressive effects of CLL cells and T cell 
abnormalities may be preventing the activation of T cells. Alternatively, this might simply 
reflect that these patients do not host a spontaneous response to Bax peptides or that responses 
in these patients may have been present but below the detection limit of the ELISpot. Due to 
reduced number of CD8+ T cells obtained from CLL patients, it was not possible to 
restimulate T cells with Bax pool for more than 3 weeks (unlike healthy donors). Further 
restimulations may be necessary to generate a Bax-specific T cell response in CLL patients.
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Despite the fact that several defects are found in both T cells and B cells of CLL 
patients, a few tumour antigens have been identified in CLL patients, such as CD23 (Bund et 
al. , 2007), CD229 (Bund et al., 2006), survivin (Schmidt et al., 2003), MDM2 (Mayr et al.,
2006), hTERT (Kokhaei et al., 2007) and fibromodulin (Mayr et al., 2005).
Some of these studies were able to demonstrate specific T cell responses using native 
CLL cells as APC after several weeks of stimulation but in some cases CLL cells had to be 
stimulated prior to co-incubation with T cells using CD40L-expressing feeders (Bund et al., 
2006; Bund et al., 2007; Mayr et al., 2006). The low immunogenicity of CLL cells is due at 
least in part to their poor antigen-presenting competence, making it extremely difficult to 
initiate an effective immune response. CD40L stimulation has been shown to be effective in 
enhancing their antigen presenting capacity by increasing the expression of adhesion and co­
stimulatory molecules. In several studies, this resulted in autologous T cell activation and 
expansion within 3 to 4 weeks of stimulation with CD40L-stimulated CLL cells, and most 
importantly allowed detection of peptide-specific T cell responses (Bund et al., 2006; Bund et 
al., 2007; Mayr e ta l., 2006).
Taken together, the findings of these studies imply that stimulation or pre-activation of 
CLL cells is required to allow antigen presentation to T cells. To induce effective Bax (or 
MART-1) specific T cell responses in CLL patients, it will likely be necessary to enhance 
antigen presentation, possibly to overcome tolerance on both the antigen presenting and 
effector mechanisms. Importantly, HLA-A2+ CLL cells were recognised by the Bax-specific T 
cells from a healthy donors, indicating that CLL cells are processing and presenting Bax 
peptides and thus it is possible that there are T cells specific for Bax in the circulation. 
Therefore, additional experiments must be attempted with improved stimulation protocols 
before excluding the possibility of Bax as a potential tumour antigen for CLL.
Different in vitro strategies could be developed to repair T cell function and overcome 
T cell tolerance. First, CLL cells need to be stimulated with CD40L prior to incubation with T
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cells. Stimulations including native CLL cells or CD40L activated CLL cells co-cultured with 
T cells in presence of Bax peptides should be tried for more than 3 weeks in vitro culture. As 
culture with CD40L-activated CLL cells allows T cell expansion with several weeks of 
stimulation, limited numbers of T cells might no longer be a major problem. An additional 
strategy can also be applied by using an antibody to block CD200, which is an immune 
suppressive molecule over-expressed on CLL cells, that is capable of inhibiting T cell 
proliferation, antigen-specific T cell responses and promoting induction of Tregs. It has been 
recently shown that expansion of antigen-specific cytotoxic T cells and suppression of Tregs 
can be enhanced by culturing T cells with CD40L-stimulated APCs and an anti-CD200 
antibody (Pallasch et al., 2009). Therefore, this approach should also be considered to assess 
Bax-specific T cell responses in CLL patients. The use of an immunomodulatory drug called 
lenalidomide to improve antigen presentation by CLL cells is also an attractive strategy to 
investigate Bax specific T cell responses in CLL patients. Lenalidomide has been recently 
shown to enhance immune synapse formation between T cells and CLL cells (Ramsay et al. , 
2008). Because of its T cell stimulatory effect, this could result in improved effector functions 
against CLL cells.
Applying these in vitro approaches will most likely provide decisive information 
whether Bax protein could be a tumour antigen in CLL, but will also help to optimise 
protocols for priming and maintaining functional T cells against other candidate tumour 
antigens in CLL patients.
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Chapter 7 
Immunophenotyping of CLL patients
CLL was studied as a model system for generation of human tumour specific T cell 
responses. The general cell-mediated immunity of patients was investigated in Chapter 6. 
These in vitro studies suggested that both naive and memory T cell responses are 
compromised in CLL patients. It is known that high numbers of systemic tumour cells in 
CLL can suppress T cell responses, but the mechanism(s) behind this suppression is still not 
clear. Recently, the development of multi-colour flow cytometry has allowed more detailed 
functional and phenotypic characterisation of T cell subsets in human disease. It has provided 
valuable information about aberrant phenotypes in diseases, such as a skewed maturation of 
CD8+ T cells in HIV-patients (Champagne et al., 2001; Hoji et al., 2007) and increased 
Tregs in cancer patients (Wolf et al., 2003). The main aim of this chapter is to use this 
technology to investigate the possibility that such skewed T cells subsets could also be 
identified in CLL patients (n=51). A smaller number of age-matched healthy donors (n=10) 
were analysed to provide direct comparators for the lymphocyte subsets under investigation. 
Eight-colour flow cytometry was used for detailed phenotypic analysis of peripheral blood 
lymphocyte populations, in particularly T cells (see table 2.6 in Materials &Methods).
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7.1 Frequencies of peripheral blood lymphocyte populations
The first investigation of this study was to assess the frequency of peripheral blood 
lymphocyte populations. The percentages of B cells (CD19+CD5+), T cells (CD3+ CD4+ 
and CD8+), innate NK (CD56+ CD 16+), y5 T cells (CD3+ TCRy5+) (Figure 7.1) and Tregs 
(CD4+ CD25hlgh Foxp3) (Figure 7.2) were analysed in both CLL patients and healthy donors. 
However, the absolute numbers of these populations were not evaluated in this study. 
Consistent with previous studies, a significant increase was seen in the percentage of 
CD19+CD5+ B cells in patients (83.4%) compared to healthy donors (8.9%) (P<0.0001), 
along with a significant decrease of percentage of CD3+ T cells (9.6% vs 62.2%, P<0.0001) 
and NK cells (CD56+CD16+) (2.3% vs 12.6%, PcO.OOOl). An increase in the frequency of 
CD8+ T cells among CD3+ T cells was observed in CLL patients (40.3% vs 28.5%, P=0.056 
not significant), while the percentage of CD4+ T cells among the CD3+ T cells was 
significantly reduced (45.6% vs 64.4%, P=0.0008). An expansion in the CD8+ T cell subset 
relative to CD4+ T cells was seen in 29/51 patients (57%) leading to a lower CD4:CD8 ratio 
compared to healthy donors (mean ratio 0.77 vs 2.26, P<0.0001). No significant difference 
was seen in the y5 T cells among the CD3+ T cells between CLL patient and healthy donors 
(4.67% vs 2.23%, P=0.05). Furthermore, a significant increase of Tregs was observed among 
CD4+ T cells in CLL patients compared to healthy donors (4.1% vs 1.8% , P=0.0096) 
(Figure 7.2).
Overall, these results showed that, besides the increase in malignant B cells in CLL 
patients, the frequency of NK cells and CD3+ T cells is significant reduced, and there is a 
tendency for an increase in frequency of CD8+ T cells and Tregs, and reduced frequencies of 
CD4+ T cells, compared with healthy donors.
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Figure 7.1 Frequency of the peripheral blood lymphocyte populations in CLL patients (n=51) 
and healthy donors (n=10). The number of positive cells was determined by flow cytometry (FACS 
CantoII). Lymphocytes were gated based on their forward and side scatter profile. % B cells 
(CD19+CD5+), CD3+ T cells, NK (CD56+CD16%) are shown within lymphocyte gate. % CD4+ T 
cells, CD8+ T cells and y8 T cells (TCRy5+) are shown within the combined lymphocyte/CD3 gate. 
The mean within each subgroup is shown. Flow cytometric and statistical analysis (Mann Whitney 
test) were carried out using FlowJo software and GraphPad Prism software, respectively.
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Figure 7.2 Frequency of Tregs in CLL patients (n =43) and healthy donors (n =10). The number 
of positive cells was determined by flow cytometry (FACS CantoII). (A) Gating strategy used to 
determine CD4+ CD25high FoxP3+. (B) % CD4+ CD25high FoxP3+ shown within 
lymphocyte/CD3/CD4 gate. The mean within each subgroup is shown. Flow cytometric analysis and 
statistical analysis (Mann Whitney test) were carried out using FlowJo software and GraphPad Prism, 
respectively.
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7.2 Expression of immunosuppressing molecules CD200, CD200R and PD-1
Several studies have shown that immunosuppressing molecules, such as CD200 and 
PD-1, are overexpressed in haematological malignancies, including CLL (McWhirter et al., 
2006; Xerri et al., 2008). Therefore, the expression of PD-1, CD200 and its receptor CD200R 
were investigated in order to see whether there is an altered expression on the different 
lymphocyte populations of CLL patients when compared with age-matched healthy donors. 
The immunosuppressive CD200 has been shown to play a part in regulating immune 
responses (Kretz-Rommel et al., 2007; McWhirter et a l., 2006; Pallasch et al., 2009). CD200 
is normally expressed on DCs, B cells and T cells among others. CD200 exerts its effect by 
binding to its cognate receptor CD200R, which is expressed on cells specifically derived 
from myeloid lineage, T cells and B cells (Rijkers et al., 2008). PD-1 is a lymphoid receptor 
that negatively regulates immune responses. PD-1 is induced in T cells, B cells and myeloid 
cells. Interaction of PD-1 with its ligands PD-L1 or PD-L2 on tumour cells may play a role in 
tumour escape from immune responses (Okazaki & Honjo, 2006; Xerri et al., 2008).
CD200 expression was examined on B cells, NK, CD4+ and CD8+ T cells. Both its 
receptor (CD200R) and PD-1 expression was examined on B cells and CD4+ and CD8+ T 
cells. A representative gating strategy to determine the frequency of lymphocyte populations 
and expression of immnosuppressing molecules is shown in Figure 7.3.
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Figure 7 3  Representative results of a CLL patient (A) and healthy donor (B). The gating strategy 
used to determine lymphocyte populations NK (CD56+CD16+), B cells (CD19+CD5+) T cells 
(CD3+ CD4+ or CD8+) and expression of immunosuppressing molecules (in this case CD200) within 
these subsets is shown. The number of positive cells was determined by flow cytometry (FACS 
CantoII) and flow cytometric analysis was carried out using FlowJo software.
CD200 expression
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CD200 expression was significantly increased on CD19+CD5+ B cells (96.4% vs 
33.8%, P<0.0001), NK (14.3% vs 3.6%, P=0.0004), CD4+ T cells (69.83% vs 16.7%, 
P<0.0001) and CD8+ T cells (55.4% vs 9.4%, PcO.OOOl) of CLL patients compared to 
healthy donors (Figure 7.4). However, no significant increase in expression of its receptor 
CD200R was observed within B cells (19% vs 21.2%) and only a slight trend of increase (but 
not statistically significant) was seen within CD4+ T cells (29.60% vs 23.5%, P=0.4220) and 
CD8+ T cells (23.71% vs 17.5%, P=0.2625) of CLL patients compared to healthy donors 
(Figure 7.5). As for PD-1 expression, a significant increase in expression was observed 
within CD4+ T cells (37.5% vs 17.2%, P=0.0113), CD8+ T cells (34.95% vs 17.1%, 
P=0.0174) and CD19+CD5+ B cells (11.2% vs 4.7%, P=0.0208) (Figure 7.6). This data 
revealed that the immunosuppressive CD200 and PD-1 molecules are increased in CLL 
patients and these may be playing a role in inhibiting anti-tumour immune responses.
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Figure 7.4 CD200 expression in CLL patients (n =50) and healthy donors (n =8). The number of 
positive cells was determined by flow cytometry (FACS CantoII). Lymphocytes were gated based on 
their forward and side scatter profile. CD200 expression was analysed within CD19+CD5+ B cells, 
NK (CD56+CD16+), CD4+ and CD8+ T cells. The mean within each subgroup is shown. Flow 
cytometric analysis and statistical analysis (Mann Whitney test) were carried out using FlowJo 
software and GraphPad Prism, respectively.
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Figure 7.5 CD200R expression in CLL patien ts (n=42-43) and healthy donors (n=8-9). The
number of positive cells was determined by flow cytometry (FACS CantoII). Lymphocytes were 
gated based on their forward and side scatter profile. CD200R expression was analysed within 
CD19+CD5+ B cells, CD4+ and CD8+ T cells. The mean within each subgroup is shown. Flow 
cytometric analysis and statistical analysis (Mann Whitney test) were carried out using FlowJo 
software and GraphPad Prism, respectively.
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Figure 7.6 PD-1 expression in CLL patients (n=42) and healthy donors (n=10). The number of 
positive cells was determined by flow cytometry (FACS CantoII). Lymphocytes were gated based on 
their forward and side scatter profile. PD-1 expression was analysed within CD19+CD5+ B cells, 
CD4+ and CD8+ T cells. The mean within each subgroup is shown. Flow cytometric analysis and 
statistical analysis (Mann Whitney test) were carried out using FlowJo software and GraphPad Prism, 
respectively.
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7.3 CD3+ T cells
A comprehensive analysis of CD4+ and CD8+ memory T cells in CLL patients 
compared with that in healthy donors was undertaken to give further insights as to why it was 
difficult to generate T cell responses in CLL patients (Chapter 6). It has been reported that a 
skewed maturation of T cells occurs with ageing and disease, including chronic viral 
infection, such as HIV (Champagne et a l ,  2001; Hoji et al., 2007; Koch et a l ,  2008). In 
particular, a progressive downregulation of CD28 and upregulation of CD57, which are 
associated with replicative senescence (proliferative exhaustion), have been observed with 
ageing and disease, including CLL (Brenchley et a l ,  2003; Scheuring et a l ,  2002; Van den 
Hove eta l., 1998a).
Therefore, co-expression of CD28, CD45RO and CD57 was analysed in CD4+ and 
CD8+ T cell compartments to elucidate whether this phenotype is more pronounced in 
patients with CLL compared to age-matched healthy donors. It was also evaluated if CD4+ 
and CD8+ memory T cell subsets differ between CLL patients and age-matched controls. The 
T cell subsets were defined by dividing both CD4 and CD8 compartment on the basis 
CD45RO and CCR7 into naive (CCR7+CD45RO-), central memory (CCR7+CD45RO+), 
effector memory (CCR7-CD45RO+) and terminally differentiated effector cells (CCR7- 
CD45RO+) (see Figure 1.3). A representative result from a CLL patient sample showing the 
detailed gating strategies using CD3, CD4, CD8, CD45RO, CCR7, CD28 and CD57 is shown 
in Figure 7.7.
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Figure 7.7 Representative results of T cell analysis. (A) Gating strategy for CD45RO+/- CD28+/- 
CD57+ in CD4+ T cells. (B) Definition of T cell subsets Naive (CCR7+CD45RO-), Central Memory 
(CM) (CCR7+CD45RO+), Effector Memory (EM) (CCR7-CD45RO+), and Effector (EMRA) 
(CCR7-CD45RO-). Representative results o f the T cell subsets are shown in a CLL patient and 
healthy donor. The number of positive cells was determined by flow cytometry (FACS CantoII) and 
flow cytometric analysis was carried out using FlowJo software.
222
Chapter 7: Results
7.3.1 CD8+ T cells
In order to corroborate previous findings showing a downregulation of CD28 in 
CD8+ T cells of CLL patients (Rossmann et al., 2003; Scrivener et al., 2001; Van den Hove 
et al., 1998a), the relationship between CD28, CD45RO and CD57 in CLL patients was 
compared to healthy donors.
There was a significant increase of CD28- cells in both CD45RO+ (41.2% vs 26.9%, 
P<0.0202) and CD45RO- (70.7% vs 38.8%, P<0.0005) compartments of CD8+ T cells from 
CLL patients compared to healthy donors (Figure 7.8A). The CD28-CD45RO- in total CD8+ 
T cells of patients was significantly enhanced compared to healthy donors (44.3% vs 23.5%, 
P<0.0038), but no significant difference of CD28-CD45RO+ in total T cells was found 
between patients and healthy donors (15.6% vs 10.6%, P=0.1807) (Figure 7.8B). This 
indicates that there is an enhanced downregulation of CD28 which is correlated with lack of 
CD45RO expression in CD8+ T cells of CLL patients.
Furthermore, it was revealed that CD28-CD45RO-CD57+ was significantly enhanced 
in total CD8+ T cells of patients compared with healthy donors (30.6% vs 16.2%, P=0.0112), 
but no significant difference was found for CD28-CD45RO+CD57+ in total T cells (11.6% 
vs 8.9%, P=0.2991) (Figure 7.8C). These results showed an apparent downregulation of 
CD28 and CD45RO inversely correlated with CD57 expression in CLL patients. In 
accordance with other findings, this suggests that there is an accumulation of highly 
differentiated T cells, supporting the concept of systemic activation of the T cell 
compartment (Rossmann et al., 2003; Scrivener et a l ,  2001; Serrano et al., 1997; Van den 
Hove et al., 1998a; Van den Hove et al., 1998b).
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Figure 7.8 Expression of CD28, CD45RO and CD57 in CD8+ T cells of CLL patients (n=49) and 
healthy donors (n=10). The number of positive cells was determined by flow cytometry (FACS 
CantoII). Lymphocytes were gated based on their forward and side scatter profile. T cells were gated 
on CD3+ CD8+. (A) % CD28- within CD45RO+ and CD45RO- CD8+ T cells. (B) % CD28- 
CD45RO- of CD8+T cells. (C) % CD28- CD45RO+ CD57+ and % CD28- CD45RO- CD57+ of 
CD8+ T cells. The mean within each subgroup is shown. Flow cytometric analysis and statistical 
analysis (Mann Whitney test) were carried out using FlowJo software and GraphPad Prism, 
respectively. CLL patients (filled symbols) and healthy donors (open symbols).
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CD8+ T cell subsets were evaluated in CLL patients and compared with age-matched 
controls (Figure 7.9). The subsets were defined by the model which subdivides the CD8+ T 
cell compartment on the basis of CD45RO and CCR7. A significant decrease in the 
proportion of naive CD8+ T cells in CLL patients was observed when compared to healthy 
donors 11.58% vs 25.6, P=0.0083). This is consistent with an increase in proportions of EM 
(32.5%) and EMRA (48%). However, no significant difference between CLL patients and 
healthy donors (EM: 34.1%, P=0.6509, and EMRA:35.5%, P=0.0809) was observed. The 
percentage of CM was low but not significantly different between patients and controls 
(6.79% vs 5.89%, P=0.4911).
The accumulation of CD28- and CD57+ cells were further shown to be in the EM and 
EMRA subsets. There was a significant increased of CD28- EMRA (39.3% vs 22%, 
P=0.0186) and CD57+ EMRA (32.8% vs 18.9, P=0.0220) in total CD8+ T cells of patients as 
compared to healthy donors (Figure 10). These results indicated that there is an accumulation 
of exhausted CD8+ T cells, supporting the concept of a chronic overstimulation of T cells in 
CLL patients.
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Figure 7.9 CD8+ T cell subsets of CLL patients (n=34) and healthy donors (n=8). The number of 
positive cells was determined by flow cytometry (FACS CantoII). Lymphocytes were gated based on 
their forward and side scatter profile. T cells were gated on CD3+ CD8+. T cells subsets were defined 
based on the expression of CCR7 and CD45RO. Naive (CCR7+CD45RO-), Central Memory (CM) 
(CCR7+CD45RO+), Effector Memory (EM) (CCR7-CD45RO+), and Effector (EMRA) (CCR7- 
CD45RO-). Heterogeneity inside each subset was defined by co-expression of co-stimulatory 
molecules CD27 and CD28 was not included. The mean within each subgroup is shown. Flow 
cytometric analysis and statistical analysis (Mann Whitney test) were carried out using FlowJo 
software and GraphPad Prism, respectively. CLL patients (filled symbols) and healthy donors =HD 
(open symbols).
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Figure 7.10 Percentage of subsets that are CD28- and CD57+ in total CD8+ T cells of CLL 
patients (n=34) and healthy donors (n=8). The number o f  positive cells was determined by flow 
cytometry (FACS CantoII). Lymphocytes were gated based on their forward and side scatter profile. 
T cells were gated on CD3+ CD8+. T cells subsets were defined based on the expression o f  CCR7 
and CD45RO. Naive (CCR7+CD45RO-), Central Memory (CM) (CCR7+CD45RO+), Effector 
Memory (EM) (CCR7-CD45RCH), and Effector (EMRA) (CCR7-CD45RO-). These subsets were 
further gated into CD28- or CD57+ cells. The percentage is o f  CD8+ total cells. The mean within 
each subgroup is shown. Flow cytometric analysis and statistical analysis (Mann Whitney test) were 
carried out using FlowJo software and GraphPad Prism, respectively. CLL patients (filled symbols) 
and healthy donors =HD (open symbols).
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7.3.2 CD4+ T cells
The co-expression of CD28, CD45RO and CD57, and naive/memory subsets were 
also examined in CD4+ T cells, in order to know whether a similar pattern of differentiation 
could be observed in CD4+ T cells. This data showed an increase of CD28- in both 
CD45RO+ (14.4% vs 4.4%, P=0.0148) and CD45RO- (11% vs 3.1%, P=0.1130) 
compartments of CD4+ T cells from CLL patients compared to healthy donors (Figure 
7.11 A). However, only CD28- cells in CD45RO+ was significantly different from healthy 
donors. Moreover, the CD28-CD45RO+ in total CD4+ T cells of patients was significant 
enhanced compared to healthy donors (8.2% vs 1.9%, P=0.0072), but no significant 
difference of CD28-CD45RO- in total T cells was found between cohorts (2.6% vs 0.7%, 
P=0.5575); Figure 7.1 IB). It was revealed that CD28-CD45RO+CD57+ was significantly 
enhanced in total CD4+ T cells of patients compared with healthy donors (6.1% vs 1.4%, 
P=0.0149), but no significant difference was found for CD28-CD45RO-CD57+ in total T 
cells (2.4% vs 0.7%, P=0.1376; Figure 7.11C). These results indicate that CD28 
downregulation is also inversely correlated with CD57 expression in the CD4+ T cells of 
CLL patients but not as pronounced as in the CD8+ T cells.
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Figure 7.11 Expression of CD28, CD45RO and CD57 in CD4+ T cells of CLL patients (n=49) 
and healthy donors (n=10). The number of positive cells was determined by flow cytometry (FACS 
CantoII). Lymphocytes were gated based on their forward and side scatter profile. T cells were gated 
on CD3+ CD4+. (A) % CD28- within CD45RO+ and CD45RO- CD4+ T cells. (B) % CD28- 
CD45RO- of CD4+T cells. (C) % CD28- CD45RO+ CD57+ and % CD28- CD45RO- CD57+ of 
CD4+ T cells. The mean within each subgroup is shown. Flow cytometric analysis and statistical 
analysis (Mann Whitney test) were carried out using FlowJo software and GraphPad Prism, 
respectively. CLL patients (filled symbols) and healthy donors (open symbols).
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The subsets of CD4+ T cells were evaluated in CLL patients compared to healthy 
donors as previously done for CD8+ T cells (Figure 7.12). There was a slight decrease in 
naive CD4+ T cells in CLL patients, however, not significant different from healthy donors 
(42.1% vs 57.1%, P=0.0518). Similar frequencies of CM were found in both cohorts (25.9% 
vs 28.1%, P=0.6168). A significant increase in EM was observed in CLL compared with 
healthy donors (27% vs 12%, P=0.0061). The frequency of EMRA was low in CLL cells but 
significantly higher than that observed in age-matched healthy controls (4.8% vs 2.7%, 
P=0.0361). The slight increase of CD28-CD45RO+ was found to be in both CM and EM 
subsets, but only percentage of CD28- EM of total CD4+ T cells, although low, was shown to 
be significant different from healthy donors (4% vs 0.8%, P=0.0045). CD57+ was also 
observed in both CM and EM, but only CD57+ EM of total cells was found to be significant 
different from healthy donors (5.8% vs 1%, P=0.011; Figure 7.13). This data indicates that 
alterations in the CD4+ T cells of CLL patients are significant but less dramatic than in the 
CD8+ T cells when compared with age-matched healthy donors.
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Figure 7.12 CD4+ T cell subsets of CLL patients (n=42) and healthy donors (n=8). The number 
of positive cells was determined by flow cytometry (FACS CantoII). Lymphocytes were gated based 
on their forward and side scatter profile. T cells were gated on CD3+ CD4+ cells. T cells subsets were 
defined based on the expression of CCR7 and CD45RO. Naive (CCR7+CD45RO-), Central Memory 
(CM) (CCR7+CD45RO+), Effector Memoiy (EM) (CCR7-CD45RO+), and Effector (EMRA) 
(CCR7-CD45RO-). Heterogeneity inside each subset was defined by co-expression of costimulatory 
molecules CD27 and CD28 was not included. The mean within each subgroup is shown. Flow 
cytometric analysis and statistical analysis (Mann Whitney test) were carried out using FlowJo 
software and GraphPad Prism, respectively. CLL patients (filled symbols) and healthy donors =HD 
(open symbols).
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Figure 7.13 Percentage of subsets that are CD28- and CD57+ in total CD4+ T cells of CLL 
patients (n=42) and healthy donors (n=8). The number of positive cells was determined by flow 
cytometry (FACS CantoII). Lymphocytes were gated based on their forward and side scatter profile. 
T cells were gated on CD3+ CD4+. T cells subsets were defined based on the expression of CCR7 
and CD45RO. Naive (CCR7+CD45RO-), Central Memory (CM) (CCR7+CD45RO+), Effector 
Memory (EM) (CCR7-CD45RO+), and Effector (EMRA) (CCR7-CD45RO-). These subsets were 
further gated into CD28- or CD57+ cells. The percentage is o f CD8+ total cells. The mean within 
each subgroup is shown. Flow cytometric analysis and statistical analysis (Mann Whitney test) were 
carried out using FlowJo software and GraphPad Prism, respectively. CLL patients (filled symbols) 
and healthy donors =HD (open symbols).
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Table 7.1 Summary of the immunophenotyping in CLL patients
% CD19+CD5+ cells in lymphocytes *
% CD3+ cells in lymphocytes *
% NK cells in lymphocytes 4/
% CD4+ T cells in CD3+T cells 4/
% CD8+ T cells in CD3+T cells T
% Tregs in CD4+ T cells *
% CD200 in CD19+CD5+ B cells 1s
% CD200 in CD4+ T cells *
% CD200 in CD8+ T cells *
% CD200 in NK cells
% CD200R in CD4+ T cells T
% CD200R in CD8+ T cells T
% PD-1 in CD19+CD5+ B cells
% PD-1 in CD4+ T cells *
% PD-1 in CD4+ T cells *
CD28- in CD45RO+ CD8+ T cells *
CD28- in CD45RO+ CD8+ T cells *
CD28-CD45RO+ in CD8+ T cells *
CD57+CD28-CD45RO+ in CD8+ T cells
Naive subset 4/
CM subset =
EM subset =
EMRA subset t
CD28-EMRA in CD8+ T cells *
CD57+ EMRA in CD8+ T cells *
CD28- in CD45RO+ CD4+ T cells *
CD28- in CD45RO+ CD4+ T cells *
CD28-CD45RO+ in CD4+ T cells *
CD57+CD28-CD45RO+ in CD4+ T cells
Naive subset i
CM subset
EM subset
EMRA subset
CD28-EM in CD4+ T cells *
CD57+ EM in CD4+ T cells *
^ /|s significantly different from healthy controls
I t  trend but not significantly different from healthy controls
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7.4 Discussion
The results presented in this chapter provide further evidence that may help in the 
understanding of the failure of T cells to mount effective responses in CLL patients. Several 
differences in the frequencies of immune cell subsets and phenotypes were detected in CLL 
patients compared with age-matched healthy donors. Some of these could explain the 
immune dysfunctions in CLL that prevent the generation of an anti-tumour response.
CLL patients have an increased frequency of leukaemia CD19+CD5+ B cells, 
accompanied by a decrease in frequency of T cells, and NK cells. Although the frequency of 
T cells and NK cells in the peripheral blood is decreased due to the accumulation of 
malignant B cells, previous studies have shown that the absolute number of circulating T 
cells and NK cells is usually elevated and associated with the clinical stage (Dianzani et al., 
1994; Goolsby et al., 2000; Totterman et a l ,  1989; Vuillier et al., 1988). Elevated numbers 
of circulating T cells with a reduced CD4:CD8 ratio has been frequently reported in CLL, 
particularly in the more advanced stages of the disease (Goolsby et al., 2000; Platsoucas et 
al., 1982; Totterman et al., 1989; Vuillier et al., 1988). Indeed, it was found in this study that 
more than half of the patients had a reduced/inverted CD4;CD8 ratio. These findings imply 
that these lymphocyte populations are expanding in response to malignant cell growth and 
may be contributing to the growth potential and survival of leukaemia cells. Despite the 
associated expansion of both neoplastic B cells and T cells, CLL patients have an abnormal T 
cell function and there may be several mechanisms that contribute to immune dysfunction.
In this study, a significant increase of Tregs was found in CLL patients compared 
with healthy donors. This is in accordance with previous reports that show that the frequency 
of Tregs was higher in patients and increased with progression of the disease (Beyer et al., 
2005; Giannopoulos eta l., 2008). These groups also showed that Treg cells were functionally 
capable of abrogating T cell responses against tumour and viral antigens (Giannopoulos et 
al., 2008), and the inhibitory function of Tregs was reduced in patients treated with
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fludarabine (Beyer et a l ,  2005). In this context, the increased frequency of Tregs could be 
inhibiting effective anti-tumour immunity. It will be interesting to correlate the present 
findings with prognosis of the patients as this may give further information about the 
relationship between immunosuppression and clinical prognosis. However, it seems likely 
that the study would require more patients in order to provide definitive results.
In accordance with previous findings (McWhirter et a l ,  2006), CD200 was shown to 
be upregulated on B cells of all CLL patients. Interestingly, CD200 was also found to be 
significantly increased on CD4+ and CD8+ T cells but was reduced on NK cells when 
compared to healthy donors. However, only a slight increase of expression of its receptor 
CD200R was shown on T cells of CLL patients and this was not significantly different from 
healthy donors. It has been reported that memory T cells express higher amounts of CD200R 
than naive or effector T cells (Rijkers et a l ,  2008). It will be interesting to examine 
expression of CD200R in the memory T cell subsets of CLL patients. Due to the limited 
availability of fluorochromes for CD200R, this antibody could not used in the same panel as 
the T cell subsets markers and thus this analysis was only carried on total CD8+ and CD4+ T 
cells. As this receptor is also found on DCs and macrophages, it will be interesting to see if 
its expression is upregulated on these myeloid cells in CLL patients. Given that it was shown 
here that T cells also have an increased expression of CD200, it can be envisaged that not 
only expression of CD200 on B cells but also on T cells may be contributing to the 
immunosuppressive interactions with DCs/macrophages, and CD200 overexpression may 
negatively affect immune responses through multiple different mechanisms.
The CD200 overexpression in CLL cells has been shown to inhibit T cell 
proliferation, suppress anti-tumour responses, and enhance Tregs (Kretz-Rommel et a l ,  
2007; Pallasch et a l ,  2009). Blockade of CD200 has been shown to be efficient in 
augmenting antigen-specific T cells and deregulating the presence of Tregs (Pallasch et a l ,  
2009). The overexpression of CD200 may explain the failure to detect T cell responses
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against Bax peptides and MART-1 peptide. Therefore, it would be interesting to evaluate if 
the blockade of CD200 can improve T cell responses against MART-1 and more importantly 
against Bax peptides.
The immunosuppressive PD-1 molecule was also found to have increased expression 
on T cells and B cells of CLL patients compared with healthy donors. This is in accordance 
with a recent report showing that PD-1 is expressed on CLL cells (Xerri et al., 2008). Higher 
percentages of PD-1 were observed in both CD4+ T cells and CD8+ T cells compared with B 
cells. This increased expression may be preventing the T cell activation and induction of an 
effective naive immune response. Further evaluation of PD1/PD-1 ligands on different 
populations, including also Tregs, may provide further elucidation about the interactions of T 
cells expressing PD-1 with malignant B cells and if PD-l/PD-Ls have a role in the survival of 
malignant B cells. A recent study showed that the blockade of PD-1 can augment expansion 
and functionality of CTLs specific for melanoma antigens (Wong et al., 2007). Thereby, it 
would be interesting to evaluate the effect of PD-1 blockade on T cell responses in CLL 
patients.
The analysis of CD4+ and CD8+ T cell repertoire revealed additional abnormalities 
that corroborate with previous findings. The results presented here showed that CD28 is 
downregulated particularly in CD8+ T cells of CLL patients and can be associated with 
increase of CD57+ T cells. The proportion of CD57+ CD28- among CD4+ T cells was less 
dramatic yet significantly increased in the CD45RO compartment of CLL patients, indicating 
that they are antigen experienced. Reduced expression of CD28 and increased expression of 
CD57 in T cells of CLL patients has been reported by other groups (Rossmann et al., 2003; 
Scrivener et al. , 2001; Serrano et al. , 1997; Van den Hove et al. , 1998a; Van den Hove et a l , 
1998b). Increased oligoclonal T cell expansions, predominantly expressing CD57+ are 
commonly found in CLL patients, and prevail in higher percentages in CLL patients with 
advanced disease stages than in early stages (Serrano eta l., 1997) .
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The present results support the concept of an ongoing activation of T cells in vivo. 
Downregulation of CD28 and expression of CD57 have been associated with replicative 
senescence, and can lead to inability of T cells to proliferate and enhanced tendency to 
apoptosis (Brenchley et al., 2003; Scheuring et al., 2002; Van den Hove et al., 1998a). Lack 
of CD28 and upregulation of CD57 can occur in response to repeated/chronic antigenic 
stimulation and has been associated with ageing. Several lines of evidence suggest that the 
alteration in the T cell subsets in both patients and healthy elderly can be associated with 
chronic antigenic stimulation by viral infections, such as CMV (Mackus et al., 2003; Pita- 
Lopez et al., 2009).
The analysis of CD8+ T cell subsets revealed a relative shift towards differentiated T 
cells. A decreased proportion of naive CD8+ T cells and an increased proportion of EM and 
EMRA were observed in CLL patients. The relative expansion of CD8+ EMRA and EM T 
cell subsets has been previously reported by another group, but only 11 CLL patients were 
analysed (Schreeder et al., 2008). This study is in accordance with those findings and extends 
these observations to a cohort of 34 patients. However, no significant difference of the 
increase of EM and EMRA was found between CLL patients and healthy donors. Analysis of 
a larger cohort of age-matched healthy donors will probably be necessary for significant 
results. The differences in the CD4+ T cell subsets were less pronounced than in the CD8+ T 
cells. A slight decrease of the naive subset (but not significant), and a significant increase of 
the EM were found in CLL patients as compared with the healthy donors. These results are 
consistent with a recent study, which assessed CD4+ T cells subsets in patients with mutated 
(n=71) and unmutated (n= 42) IgVH genes. This study showed a significant increase in 
relative numbers of CM and EM T cells which was associated with progressive disease 
(Tinhofer et al., 2009).
The present observations confirmed previous reports and in addition demonstrated 
that increased CD28- or CD57+ cells in total CD8+ T cells were found particularly in the EM
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and EMRA subsets. As for CD4+ T cells, the CD28- or CD57+ cells were found to be in the 
CM, EM and EMRA subsets, but only CD28- EM / CD57+ EM were significantly different 
from age-matched controls. These observations indicate that several alterations in the T cell 
subsets in CLL patients may contribute to the impaired regulation of malignant B cells.
Initiation of a T cell response requires priming in the presence of CD28 co­
stimulation. The reduced CD28 expression may cause an impaired capability of T cells to 
interact with DCs and CLL cells, consequently leading to impaired interaction and prevention 
of T cell activation. Furthermore, these findings are consistent with functional studies 
demonstrating a defective immune synapse between T cells and CLL (Ramsay et a l ,  2008), 
and with the observations that CLL can manipulate the gene expression profile of T cells 
through cell-cell contact, such as abnormal expression of genes involved in CD4+ T cell 
differentiation and impaired production of cytolytic granzyme granules in CD8+T cells 
(Gorgun et al., 2005). It appears that malignant B cells exert suppressive effects upon 
systemic T cells to prevent generation or amplification of an anti-tumour response. Taking 
these investigations into account, it is not perhaps surprising that priming of naive T cell 
responses even against the highly immunogenic tumour antigen MART-1 is compromised in 
CLL patient samples. These results suggest that T cells in CLL may be incapable of 
initiating, continuing or completing an immune response to the leukaemia B cells and other 
antigens and thus may be involved directly in sustaining the tumour.
This data implies that peripheral CD8+ and CD4+ T cell repertoires are skewed 
towards an effector memory/effector phenotype in CLL patients. The expansion of these 
subsets supports the concept that the generation of these cells is driven by repeated/chronic 
stimulation. The expansion of EM and EMRA might be related with the fact that CMV 
infection can drive cells to chronic stimulation and exhaustion. Nevertheless, serological 
analysis needs to be performed in these patients to confirm whether they are CMV positive 
and the presence of CMV has an impact in the changes of T cell subsets observed in these
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patients. Intuitively, large numbers of effector T cell subsets appear to be beneficial because 
of their ability to mount immediate protection. However, these cells may not be suitable for 
long-term protection as there is a reduction in the diversity and functional integrity of the T 
cell subsets. The increase of CD57+CD28- effector T cells indicates that a large proportion of 
the effector cells are highly differentiated in a state of replicative senescence and thus have 
the least proliferative potential amongst the T cell subsets. This contributes to a decrease 
competence to effectively respond to re-infection or maintain memory for tumour antigens 
expressed by relapsing tumour cells. Moreover, decreased diversity of the naive T cell 
repertoire can affect the capacity of these patients to resist infections to which they had not 
previously encountered, or to respond to the appearance of new tumour antigens. This 
atypical differentiation could contribute to the inability to respond appropriately to persistent 
infections or persistent exposure to tumour antigens, and thus to the failure of cellular 
immune control of CLL cells.
In line with other reports, the findings of this pilot study indicate there are prominent 
dysregulations in both CD8+ and CD4+ T cells that are almost certainly involved in the 
unresponsiveness of T cells to tumour antigens, explaining the failure to prime T cell 
responses against Bax and MART-1. Although some of the frequencies were not significantly 
different between CLL patients and healthy donors, it must be taking into consideration that 
only 8-10 healthy donors were included in this analysis due to the limited availability of age- 
matched controls; most people in the department are under 50 years of age, with an average 
of 30 years, whereas age of CLL cohort was between 45 to 90 years. Further experiments 
including larger numbers of age-matched controls will be done to confirm these differences. 
Furthermore, additional differences may potentially be found between patients with different 
disease stages and thus correlation between this analysis with clinical data of these patients is 
going to be performed in the near future.
239
Chapter 7: Results
In order to gain further insight into the emergence of T cell abnormalities and 
expression of immunosuppressive molecules in CLL, this study will be extended to 100 
patients and other parameters, such as mean fluorescence intensity of certain markers, 
frequencies of populations within lymphocytes gate, CD3+ gate and inside each subgate, will 
be included. Both CD4+ and CD8+ T cell subsets will be further characterised using the 
heterogeneity analysis (CD57, CD27 and CD28). Altered numbers and abnormal functions of 
T cells have extensively been reported in CLL patients, but differences within the specific 
naive and memory T cell subsets has not been studied in great detail. In conjunction with 
these markers, it will also be of great interest to study T cell function, such as cytokines and 
cytotoxic granule secretion. This study will provide useful data to discriminate T cell changes 
in CLL patients, namely by showing that these are caused entirely by altered frequencies of 
the naive/memory subsets or by altered heterogeneity within each of the subset. The data 
generated will be analysed in conjunction with a large pre-existing patient database to find 
cell phenotypes that may correlate with clinical outcome. This will most likely allow 
grouping patients with different distributions of naive and memory T cell subsets and/or with 
other immune alterations described here.
Immunophenotyping by flow cytometry is a valuable tool in the evaluation of 
immunological status, especially in haematological malignancies that involve alterations in 
lymphocyte populations. This study has defined phenotypes that may correlate with disease 
progression/response to treatment and may have implications in the development of strategies 
to overcome T cell tolerance for immunotherapy of CLL using Bax or other tumour antigens. 
Different strategies could be carried out in vitro to overcome T cell tolerance. These include 
improving antigen presentation by CLL cells, antigen-specific T cell activity by blocking 
immunosuppressing molecules, such as CD200 and PD-1 and/or using immunomodulating 
drugs. Studies are underway to address these issues.
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Chapter 8 
Final Discussion
The results presented in this study have provided evidence that supports a novel 
approach of immune targeting Bax protein based on its unique expression pattern in cancer. 
This is a novel concept because definition of tumour antigens usually relies on steady-state 
over-expression of proteins in cancer cells. Here, it was proposed that a self-protein with low 
or unstable expression can be a candidate tumour antigen. This was based on the hypothesis 
that its abnormal proteasomal degradation in cancer cells will result in enhanced generation of 
Bax peptides that can bind to HLA class I molecules and be displayed at the surface of cancer 
cells for CD8+ T cell recognition. Thus, Bax-specific T cells should be able to recognise and 
kill tumour cells, but not healthy cells.
This research defined Bax as a new potential tumour antigen for immunotherapy. 
Chapter 3 showed for the first time that Bax peptides can be immunogenic to human CD8+ T 
cells. Chapter 4 demonstrated that Bax-specific T cell lines/clones can be generated from low 
frequency peptide-specific T cells, and proved the concept that Bax-specific T cells can kill 
tumour cells in HLA-A2 restricted manner. Bax specific T cells were capable of recognising 
tumour cells from several types of cancer, revealing a unique pattern of specificity. Chapter 5 
provided further evidence to support the hypothesis, by showing that Bax is targeted for 
proteasomal degradation in selective tumours, but not in healthy cells. A correlation between 
T cell reactivity and Bax degradation was observed. Chapter 6 showed that it is difficult to 
generate T cell responses against Bax and other tumour antigens in CLL patients, indicating 
that both naive and memory T cells are compromised in CLL patients. Chapter 7 
demonstrated that the unresponsiveness of T cells in CLL patients could be related to various 
immune abnormalities, such as increased expression of immunosuppressing molecules, Tregs 
and skewed T cell differentiation.
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Using a reverse immunology approach, this study revealed that T cell precursors for 
Bax-derived peptides are present in the peripheral blood of healthy donors. The first major 
implication from this study is the identification of four potential immunogenic Bax-derived 
peptides (p610, p612, p613 and p614). Furthermore, implementation of a technology of 
selecting T cells with low frequency based on their IFNy secretion resulted in the generation 
of purified Bax specific T cell lines and clones from two donors. Characterisation of Bax- 
specific T cell lines/clones unveiled Bax p610 and p613 peptides as the most promising 
epitopes. These HLA-A2-binding epitopes were able to elicit Bax-specific CTL responses in 
vitro against tumour cells expressing endogenous Bax peptides, but not against non­
transformed cells (PHA blasts and skin fibroblasts).
A Bax-specific T cell clone was able to recognise HLA-A2+ tumour cells of various 
types, including CLL, HPV transformed cervical, osteosarcoma and hepatocellular carcinoma 
cells. This implies that similar Bax peptides are expressed and complexed with MHC class I 
molecules on different cancer cell types. Killing of tumour cells by the T cell clone was 
antigen-specific and HLA-A2 restricted. Moreover, it was established that the proteasome 
pathway was involved in the generation of endogenous Bax peptides in tumour cells as lysis 
by Bax-specific T cells was reduced in tumour cells treated with a proteasome inhibitor.
T cell reactivity against the tumour cells appeared to be correlated with Bax 
expression in these cells. The hypothesis was strengthened by the observation of increased 
Bax degradation by the proteasome in selective cancer cells, as detected by western blotting. 
Cancer cells that showed increased degradation of Bax were recognised by the Bax-specific T 
cells, whereas the normal cells and cancer cells with no substantial increased degradation 
were not recognised by the T cells. Together, these findings provide key evidence that support 
the central hypothesis. To further prove the hypothesis, Bax stability needs to be evaluated in 
the different cells tested as this will confirm that rapid/high degradation rates of Bax occurs in 
the tumour cells and probably is involved in the generation of T cell epitopes in the tumour
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cells. However, increased Bax degradation is not a guarantee for recognition of tumours by 
Bax-specific CTLs as other tumour cells may be presenting different Bax epitopes (other than 
the Bax p610 and p613). Additionally, it would be of interest to use mitochondrial and 
cytosolic fractions to evaluate the location of Bax in these cancer cells compared with normal 
cells.
A way to directly validate this hypothesis will be by elution of natural processed 
peptides complexed with MHC class I molecules from the tumour cells tested in this study 
and analyse their sequences by mass spectometry. This will prove that the Bax protein is 
indeed endogenously processed and Bax-derived peptides associated with MHC class I 
molecules are present in these tumour cells. This is currently being evaluated as one of the 
next steps to explore Bax protein as a tumour antigen.
The results in this thesis support the concept that decreased stability of the Bax protein 
is contributing to T cell recognition. This is not an unusual concept, since several studies have 
shown that CTL recognition of endogenously processed antigens can be governed by 
instability or susceptibility to degradation of proteins, rather than high levels of steady-state 
expression (Castilleja et al., 2001; Gileadi et al., 1999; Tobery & Siliciano, 1997; Vierboom 
et al., 2000). In particularly, CTL recognition of the ubiquitously expressed tumour 
suppressor self-protein p53 was found towards tumour cells with enhanced proteasomal 
degradation of p53 (Sirianni et al., 2004; Vierboom et al., 2000). Importantly, these findings 
corroborate with the concept that enhanced protein degradation by the ubiquitin-proteasome 
pathway can lead to the induction of vigorous CTL responses in vitro and in vivo.
To fully exploit the potential usefulness of Bax epitopes for immunotherapy, it is 
necessary to screen for T cell responses against Bax in cancer patients. T cell responses 
against Bax were evaluated to a limited extent in CLL patients in this thesis. CLL is a good
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model system for this study because autologous primary tumour cells can be used as targets 
for evaluation of T cell recognition, whereas for other types of cancer, no tumour biopsies 
could be obtained and only cancer cell lines were used. Detection of T cell responses was 
limited and only two patients were capable of mounting a response against Bax peptides. In a 
way, this was expected as even the MART-1 antigen, which is a strong model antigen for 
naive T cell responses, was not able to prime immune responses in most patients. In addition, 
the immunophenotyping data revealed a decrease in the percentage of naive CD8+ T cells and 
a skewed phenotype towards memory, as well as an increase expression of 
immunosuppressive molecules, such as CD200 and PD-1 in most patients. This would have a 
suppressive effect in priming tumour specific T cell responses and thus explains why it is so 
difficult to mount a naive response in these patients using protocol similar to the one used for 
healthy donors.
Along with the defects on both antigen presenting and effector mechanisms, the lack 
of appropriate stimulation protocol and low numbers of CD3+ T cells obtained from each 
sample made it difficult to fully investigate T cell responses against Bax in CLL patients. 
However, by developing appropriate in vitro stimulation strategies to overcome the tolerance 
mechanisms, such as the use of CD40-activated B cells as APC, addition of antibodies to 
block immunosuppressive effects and/or the immunomodulatory drug lenalidomide to 
recover antigen presentation, there is the potential to improve the detection of both naive and 
memory peptide-specific T cells. The Bax-specific T cell clone was able to recognise CLL 
cells from most of the HLA-A2+ patients tested, thus implying that Bax-derived peptides are 
present in these malignant cells. Therefore it will be important to fully investigate the 
frequency of Bax specific T cells in patients, so as to evaluate their potential utility in an 
immunotherapeutic setting.
Following on from this, it would be interesting to screen for T cell responses against 
Bax epitopes in HLA-matched osteosarcoma patients and women with varying severity of
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cervical disease due to the fact that Bax-specific T cell clone was able to kill osteosarcoma 
cell lines, HPV-transformed cervical cancer cell lines, but not HPV-negative cervical cancer 
cells. Infection with high risk HPVs is associated with the development of high grade cervical 
intraepithelial neoplasia (CIN) and cervical cancer (Walboomers et al., 1999; zur Hausen, 
1996). A study including women with incident HPV infection, low grade CIN, high grade 
CIN or cervical cancer would give an indication as to how frequently responses can be 
detected against these epitopes in the different disease states. By studying these cohorts over 
an extended period of time it would also be possible to track changes in the immune 
responses to these epitopes that may correlate with disease clearance or progression. Together 
with the screening of patients, it would also be helpful to obtain tumour biopsies during the 
course of disease to analyse Bax expression and its degradation, so it would be possible to 
correlate T cell responses with the degree of Bax degradation. It would be predicted that Bax 
degradation would increase as disease progresses and possibly increased frequencies of Bax- 
specific T cells would be detected.
One benefit of identifying Bax epitopes is that, armed with the knowledge of the 
HLA-A2 restriction, it will be possible to directly monitor the appropriate donors/patients to 
identify the frequency and nature of immune responses in an epitope-specific context. This 
knowledge also allows the design and generation HLA class I-peptide tetramers, which is 
currently being considered as the next step for this research. Tetramers are a helpful 
immunological tool for monitoring peptide-specific T cell responses, which can be used to 
facilitate precise phenotyping of peptide-specific T cells by flow cytometry and have the 
ability to detect low frequency T cells directly ex vivo from PBMC. So, it will of great interest 
to design a tetramer for Baxp613:HLA-A2 for monitoring T cell responses directly ex vivo 
and after stimulation in vitro in CLL patients.
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Based on the reactivity of the T cell clone KSBV17 (Chapter 4), Bax could be 
regarded as a broad cancer antigen and Bax peptides as substrate for a possible 
immunotherapy for multiple human cancers. To our knowledge, no other tumour antigen has 
this unique pattern towards CLL, osteosarcoma and HPV-transformed cervical cancer. 
Although several conventional therapies exist for these different cancers, they still remain 
incurable and thus the development of new immunotherapeutic approaches for these cancers 
is warranted to improve the survival and quality of life of patients.
Bax epitopes identified in this study offer the opportunity to design novel 
immunotherapies for multiple cancers. However, the possibility that this self-antigen would 
exhibit a level of autoimmunity in the host immune system is a concern. It has been reported 
for certain self-antigens that anti-tumour responses can also result in autoimmunity. For 
example, autoimmune reactions against melanocytes causing vitiligo can occur during 
melanoma treatment (Yee et al., 2000). Studies of immunity against CEA, an oncoprotein 
also expressed in normal colon epithelium and in most gut carcinomas, raised more serious 
concerns about autoimmune side effects. Vaccination for an anti-tumour response resulted in 
severe intestinal autoimmunity associated with weight loss and mortatility in mice (Bos et al. , 
2008).
However, a number of previous reports using self-antigens, such as the ubiquitous 
self-protein p53 (wild-type), revealed that tolerance can be overcome without any 
autoimmune damage to normal tissue, yielding CTLs of sufficient avidity to recognise tumour 
cells expressing endogenous antigen (van der Burg et al., 2002; Vierboom et al., 1997; 
Vierboom et al., 2000). It has been shown that potentially autoreactive wild-type p53-specific 
CTLs can eradicate established tumours and persist in mice without autoimmune tissue 
damage (Vierboom et al., 1997; Vierboom et al., 2000). A explanation for the tumour 
selectivity could be that the normal tissues lack danger signals and have insufficient quantities 
of peptides display by the MHC class I molecules and be immunologically ignored, thus
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might be protected against the destruction by the autoreactive peptide-specific CTLs 
(Vierboom et al., 1997). Several other self-proteins that are ubiquitously expressed have been 
tested in clinical trials, such as HER2/neu, hTERT and survivin (Brunsvig et al., 2006; 
Honma et al., 2009; Peoples et al., 2005; Tsuruma et al., 2004). These clinical trials have 
shown that vaccination against these self-proteins was feasible and safe, without any serious 
autoimmunity reaction being observed.
Although the possibility of an autoimmune attack was not formally ruled out in this 
present study, it was possible to show that the Bax-specific T cell clone had no specific 
cytotoxic activity towards normal healthy cells. It is proposed that in normal cells Bax is 
largely confined in the cytosol in an inactive stable form and not efficiently targeted for 
proteasomal degradation. A recent report has shown that only when Bax undergoes 
conformational changes and translocation to the mitochondria, it triggers ubiquitin 
recognition and Bax proteasomal degradation in cancer cells (Yu et al., 2008). Thus, it is 
likely that there will not be sufficient peptides for MHC class I pathway on normal cells for 
recognition by CD8+ T cells. A distinctly higher degradation rate of Bax resulting in higher 
density of the CTL epitopes of interest on MHC class I of the tumour cells should allow the 
tumour cells to be distinguished from normal cells for T cell recognition. Another possibility 
is that tumour cells have different proteasomes compared with normal cells and can process 
epitopes differentially. Nevertheless, it will be of great importance to test Bax in pre-clinical 
in vivo models to exclude the possibility of autoimmunity. This could be done by adoptive 
transfer of autologous Bax-specific T cells grown ex vivo into HLA-A2/Kb transgenic mice to 
observe whether any autoimmunity incident develops.
The findings from this study argue that potential tumour antigens should not be 
restricted to stable self-proteins that are over-expressed, and that self-proteins that are short­
lived and have an increased rate of degradation in tumours should also be taken into
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consideration. Similar to Bax, p53 degradation by the proteasome appears to be correlated to 
enhanced processing of p53 epitopes and increased T cell recognition (Sirianni et a l., 2004; 
Vierboom et al., 2000). This study together with those findings constitutes the ultimate 
illustration of a potential novel category of tumour antigens: unstable self-proteins with an 
increased degradation rate by the proteasome. Another protein (retinoblastoma protein) with 
a similar pattern in cancer that could belong to this category is currently being studied in our 
laboratory.
Definition of novel tumour antigens is essential for their potential use in 
immunotherapy and also as a way of tracking tumour-specific T cells during the course of 
treatment and disease. An advantage of the identification of new tumour antigens is that it 
increases the pool of immunogenic peptides that can be used to recruit a larger, more potent 
repertoire of T cells targeting the tumour. A rational immunotherapy should satisfy various 
criteria such as range of application in terms of tumour types addressed, diversity of antigens 
addressed to ensure disease coverage and prevent tumour escape, and broad coverage of 
patient populations.
Approaches that target multiple parts of immunity and integrate elements that target 
tumour escape simultaneously are more likely to result in clinical success. The identification 
of multiple CTL epitopes from several tumour antigens involved in several cancer traits, such 
as resistance to apoptosis, abnormal cell cycle regulation and mestatasis, represent broadly 
applicable vaccination targets and should allow the development of various types of 
immunotherapy (Andersen et al., 2008). Therapeutic vaccines using a mixture of peptides 
from various antigens alone or pulsed on to DCs would probably be useful to elicit in vivo 
anti-tumour immunity for early stages of cancer or as adjuvant setting in more advanced 
stages. Combination of anti-cancer vaccination to increase the frequency of tumour-reactive 
T cells prior, or immediately after, ACT therapy may be another mechanism to boost the
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immune system of patients with advanced and metastatic disease that underwent 
chemotherapy or radiotherapy (Andersen et al., 2008; Copier eta l., 2009) .
Since Bax is a ubiquitously expressed self-protein, the choice of patients receiving 
immunotherapy targeting Bax will be critically dependent on the balance between therapeutic 
anti-tumour immunity and toxicity. Bax antigen could probably be used for immunotherapy 
of patients with early stages of diseases. For early and small tumours, only low CTL activities 
will be required to clear tumour and thus tumour elimination may be accomplished without or 
before causing any apparent autoimmune symptoms. As for established tumours, strong 
sustained CTL responses will be required to complete remission of large tumours, and thus 
may induce strong CTLs responses against the tumour with potential autoimmune reactions 
(Ludewig et al., 2000). Furthermore, targeting multiple tumour antigens seems important to 
augment the efficacy and diversity of antitumor immunity, and provide coverage of various 
tumours of any particular type. An interesting approach would be to incorporate proteins, 
such as p53, Bax and other proteins from Bcl-2 family, in a multi-epitope setting. Since 
alterations of these proteins contribute to apoptosis resistance through different mechanisms, 
targeting these proteins may represent a more efficient strategy to achieve potent anti-tumour 
immune response, tumour regression and prevent escape in clinical settings.
The results in this study have defined several parameters likely to be important for 
cancer immunotherapies. These revealed that the selection of appropriate epitopes from Bax 
protein is relevant to tumour immunity, and imply that not only self-protein that 
overexpressed in cancer can provide a repertoire of peptide epitopes that are actually 
presented by tumour cells. It has been proposed that proteins that regulate apoptosis may be 
widely applicable targets for immunotherapy and strategies designed to target regulators of 
apoptosis have gained considerable interest for treatment of cancer (Andersen et al. , 2005). 
Since dysregulation of Bax is an essential factor for resistance to apoptosis in several cancers,
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Bax derived epitopes may be able to circumvent tumour evasion and thus could be potential 
immunotherapeutic targets.
In conclusion, this present study provided a first insight into the relationship between 
expression of Bax protein, CTL recognition of Bax-derived epitopes and tumour antigenicity. 
A reverse immunology approach demonstrated the ubiquitously expressed Bax as a novel 
tumour antigen. Several tumour cells naturally processed and presented Bax immunogenic 
epitopes and induce responses from Bax specific T cells, supporting Bax as a target for anti­
cancer T cell immunity.
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